ARISING HEALTH

The Arising

HEALTH INTELLIGENCE

LONGEVITY
SCIENCE
MARKETS
HUMAN HEALTH

Tracking emerging Medical Intelligence from a Physician's View

SATURDAY, OCTOBER 24, 2026 | VOL 1 NO 22 | ARISING HEALTH


47 stories across 7 desks | ~117 minutes to read | 240 briefs grouped by topic

Checked before print. 1,225 claims in 47 articles and 240 briefs verified against their sources by a separate reviewer · 20 articles and 36 briefs corrected before publication

LONGEVITY & HEALTHSPAN

30 STORIES · 65 MIN →

1



Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds

Among the many tests that claim to measure biological age, one family of...

2 MIN READ

2

Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds

Over 12 years, researchers watched sleep change in Indigenous Toba/Qom communities in northern...

2 MIN READ

3

Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed

When memory starts to slip, which kind of exercise is the best bet?

2 MIN READ

4

FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment

For people with mild memory problems, the hardest question is often what comes...

2 MIN READ

5

Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk

Adults who stayed both physically inactive and physically weak over several years were...

2 MIN READ

6



Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia

Of all the diet strategies tested against age-related muscle loss, a protein intake...

2 MIN READ

7

Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial

Side effects are often what decide whether someone can stay on a weight-loss...

2 MIN READ

8

Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness

Adults aged 45 and older who had both sight and hearing loss were...

2 MIN READ

9




NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice

Eating less is one of the best-studied ways to slow aging in animals...

2 MIN READ

10



Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells

Blood from people with a heart-weakening protein disease harmed human blood vessel cells...

3 MIN READ

11

Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial

For older adults with advanced dry macular degeneration, today's approved treatments can slow...

2 MIN READ

12

Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness

Climbing a few flights of stairs at a brisk pace is easy to...

3 MIN READ

13

Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients

People with depression who are night owls, sleep long hours and wake up...

2 MIN READ

14

Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes

People with type 1 diabetes and kidney disease looked about two years older...

3 MIN READ

15

Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds

Epigenetic age tests promise to measure how fast a body is aging.

2 MIN READ

16

Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers

Morning or evening?

1 MIN READ

17

Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics

People in the UK with type 2 diabetes or obesity may soon be...

2 MIN READ

18



AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's

A company that uses artificial intelligence to decide which drugs to develop is...

2 MIN READ

19



APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially

Most American adults now treat stress as a fact of life, and nearly...

3 MIN READ

20



Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use

Arteries can slowly fill with mineral deposits that make them stiff, and a...

2 MIN READ

21

Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause

Women who use hormone therapy after menopause may have migraines that come more...

3 MIN READ

22

Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults

A new systematic review asks a practical question for people past midlife who...

1 MIN READ

23

2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70

Among 2,711 people whose brains were examined after death in São Paulo, Alzheimer's-type...

2 MIN READ

24



Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing

Childbirth leaves a measurable mark on the body, and for many measures it...

2 MIN READ

25



Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics

In a small randomised trial of adults aged 65 and older with type...

2 MIN READ

26



Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

Ultra-processed food is often discussed as one thing, but a new review in...

3 MIN READ

27



AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing

A molecule just nine amino acids long may be the next test of...

2 MIN READ

28




Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study

Eggs age, and so far scientists have understood that process mainly through the...

2 MIN READ

29




Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women

Twelve weeks of aquatic or dance-based aerobic exercise went along with less body...

1 MIN READ

30



Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

A common idea in aging science says that as we get older, our...

2 MIN READ

MARKETS & STRATEGY

5 STORIES · 11 MIN →

1



Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies

2 MIN READ

2



Fractyl Cuts 45% of Staff to Focus on Revita After Pivotal Win

2 MIN READ

3

CMS and States Launch $275M Program to Recruit Nursing Home Nurses

2 MIN READ

4

Insurers Split on How the Pandemic Should Shape Future Mortality Assumptions

2 MIN READ

5

Owners Reportedly Explore $1 Billion Sale of Largest US Senior Living Operator

2 MIN READ

LONGEVITY & HEALTHSPAN · LONG READS

4 STORIES · 13 MIN →

1

A 6.3-Million-Cell Brain Atlas Finds Alzheimer's Is Not Just Faster Aging

3 MIN READ

2

Does Annual Flu Vaccination Blunt the Next Shot? A Korean Trial Is Testing It

3 MIN READ

3

Does Where Stem Cells Fail Matter as Much as How Many?

3 MIN READ

4

Does Fading Nitric Oxide Silence Cell Recycling in Aging Arteries? Evidence Points the Other Way

4 MIN READ

MARKETS & STRATEGY · LONG READS

2 STORIES · 6 MIN →

1

C2N, Cambridge Cognition and a New Alzheimer's Trust Bundle UK Dementia Testing Into One Pathway

2 MIN READ

2

Refiner Stocks Have Doubled in 2026 as the World Runs Short of Diesel

4 MIN READ

MEASUREMENT & AI

2 STORIES · 7 MIN →

1

Cloudflare Plans a Post-Quantum Certificate Authority Using Merkle Tree Certificates

3 MIN READ

2

Rule-Last Prompts and Hostile Filenames: Our First Test Did Not Finish

4 MIN READ

SCIENCE & FRONTIERS

2 STORIES · 8 MIN →

1

Can Earth's Magnetic Field Help Microbes Clear Toxic Sulfide? A Long Shot

4 MIN READ

2

After Gene Editing, Do Corrected Cells Gain or Lose Ground Over Time?

4 MIN READ

HISTORY & IDEAS

2 STORIES · 7 MIN →

1

Losing Experts All at Once May Destroy Skills That Gradual Turnover Would Not

3 MIN READ

2

Did Selection Start Before Life? A Testable Idea About Chemistry That Remembers

4 MIN READ

BRIEFS

240 SHORT STORIES · 70 MIN →

Fasting, autophagy & metabolic health 12 · Mitochondria & cellular energy 10 · Epigenetic reprogramming & age reversal 13 · Exercise as medicine & longevity 11 · Proteins & amino acids 11 · Clinical trials 60 · In the news 11 · Alzheimer's & cognitive decline prevention 11 · Women's health & hormonal transitions 11 · Ultra-processed food & ultra-processed diet 10 · MRNA & gene therapy 10 · AI biology & diagnostics 10 · VO2 max & zone 2 training 10 · Sleep science & circadian biology 10 · Gut microbiome & brain axis 10 · Stress resilience & nervous system 10 · Longevity research 10 · Nitric oxide & vascular health 10

The Arising

HEALTH INTELLIGENCE

SATURDAY, OCTOBER 24, 2026 · LONGEVITY & HEALTHSPAN DESK

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. **Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds**
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause

22 Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24 Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25 Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26 Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk
27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

MEDRXIV PREPRINT, NOT PEER REVIEWED · 2 SOURCES

Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds

Among the many tests that claim to measure biological age, one family of blood-based tests now has a large body of evidence behind it: people whose DNA looks older than their calendar age tend to die sooner, as a group, than people whose DNA looks younger.




Photo: by Goleisureintl, CC BY 4.0

That is the finding of a systematic review and meta-analysis posted on medRxiv by Tay and colleagues. It is a preprint, which means it has not been peer reviewed. The work pools observational studies in people, so it shows associations, not causes. According to the abstract, 125 articles with 380,705 participants met the inclusion criteria, and 53 of them were combined in the meta-analyses.

The tests are called DNA methylation clocks. They read chemical tags on DNA and turn the pattern into an estimated age. "Epigenetic age acceleration" is the gap between that estimated age and a person's actual age. A positive gap means the DNA looks older than the calendar says.

The team searched six databases for studies published from January 2011 to April 15, 2026. They screened 42,023 records. Across the included studies, 48 distinct clocks were evaluated. Higher DNA methylation ages were associated with higher risks of death from any cause, from cardiovascular disease and from cancer.

The clearest results were for a clock called GrimAge, in general populations. In 31 cohorts with 53,642 people, each one-year increase in GrimAge acceleration was associated with a hazard ratio of 1.09 for all-cause death (95% confidence interval 1.08 to 1.11). A hazard ratio compares the rate of death between groups. Here, it means about 9% higher risk per year of acceleration.

For cardiovascular death, the pooled figure was 1.10 per year (6 cohorts, 30,751 people). For cancer death, it was 1.06 per year (5 cohorts, 27,187 people). The authors summarise this as roughly 6% to 10% higher risk per year across the three outcomes.

Newer versions of the clock scored somewhat higher. Per standard deviation of acceleration, GrimAge2 had a pooled hazard ratio for all-cause death of 1.65 (1.53 to 1.77), against 1.46 (1.38 to 1.55) for GrimAge. PCGrimAge scored 1.56 (1.36 to 1.78) against 1.51 (1.32 to 1.74) for the version it was compared with. The authors describe these differences as numerical. The PCGrimAge intervals overlap heavily.

What does this mean for a single test result? The abstract reports group-level averages. A hazard ratio describes how risk differs between large groups of people. It does not say what will happen to one person. A higher-than-expected epigenetic age is best read as a risk signal that tracks with outcomes in populations, not as a diagnosis of disease.

There are other reasons for caution. The all-cause GrimAge result had high heterogeneity (I^2 of 84.1%), meaning the studies differed a good deal from one another. The abstract does not say why. Because only the abstract was available to us,

we cannot report how individual studies were designed or how they adjusted for other factors.

The authors also note what is still unknown. They write that further work is warranted to evaluate whether these clocks respond to interventions, and whether they have clinical utility. Those questions matter most for anyone deciding what a biological-age number should change. Watch for peer review of this analysis, and for studies testing whether clock scores move in step with real health outcomes after an intervention.

Sources: medRxiv preprint, not peer reviewed (2026), medRxiv

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. **Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds**
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

BIORXIV PREPRINT, NOT PEER REVIEWED · 2 SOURCES

Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds

Over 12 years, researchers watched sleep change in Indigenous Toba/Qom communities in northern Argentina as electricity, then the internet and smartphones, arrived. Sleep moved later in every group studied, and in rural communities it also grew shorter by about an hour.

The evidence is an observational, longitudinal study in people, posted as a bioRxiv preprint in 2025. It has not been peer reviewed. It followed 156 participants and analysed more than 12,000 sleep events recorded with actigraphy, a method that estimates sleep from body movement. We could read only the abstract, so this article covers only what the abstract reports.

The work ran from 2012 to 2024. Some rural groups were newly introduced to electricity after 2016. Other, semi-urban groups had had electricity for longer. Because the same communities were followed over time, the team could see sleep change as it happened. Many earlier studies compare different groups at a single moment.

According to the authors, both groups showed delays of up to 1.4 hours in sleep timing. Participants from rural communities lost a full hour of sleep within just a decade. The authors analysed the data with linear mixed-effects models, a statistical approach for repeated measurements on the same people.

The period covered the arrival of electricity in rural areas and, later, the spread of the internet and smartphones. It is tempting to blame evening light and screens. The authors say their models do not support that simple story. They report that these

events alone cannot fully explain the shifts in sleep timing.

Instead, they suggest that broader processes of modernization and acculturation, beyond electric light and digital devices alone, may be driving the changes. That is an interpretation, not a tested result. The abstract does not say which parts of modern life matter most.

The authors say direct, long-term evidence that artificial light and digital technology delay and shorten sleep has been scarce. They write that the changes seen here mirror, within a single decade, the likely path of human sleep across the 20th and early 21st centuries. For people elsewhere, the finding is a reminder that later, shorter sleep is linked to many features of modern environments, not only to a bright screen at night.

Press coverage went in a slightly different direction. Nature's news report said residents slept an average of 35 minutes less per night after gaining electricity, which it linked to access to the internet and smartphones. That figure does not appear in the preprint abstract, which gives a one-hour loss for rural participants. The abstract also does not link the sleep changes to electricity alone. Nature cites a peer-reviewed version of the study in Current Biology. We have not seen that version, and its numbers may differ from the preprint.

Other limits follow from what is available. The abstract does not describe the ages of participants, their health, or how sleep changed for individuals. The results come from one set of communities and may not apply to other populations.

WHAT TO WATCH NEXT

What to watch next is whether the peer-reviewed Current Biology paper confirms the preprint's figures, and whether later work can separate the effects of light, devices and wider social change on sleep.

Sources: bioRxiv preprint, not peer reviewed (2025), Nature (news); study in Current Biology

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. **Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed**
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

ISCIENCE

Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed

When memory starts to slip, which kind of exercise is the best bet? An iScience network meta-analysis addresses that question. We could not confirm its findings. Our research notes say it ranked combined physical and brain training as most likely best, but nothing we retrieved verifies that, so treat it as unconfirmed.

The confirmed details are limited to the journal and the title: "Comparative efficacy of exercise modalities for mild cognitive impairment in older adults: A network meta-analysis." The source page we retrieved contained only the word "Redirecting", so no coverage actually confirms the ranking. Mild cognitive impairment is a stage of memory or thinking trouble that is more than normal aging but not dementia.

A network meta-analysis compares several types of exercise at once. It pools results from earlier trials and uses them to rank the options. Many of those comparisons are indirect. Two exercise types may never have been tested head to head, so a ranking shows which option is probably best. It does not prove that one beats another.

The paper itself was not reviewed, so details such as how many trials were included, how cognition was measured and how large any benefit was are not covered here.

A simple idea would fit a ranking like the one our notes describe: an activity that challenges both movement and thinking may offer more than either alone. That idea is a proposal, not something we have verified. It also says nothing about how much training, how often, or for whom it works best. This is the weakest part of the story, because the central finding rests on unverified notes.

On October 20, The Arising reported on a small, separate study of gut bacteria and chemicals in mild cognitive impairment. That work looked at possible biological markers, not at treatment. The exercise analysis asks a different question: which activity might help once memory trouble has begun.

WHAT TO WATCH NEXT

The full paper's methods and results, and whether they confirm the reported ranking. Future trials that compare combined training with other exercise types directly would also help.

Anyone considering a change in exercise, especially with memory concerns, should talk with their own clinician before starting or stopping anything.

Source: iScience

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. **FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment**
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN LONGEVITY.TECHNOLOGY

FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment

For people with mild memory problems, the hardest question is often what comes next, and a newly cleared software tool is designed to help doctors address it.

The U.S. Food and Drug Administration has granted 510(k) clearance to NEXT-Cue, made by NeuroXT Inc., according to Longevity.Technology. The software is classified as a Class II medical device. It is described as an AI-based tool meant to help clinicians assess whether a patient with mild cognitive impairment may progress to Alzheimer's dementia within five years.

Mild cognitive impairment means a person has memory or thinking difficulties beyond what is expected, but still manages daily life. Not everyone with it goes on to develop dementia. That uncertainty is what makes a risk estimate potentially useful.

According to the report, NEXT-Cue combines three kinds of information: brain MRI images, demographic information and cognitive assessment data. It then provides what the company calls supplementary information. In other words, it is meant to add to a clinician's judgment, not replace it.

The source reports no figures on how accurate the tool is, and no validation data. That is the key gap for patients and families. Clearance by the FDA tells us the software met the agency's requirements for this pathway. The source does not say how well its estimates match what happens to patients over time.

That leaves open questions that families may reasonably want answered. How many people with mild cognitive impairment were used to test the tool? Did the results hold up in people who were not used to build it? How often does it wrongly flag

someone as high risk, or miss someone who later declines? And how does it handle people of different ages, backgrounds and education levels? The source does not address any of these.

A risk estimate is also not a diagnosis. A five-year estimate describes a likelihood, not a certainty, and the source does not describe any treatment decisions tied to it. What a person would do with the result is a conversation for them and their clinician.

This differs from another recent topic in our pages. On October 20, we reported on a small study of gut bacteria and chemicals in mild cognitive impairment, which was an early look at possible markers and did not test a cleared tool. Both address the same uncertainty, but only NEXT-Cue has reached the regulatory stage.

NeuroXT says it intends to expand U.S. commercialization and adoption at healthcare institutions. It is also pursuing authorization from the Ministry of Food and Drug Safety in the Republic of Korea, with plans to begin commercialization there early next year. What to watch next: whether NeuroXT publishes performance data that clinicians and families can examine.

Source: Longevity.Technology

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. **Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk**
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

INTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND PHYSICAL ACTIVITY · 2 SOURCES

Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk

Adults who stayed both physically inactive and physically weak over several years were more likely to develop cognitive impairment later, according to a large study of older adults in the United States, China and South Korea.

This is an observational study in people, published in 2026 in the International Journal of Behavioral Nutrition and Physical Activity. Researchers analysed data from 11,381 adults aged 50 and older. All were free of cognitive impairment and daily-living disability at the start. Observational work can show that two things go together. It cannot show that one causes the other.

The data came from three national aging studies: the Health and Retirement Study in the US, the China Health and Retirement Longitudinal Study, and the Korean Longitudinal Study of Aging. The team tracked each person's physical activity and grip strength together across three survey waves. Grip strength is a common, simple measure of muscle strength. The researchers then grouped people by how both measures changed over time.

After those three waves, the team followed participants for 6 to 10 years to see who developed cognitive impairment. In total, 4,068 people did. To reduce the chance that early illness was driving the results, the researchers excluded anyone with cognitive impairment during the tracking period, or with daily-living disability at the first wave.

The comparison was between two groups. One had persistently high activity and high strength. The other had persistently low activity and low strength. The low-low group had a higher risk of cognitive impairment in every cohort. The hazard ratio

was 1.41 in the US data (95% confidence interval 1.20 to 1.66). It was 1.26 in China (1.03 to 1.53) and 1.22 in South Korea (1.02 to 1.46). A hazard ratio compares how quickly new cases appear in one group versus another. So these figures translate to roughly 22% to 41% higher risk.

The authors say the pattern was directionally similar when they used other statistical approaches. These included a method that accounts for people dying of other causes first. However, they note that some secondary estimates differed across models and subgroups.

The team also tested machine learning models to see whether the activity and strength pattern could help predict who would develop cognitive impairment. The combined trajectory ranked as an important feature in those models. But the authors describe this work as exploratory. Prediction accuracy was only moderate, and it was lower on held-out validation data than on the data used to build the models.

FOR YOU

What does this mean for personal health? The study looked at activity and strength together, and the risk showed up when both stayed low. It did not test whether starting strength training or becoming more active changes brain outcomes. It also cannot rule out that other factors explain the link. The authors conclude only that the findings support further investigation of these combined patterns as possible markers of cognitive risk in aging populations.

According to the journal page, the work was funded by the National Natural Science Foundation of China and the China Postdoctoral Foundation. The authors declared no competing interests, and the funders had no role in the study.

WHAT TO WATCH NEXT

Studies that test whether raising activity and muscle strength together actually lowers later cognitive risk, and whether the prediction models hold up in new groups of people. Anyone thinking of changing their exercise habits should first talk with their own clinician.

Sources: International Journal of Behavioral Nutrition and Physical Activity (2026), International Journal of Behavioral Nutrition and Physical Activity

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. **Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia**
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics

26 Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk
27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

THE JOURNAL OF NUTRITION · 2 SOURCES

Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia

Of all the diet strategies tested against age-related muscle loss, a protein intake of at least 1.0 to 1.2 grams per kilogram of body weight a day, paired with resistance training, has the strongest support, according to a new review of 248 studies.



Photo: by PattayaPatrol, CC BY-SA 4.0

The paper appears in The Journal of Nutrition (2026). It is a systematic review, not a new experiment. Dharmansyah and colleagues searched three databases for studies from January 2010 to April 2026. They found 2,543 records and included 248 studies in adults aged 60 and over. Of these, 236 were primary studies and 12 were systematic reviews or meta-analyses. The primary studies included 100 randomised trials, 62 cohort studies, 68 cross-sectional studies,

3 case-control studies and 3 quasi-experimental studies. The authors pre-registered their protocol. Only the abstract was available to us, so details beyond it are not covered here.

The condition is sarcopenia: the loss of muscle mass, strength and physical performance with age. The authors say it affects 6 to 22 percent of adults aged 65 and over. They call it a leading driver of disability and mortality.

The team did not pool results into one number. Instead, they counted how often studies pointed toward benefit. Among randomised trials, 84 percent of single-nutrient trials reported a beneficial direction of effect. These were mainly trials of protein or leucine, an amino acid found in protein, and of vitamin D at 800 IU a day or more. The figure was 75 percent for whole-diet trials and 78 percent for gut-targeted trials. Across all study designs, the figures were 70, 65 and 62 percent. The authors stress that these show direction only. They are not success rates.

From this, the authors built a ranking that also weighs how certain the evidence is. Protein-anchored strategies rated moderate-to-high certainty. That means at least 1.0 to 1.2 g/kg/day, leucine-enriched, paired with resistance training. Vitamin D repletion in older adults who are deficient rated the same. The authors say both align with existing guideline thresholds.

Mediterranean-style eating ranked next, with moderate certainty. That evidence is largely observational. In those studies, Mediterranean and MIND-style diets, higher protein quality and more dietary fibre were each inversely associated with sarcopenia. That is an association. It does not show that the diets prevent muscle loss.

Approaches aimed at the gut microbiome, the community of microbes in the digestive tract, ranked last. The authors call the gut-muscle link an emerging fourth pillar. Results leaned favourable but varied widely, and the certainty was low to very low. Proposed pathways include short-chain fatty acids and more Akkermansia and Faecalibacterium bacteria. The authors say targeting the microbiome is a research priority, not current practice.

There are limits. Studies used different diagnostic criteria and reported outcomes differently. The authors name this as the main barrier to firm clinical recommendations. Their conclusions apply to the general population aged 60 and over.

WHAT TO WATCH NEXT

Large, standardised trials of gut-targeted approaches, and more consistent definitions of sarcopenia across studies. Anyone considering changes to protein intake, vitamin D or exercise should not start or stop anything without talking to their own clinician.

Sources: The Journal of nutrition (2026), The Journal of Nutrition

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. **Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial**
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN LONGEVITY.TECHNOLOGY

Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial

Side effects are often what decide whether someone can stay on a weight-loss drug. In a new mid-stage trial, almost no one taking an experimental weekly injection called petrelintide quit because of stomach problems, according to Longevity.Technology's report of the study.

This article is based on that report. The paper itself was not reviewed, and the figures come from a company announcement.

According to Longevity.Technology, Zealand Pharma announced topline results on 7 October from ZUPREME-2, a Phase 2 trial. It enrolled 220 people in the United States who had overweight or obesity and type 2 diabetes. All were taking metformin, with or without a type of diabetes drug called an SGLT2 inhibitor. On average, they started with a BMI of 36.3 and an HbA1c of 8.0%. HbA1c is a blood test that reflects average blood sugar over recent months.

Participants got a once-weekly injection at one of three doses, or a placebo, for 28 weeks, the report says. Everyone also followed a reduced-calorie diet and was encouraged to be more active.

By week 28, weight loss reached up to 9.2% of starting body weight, with the three dose groups between 7.4% and 9.2%. Placebo came in at 2.0%, according to the report. The 9.2% figure counts results as if everyone took the drug as planned. The company says results were largely consistent under a stricter method that includes people regardless of their dosing.

HbA1c fell by up to 0.65% on petrelintide and rose by 0.23% on placebo, per the report. After subtracting the placebo effect, the company reports reductions of 0.61% to 0.88% across the dose groups.

The tolerability figure is the one that stood out. Longevity.Technology reports that 1.9% of people on petrelintide stopped because of stomach-related side effects, versus 1.7% on placebo. The most common side effects were stomach-related. The report says the vast majority were mild and appeared while doses were being raised. No unexpected safety signals appeared, according to the company.

Petrelintide works differently from the widely known GLP-1 drugs. It is a long-acting version of amylin, a hormone the pancreas releases alongside insulin when people eat. According to the company, activating amylin receptors can restore sensitivity to leptin, a hormone involved in fullness, so people feel full sooner.

This adds to an earlier Arising report on Eli Lilly's daily pill Foundayo (orforglipron), which a European drug committee recommended for approval. That story covered a GLP-1 tablet. This one covers a different hormone target, and the two are separate products and trials.

The caution is real. These are topline numbers from a company press release, and 28 weeks says little about how long people can stay on treatment or how well benefits last. The small gap in dropouts is encouraging, but it does not show that petrelintide is better tolerated than other drugs, because it was not compared with them.

According to the report, Zealand and Roche have started a Phase 3a program of three trials, ZUPREME-3, -4 and -5, with roughly 7,000 participants expected. They cover people without type 2 diabetes, people with it, and people with established cardiovascular disease. Full ZUPREME-2 results are due at an upcoming scientific conference, and those details, along with the Phase 3 data, will show whether the early signal holds. Readers should not start or stop any medication without talking to their own clinician.

Source: Longevity.Technology

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. **Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness**
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH · 2 SOURCES

Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness

Adults aged 45 and older who had both sight and hearing loss were more likely to go on to develop physical disease, a psychological disorder and cognitive impairment together, and loneliness appears to explain a small part of why.

That is the finding of a cohort study in the International Journal for Equity in Health. It is an observational study in people. It followed 15,022 adults aged 45 and older for 6 to 8 years. Observational work can show links between factors. It cannot show that one thing causes another.

The data came from three national ageing studies: CHARLS in China, HRS in the United States and ELSA in England. At the start, participants reported whether they had vision impairment, hearing impairment, or both. The researchers call both together dual sensory impairment. Of the group, 52.8% reported no impairment, 10.9% hearing loss only, 17.2% vision loss only and 19.1% both.

The authors tracked a pattern they call physical–psychological–cognitive multimorbidity. This means having physical disease, a psychological disorder and cognitive impairment at the same time. They also looked at pairs of these three: physical and psychological, physical and cognitive, and psychological and cognitive.

The risk rose in steps. Compared with people with no impairment, those with dual impairment had the strongest associations. The hazard ratio was 2.18 for physical plus psychological problems and 2.36 for psychological plus cognitive problems. A

hazard ratio of 2 means roughly double the rate of developing the outcome over the follow-up period. For all three conditions together it was 1.56 (95% confidence interval 1.19–2.03). Vision loss generally showed stronger links than hearing loss.

According to the authors, results pointed the same way in all three countries. They held up in several checks, including matching participants on likelihood of impairment, accounting for deaths during follow-up, and using other definitions of impairment and outcomes. The models adjusted for demographics, education, marital status and health behaviours.

The study also looked at progression. Models that track people moving between conditions suggested faster transitions from a single type of condition to combined multimorbidity among those with dual impairment.

Loneliness was the mechanism the team tested. Using a statistical method called counterfactual mediation, they estimated that loneliness accounted for about 10–12% of the associations across impairment types. That is a meaningful share but a minority. Most of the link remains unexplained by loneliness. The authors describe it as a potential psychosocial pathway, not a proven one.

There are limits. Impairment was self-reported, not measured by testing. We had access only to the study's abstract, so details such as the cohort-by-cohort results and how each condition was defined are not covered here. The authors conclude that pairing accessible, affordable vision and hearing services with efforts to reduce loneliness may help identify older adults at higher risk and support equitable healthy-aging strategies. The study did not test whether such steps change outcomes.

WHAT TO WATCH NEXT

Trials that test whether treating sensory loss and easing loneliness actually lowers the risk of combined multimorbidity. Readers should not start or stop any treatment without talking to their own clinician.

Sources: International Journal for Equity in Health (2026), International Journal for Equity in Health

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. **NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice**
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

AGING CELL · 2 SOURCES

NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice

Eating less is one of the best-studied ways to slow aging in animals, and a new study suggests that part of its effect may run through tiny antenna-like structures on brain cells.




Photo: "Dissecting Neurons" by Katherine Stember, CC BY 4.0

The work was done in cultured brain cells and in aged mice, not in people. It was published in 2026 in the journal Aging Cell. Only the study's abstract was available to us, so this article does not cover details such as how many animals were used.

The structures are called primary cilia. They are hair-like projections on the cell surface that act as signaling hubs. The researchers studied them in neurons of the hypothalamus, a brain region involved in metabolism.

They also looked at NAD+, a molecule that cells use in many metabolic processes. According to the abstract, NAD+ levels are key regulators of cilia growth and of lysosome function in these neurons. Lysosomes are the cell's recycling compartments.

When NAD+ was depleted, the cilia became shorter and lysosomes became less active, and the lysosome effect depended on the cilia. The abstract reports a possible mechanism. A repair protein called CHMP4B moves from the base of the cilium to lysosomes under stress, and this move is impaired when cilia are poorly formed. Without it, lysosomes showed abnormal calcium signaling and dysfunction.

In aged mice with low NAD+ in the hypothalamus, cilia were shortened and lysosomes showed signs of stress. Calorie restriction restored both. The authors also report that calorie restriction improved age-related metabolic problems, "at least in part," through mechanisms that depend on hypothalamic cilia.

Lifespan.io, which covered the study, reported further details that the abstract does not give. According to that coverage, NAD+ and cilia length both fell in the mouse hypothalamus between 3 and 24 months of age. Raising NAD+ with precursors lengthened cilia in cultured neurons, and blocking CD38, an enzyme that uses up NAD+, worked even better. The coverage also said the effect needed the enzyme SIRT1. Lifespan.io wrote that the findings may explain "many of the benefits" of calorie restriction. The study's own wording is more limited: "at least in part."

FOR YOU

What does this mean for personal health? It offers a possible explanation of how eating less and raising NAD+ could be connected. It does not show that NAD+ supplements work in people. The study was in mice and cells, and the abstract does not report any test of supplements in humans. Whether any supplement could reach these brain cells and lengthen their cilia in a person is unknown. Mouse results often fail to carry over to people, so they do not yet justify buying supplements.

Researchers will need to confirm the findings in other labs. They will also need to learn whether the cilia pathway exists and matters in people. The authors' own conclusion is limited to a signaling axis that, when disrupted, drives metabolic aging in these neurons. Readers should not start or stop any supplement, diet or other health practice without talking to their own clinician.

Sources: Aging Cell (2026), Lifespan.io

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. **Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells**
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 3 MIN

AMYLOID : THE INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF AMYLOIDOSIS · 2 SOURCES

Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells

Blood from people with a heart-weakening protein disease harmed human blood vessel cells in the lab, and blood taken after six months of treatment with the drug tafamidis harmed them less. That is the central finding of a new study in Amyloid, and it hints that the condition may reach beyond the heart.




Photo: “Agar plates different types” by Lilly_M, CC BY-SA 3.0

The study combines two kinds of evidence. Most of it is laboratory work on human umbilical vein endothelial cells, which are lab-grown cells of the kind that line blood vessels. A smaller part is a longitudinal check of arterial

stiffness in patients. The abstract, which was the only part of the paper available to us, does not give the number of patients or samples. It is not a randomised trial.

The disease is transthyretin cardiac amyloidosis, or ATTR-CM. In it, the protein transthyretin (TTR) misfolds and damages the heart. The study looked at two forms: the wild-type form (ATTRwt-CM) and the hereditary form (ATTRv-CM). Until now, the authors write, the effects of these forms on blood vessels, and the effect of tafamidis on them, have been unclear.

The team applied serum, the liquid part of blood, from patients to the cells. Samples were taken before treatment and six months after starting tafamidis. Serum from elderly and young people without the disease served as controls. The researchers then measured cell survival, movement and stress responses. They also profiled inflammatory signals and proteins in the serum.

According to the paper, serum from patients with either form reduced the survival and movement of the cells. It also caused proteotoxic stress, meaning strain on the cell's systems for handling and clearing proteins, and oxidative stress, a form of chemical damage. The serum showed inflammation-related signatures. All of these effects were attenuated when cells were exposed to serum taken after tafamidis treatment. The abstract does not say by how much.

Purified, recombinant TTR also caused proteotoxic stress in the cells. Tafamidis added alongside it reduced that stress, within a concentration the authors call a safety range of up to 16 micromolar. This suggests the protein itself can be toxic to these cells.

The study also looked at people. Pulse wave velocity, a measure of arterial stiffness, was followed over time in patients with the wild-type form before and after tafamidis, and in elderly controls. It was lower in treated patients than in controls. The change tracked with higher serum transthyretin and lower proteasome activity in white blood cells. The proteasome is the cell's protein-disposal machinery. The abstract does not give the size of the change.

The authors conclude that tafamidis may have protective vascular effects beyond stabilising transthyretin in the heart muscle. That is an interpretation, not a proven result. Umbilical vein cells are not aged human arteries. Serum exposure in a dish is not the same as what happens in the body. The abstract does not describe how the patient groups were chosen, so conclusions about cause and benefit should wait for larger studies.

The findings also differ in kind from The Arising's October 15 report on brown fat scans, which described an association in about 100,000 patients. This study works mostly at the cell level, and its patient numbers are not given in the abstract, but it asks a similar question about how one condition may affect the body well beyond a single organ.

WHAT TO WATCH NEXT

What to watch next is whether larger studies in patients confirm the drop in arterial stiffness and show whether it changes outcomes such as strokes or heart events. Readers should not start, stop or change any medication without talking to their own clinician.

Sources: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2026), Amyloid (journal)

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. **Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial**
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

OPHTHALMOLOGY TIMES

Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial

For older adults with advanced dry macular degeneration, today's approved treatments can slow the damage but cannot bring back sight that is already lost. A one-time eye injection now headed for a new trial aims at that gap, though the evidence for this disease is still limited to animals.

This article is based on Ophthalmology Times's report of data shown at the American Academy of Ophthalmology meeting in New Orleans. The underlying paper was not reviewed.

The advanced form of dry macular degeneration is called geographic atrophy. According to Ophthalmology Times, it is estimated to affect around 1 million people in the United States. Two drugs were approved for it in 2023, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay). Both slow the growth of damaged areas in the retina. According to the report, neither has been shown to improve visual acuity, and no approved therapy restores function where light-sensing cells are already gone.

The new approach is called sonpiretigene isteparvovec, or son-vec, formerly MCO-010. It is an optogenetic therapy. According to Ophthalmology Times, a harmless virus delivers a gene for a light-sensitive protein into ON bipolar cells. These cells often survive after the photoreceptors degenerate. The cells then respond to light directly. The report says this approach does not target a specific mutation, and that the injection is given in the office.

The human data come from Stargardt disease, an inherited condition that damages the macula. According to the report, patients with vision of 20/200 or worse received a single injection. Those whose atrophy was limited to the macula gained an average of 12 letters on an eye chart. The report says the therapy was well tolerated, with no serious adverse events.

The report also describes an earlier published trial, called STARLIGHT, of six adults with Stargardt disease. At 48 weeks, average best-corrected acuity had improved by 5.5 letters. Acuity measured with a wearable magnifier improved by 13.3 letters. The reported side effects included conjunctival hemorrhage, ocular hypertension and vitreous cells. The report lists no deaths, hospitalizations, retinal detachments or endophthalmitis.

For geographic atrophy itself, the evidence is from animals. According to the report, monkeys with laser-induced lesions that model the disease showed stronger electrical responses in treated eyes than in untreated eyes. Those data have not been published in a peer-reviewed journal.

Several cautions apply. The report says the 12-letter figure comes from conference data. It does not give the subgroup size or the follow-up time, and the figure has not been published. Both Stargardt studies were open-label, with no masking or sham control. The people studied had an inherited disease, not age-related macular degeneration. Whether the effect carries over to older adults with geographic atrophy is unknown.

The investigators plan a randomized, controlled phase 2 trial in geographic atrophy, skipping a separate phase 1 safety study in that group. According to the report, positive results would lead to larger phase 2b/3a trials aimed at regulatory approval. The report says no registry record for the geographic atrophy trial could be identified. Those steps remain ahead, which is why any benefit for patients with this condition is still distant.

WHAT TO WATCH NEXT

The registration and launch of the geographic atrophy trial, and publication of the Stargardt subgroup data. Son-vec is not an approved treatment for geographic atrophy, and anyone considering starting or stopping any eye treatment should talk to their own clinician first.

Source: Ophthalmology Times

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. **Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness**
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 3 MIN

CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING · 2 SOURCES

Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness

Climbing a few flights of stairs at a brisk pace is easy to do anywhere. A small new study asked how much that simple act can reveal about aerobic fitness, a key marker of healthy aging. The answer, according to the researchers: something, but not much precision.

The work is a pilot study in people, published in 2026 in Clinical Physiology and Functional Imaging. It is observational. It compared stair-climbing measures with laboratory results in 28 adults aged 40 to 70 (20 women and 8 men). It was small, and the authors call their findings preliminary.

The researchers recruited healthy, sedentary adults in the Jyväskylä region. People with chronic diseases needing medication, a body mass index above 30, or regular moderate-to-vigorous exercise of more than 60 minutes a week were excluded. Smokers were also excluded.

Each person did two lab tests. One was a maximal treadmill test that measures VO2 max, the highest rate at which the body can use oxygen. It is a standard gauge of aerobic capacity. The other was a leg press test that measured the peak force the legs can produce while held still.

On a second visit, about a week later, participants climbed indoor stairs at a constant, self-chosen brisk pace. One climb was four flights (81 steps, 14.28 metres of vertical rise). The other was six flights (121 steps, 21.48 metres). The team recorded climb time and mean vertical power, which is body weight lifted over the height climbed, divided by time. They also recorded perceived exertion and heart rate right after each climb.

Faster climbs and higher vertical power were linked to higher VO2 max and stronger legs. The standardized coefficients, a measure of how closely two things move together, ranged from −0.61 to −0.27 for climb time and from 0.41 to 0.73 for vertical power. Climb time is negative because a longer climb time went with lower VO2 max and weaker legs, while higher vertical power went with higher values of both.

Those links did not hold up under a basic check. After the researchers accounted for age and sex, the associations weakened and were no longer statistically significant. Age and sex both affect how fast people climb and how fit they are, so the stair measures may have been partly reflecting those two factors.

The team then built prediction models. For each outcome, a statistical method called LASSO regression picked the two best stair-based predictors. For VO2 max, the models explained between 21% and 52% of the differences between people (R^2 of 0.21 to 0.52). The authors describe this as weak to moderate. Cross-validated performance, a test on data held back from model building, was significantly different from zero. The models did not significantly predict lower-limb strength.

The authors conclude that a short, self-paced stair test may be a feasible field-based way to estimate aerobic capacity in middle-aged and older adults. They add that its predictive accuracy appears limited and should be further examined in larger samples.

For anyone tracking VO2 max over the years, the study offers a caution about simple do-it-yourself tests. A stair climb is easy and needs little equipment, but this one gave a rough estimate, not a measurement. The participants were also a narrow group: healthy, mostly women, and not very active. The findings may not apply to other people.

WHAT TO WATCH NEXT

Larger studies that test whether stair-climb estimates hold up across more varied groups, and whether they can follow changes in fitness within the same person over time.

Sources: Clinical physiology and functional imaging (2026), Clinical Physiology and Functional Imaging (via PubMed)

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. **Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients**
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

THE BRITISH JOURNAL OF PSYCHIATRY · 2 SOURCES

Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients

People with depression who are night owls, sleep long hours and wake up exhausted may belong to a distinct group that responds less well to common antidepressants, according to a new Australian study.

The work is an observational, cross-sectional study, published in 2026 in The British Journal of Psychiatry. It drew on the nationwide Australian Genetics of Depression Study. Of the participants, 2,604 (23%) were classed as having a "circadian" subtype of depression. They were 80% female, with an average age of about 38. Observational means the researchers compared groups of people. They did not test a treatment.

The team defined the subtype by sleep and body-clock traits. A person qualified by meeting at least three of six features: social jetlag, seasonality, a late sleep midpoint, an evening chronotype (being a night owl), morning tiredness and hypersomnia (sleeping too much).

Compared with people without the subtype, this group reported an earlier age at onset. They also reported more severe features: (hypo)manic-like and psychotic-like experiences, suicidality, psychological distress and physical complaints. They reported weight gain during depressive episodes too. The study says all of these differences were statistically significant.

Medication findings were self-reported. The circadian group reported a poorer response to selective serotonin reuptake inhibitors, or SSRIs (odds ratio 0.88, 95% confidence interval 0.82 to 0.94). They also reported a poorer response to serotonin–noradrenaline reuptake inhibitors, or SNRIs (odds ratio 0.89, 0.83 to 0.97). An odds ratio below 1 here means lower odds of a good response. This group also reported more side effects.

The researchers also looked at polygenic risk scores, which add up many small inherited variations into one estimate of a person's genetic tendency toward a trait. The circadian group scored higher for ADHD, major depression, anxiety and bipolar disorder, with odds ratios of 1.09 to 1.11. They also scored higher for body mass index, triglycerides, interleukin-6 (an inflammation marker) and insulin resistance, and for later sleep midpoint and insomnia. These effects are modest, and they are links, not causes.

The design has limits. Data were collected at one point in time, so it cannot show that body-clock disruption causes depression or poor drug response. The authors say the findings support the face validity and potential clinical utility of the subtype as a clinical profile. They add that independent replication is needed, and that its biology and predictive value need further study.

The University of Sydney's coverage of the study went further than the abstract. It said the subtype is more responsive to light therapy, melatonin and melatonin-targeted antidepressants. The abstract reports no test of those treatments. The coverage also put the full sample at more than 10,000 people. Co-senior author Dr Jacob Crouse was quoted there saying that treatments targeting the circadian rhythm "may be much more relevant." Professor Ian Hickie said not recognising the subtype in young people often led to early treatment failures and more side effects.

WHAT TO WATCH NEXT

What to watch next is whether other research groups reproduce the subtype, and whether trials show that body-clock-focused treatments work better for it. Anyone considering a change to their depression care should not start or stop any treatment without talking to their own clinician.

Sources: The British Journal of Psychiatry (2026), The University of Sydney (British Journal of Psychiatry)

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. **Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes**
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 3 MIN

DIABETES · 2 SOURCES

Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes

People with type 1 diabetes and kidney disease looked about two years older on a DNA-based age measure than people with type 1 diabetes whose kidneys were spared, according to a new study in the journal Diabetes.

The work is an observational study in people. It cannot show that faster biological ageing causes kidney damage. Researchers analysed two groups of people with type 1 diabetes: 464 in the UK and Republic of Ireland cohort and 795 in the Finnish Diabetic Nephropathy (FinnDiane) cohort. In each, some had diabetic kidney disease (the cases) and some did not (the controls). Only the abstract was available to us, so details beyond it are not covered here.

The study used epigenetic clocks. These are tools that read chemical marks on DNA, called methylation, to estimate how old the body is biologically rather than by the calendar. The team generated 10 different clocks. They also compared telomere length measured in the lab with telomere length predicted from methylation. Telomeres are the protective caps on the ends of chromosomes.

Two measures stood out. A higher PhenoAge score and a shorter methylation-predicted telomere length were both linked to greater odds of diabetic kidney disease. These results were adjusted for age, white blood cell proportions and sex. For the principal-component version of PhenoAge, the odds ratio was 1.4 (95% confidence interval 1.2–1.8) in the UK and Ireland group and 1.8 (1.5–2.1) in the Finnish group. For predicted telomere length, the odds ratios were 0.6 (0.5–0.8) and 0.7 (0.6–0.8). Values below 1 mean that longer telomeres went with lower odds.

The authors also reported a male-specific link between kidney disease and DunedinPACE, a clock that estimates the pace of ageing. The odds ratio was 1.3 (1.0–1.7) in the UK and Ireland group and 1.5 (1.3–1.8) in the Finnish group. The abstract does not explain why the link appeared in men, so that remains an open question.

The researchers then looked at change over time. In one analysis, 52 people had methylation measured twice, a median of 7.5 years apart. Progression from normal albumin levels in the urine to severely increased levels, a sign of worsening kidney damage, was associated with increased epigenetic age acceleration.

A second analysis followed 384 people who already had kidney disease for a median of 7.7 years, using Cox regression to look at who progressed to end-stage kidney disease. Chronological age, epigenetic age and age acceleration were all significant predictors. For PhenoAge acceleration, the hazard ratio was 1.07 per year (1.03–1.11; P = 0.0011). The C-index was 0.67. That statistic runs from 0.5, no better than chance, to 1.0, perfect. So the signal is real but modest on its own.

The authors conclude that these epigenetic markers show accelerated biological ageing linked to diabetic kidney disease and to progression to end-stage kidney disease. They say the results support developing epigenetic biomarkers to predict onset and progression. That is a goal, not a current test. The abstract does not say whether the markers add information beyond the standard kidney tests now used in clinics.

This study differs from the paper's October 18 report on longer sleep and kidney disease risk in type 2 diabetes. That story concerned a behavioural signal in a different type of diabetes. This one concerns a molecular signal in type 1. Both are observational and point to possible early warning signs.

WHAT TO WATCH NEXT

Studies that test whether epigenetic age measures can flag kidney risk earlier or more accurately than the tests already in use, and whether the findings hold in more varied groups of people.

Sources: Diabetes (2026), Diabetes

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. **Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds**
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

MEDRXIV PREPRINT, NOT PEER REVIEWED · 2 SOURCES

Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds

Epigenetic age tests promise to measure how fast a body is aging. A new pooled analysis suggests that, for dementia, most of them say little.

The work is a systematic review and meta-analysis posted on medRxiv as a preprint. A preprint has not been peer reviewed, so other experts have not yet checked it. The authors, led by Kua Z, combined 37 observational studies covering 46,365 people with seven Mendelian randomization studies. Observational studies can show links between two things. They cannot show that one causes the other.

These tests read DNA methylation, which are chemical tags on DNA that change with age. Different "clocks" turn those tags into an estimate of biological age. "Epigenetic age acceleration" means the estimate is older than the person's actual age.

The team searched six databases for studies from January 1, 2011 to April 15, 2026. They screened 42,023 records. The studies looked at all-cause dementia, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis. Participants were 60.5% female. The median of the studies' average ages was 69.4 years.

In the longitudinal analyses, which follow people over time, only one clock showed a clear link to dementia. Higher GrimAge acceleration was associated with higher dementia risk. The hazard ratio was 1.11 per standard deviation (95% confidence interval 1.02 to 1.20; p = 0.018). In plain terms, that is about 11% higher risk for each step up on the scale, and the range of plausible values runs from a very small increase to about 20%.

Four other measures were not significantly associated with dementia risk: Horvath1, Hannum, PhenoAge and DunedinPACE. The authors say GrimAge was the only DNA methylation age measure that consistently predicted higher all-cause dementia risk.

Results for the other neurodegenerative diseases were mixed. According to the abstract, the evidence varied across clock generations and study designs. Mendelian randomization, a method that uses genetic variation to probe cause and effect, gave limited evidence that faster epigenetic aging drives these diseases.

The authors conclude that the clocks show limited and inconsistent associations with neurodegenerative disease. They say this is insufficient support for using them as disease biomarkers.

For anyone weighing a consumer epigenetic age test, the message from this analysis is cautious. A group-level link, as seen with GrimAge, is not the same as a reliable prediction for one person. The abstract does not report how well any clock sorts individuals into higher or lower risk. It also does not say which commercial tests use which clocks, so that is unverified.

The authors call for disease-specific clocks that are independently validated. They also want pathway analyses to show which methylation changes relate to neurodegeneration and what biology they reflect. Watch for peer review of this preprint and for tests of newer, dementia-specific clocks.

Sources: medRxiv preprint, not peer reviewed (2026), medRxiv

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. **Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers**
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 1 MIN

PUBLIC HEALTH

Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers

Morning or evening? A new review in Public Health takes on one of the most common questions about exercise: does the time of day change what a workout does for heart and metabolic health?

According to Public Health's listing, the paper is titled "Timing of supervised exercise and cardiometabolic risk markers in adults: A systematic review and meta-analysis of randomized controlled trials." A systematic review gathers studies on one question using a set method. A meta-analysis pools their results. Randomized controlled trials assign people to a group by chance, which is the strongest design for testing an intervention. Cardiometabolic risk markers are measurable signs linked to heart disease and metabolic conditions.

This article is based on that listing, and the paper itself was not reviewed. The text available to us contained the title but no findings, so we are not reporting results, sample sizes or effect sizes here.

The title does show the review's scope. It concerns supervised exercise in adults. That is an interpretation, not a reported finding, but it leaves open whether any result would apply to people who exercise on their own, where timing is often less controlled.

A clear answer would matter either way. A real timing effect could shape when people schedule exercise. No effect would mean other factors count for more. Which of these the review supports is not something we can say from the material available.

WHAT TO WATCH NEXT

The full paper's results, including which markers were measured, how large any differences were, and how consistent they were across the pooled trials. Anyone considering a change to their exercise routine should talk to their own clinician before starting or stopping anything.

Source: Public Health

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. **Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics**
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics

26 Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk
27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

LONGEVITY.TECHNOLOGY

Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics

People in the UK with type 2 diabetes or obesity may soon be able to try a medically supervised fasting-based programme through their clinic, and the first practice began enrolling patients this week.

According to Longevity.Technology's report, L-Nutra Health has launched a clinician-led metabolic health programme in the United Kingdom. It is the first time the programme has been offered to clinics and medical practices here. It is built on more than 25 years of research led by Dr Valter Longo.

The programme centres on the Fasting Mimicking Diet. Longevity.Technology says the company describes it as a patented, plant-based nutrition plan. The idea is to follow a specific eating pattern for a short period, in cycles, rather than fast completely.

According to the report, the programme combines periodic cycles of the diet with personalised nutrition consultations, laboratory review and ongoing monitoring. It also includes medical oversight where a patient's medication needs supervision. That matters for people with diabetes, whose medicines may need attention when eating patterns change.

Under the model described, partner practices supply the clinical team, nutrition professionals and laboratory testing. L-Nutra Health provides the diet kits, practitioner training and patient materials. The report says this follows the model the company runs in the US.

On the evidence, Longevity.Technology reports that the company claims the diet is shown in clinical trials to support improvements in blood glucose, insulin sensitivity and body weight. The company's release cites a 12-month randomised controlled trial in primary care, published in Diabetes Care in 2024. It also cites real-world results presented at the American Diabetes Association in 2025. These are the company's claims as relayed by the report. The coverage does not give trial sizes or results, and it does not say they were independently assessed.

This article is based on Longevity.Technology's report of the research. The underlying papers were not reviewed. Cost was not disclosed in the report.

According to the report, the first UK practice, HealthMatters Group in London, began enrolling patients on 20 October 2026. What to watch next: whether other UK practices join, what the programme costs, and whether independent results from UK patients match the figures the company cites. Anyone considering a change to their diet or diabetes care should not start or stop anything without talking to their own clinician.

Source: Longevity.Technology

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. **AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's**
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27. AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28. Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29. Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30. Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

---

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

STAT

AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's

A company that uses artificial intelligence to decide which drugs to develop is turning its attention to Alzheimer's disease, and a major drugmaker is putting money behind the move.



Photo: "Generic Drug Research (5896) (8493711422)" by The U.S. Food and Drug Administration, Public domain

According to STAT, Pathos announced on Friday that it is raising $237 million in a Series E funding round led by Bristol Myers Squibb. The round values Pathos at about $3 billion.

Pathos has worked in cancer drug development. It is now expanding into neurological conditions. STAT reports that the move relies on new datasets from Tempus AI and on a partnership with Bristol Myers Squibb that will first focus on Alzheimer's treatments.

The reason for the bet is a familiar problem. STAT notes that most drugs that enter clinical trials never reach patients. Pathos' pitch, according to STAT, is that AI can improve those odds.

Its system is called Foundry. It runs thousands of software agents, which are programs that each work on a piece of the analysis. They calculate the probability that a drug the company is developing will succeed. STAT says they look at clinical data, genomics, data from biological specimens and competition from other developers.

That analysis guides three kinds of choices, according to STAT: which drugs to pursue, which groups of people to test them in, and how to design the clinical trials.

For people interested in healthspan, the relevance is indirect. Better choices about drugs, patients and trial design could, in principle, make dementia trials more likely to give clear answers. That is an interpretation of the company's pitch, not a finding.

It is also important to be clear about what this news is. It is a funding and partnership announcement. The portion of the STAT story available to us reports no patient results, no named Alzheimer's drug and no trial data. Whether Foundry's probability estimates are accurate, or whether they improve on how drugs are chosen today, is not shown in that text.

Much of the STAT article is behind a subscription wall, so details such as the specific drug candidates and timelines are not covered here.

WHAT TO WATCH NEXT

Whether the Bristol Myers Squibb partnership names Alzheimer's drug candidates and begins clinical trials, and whether any results from those trials are published.

Source: STAT

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. **APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially**
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 3 MIN

CARRIER MANAGEMENT

APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially

Most American adults now treat stress as a fact of life, and nearly half say it has led them to pull back from other people, according to the American Psychological Association's 2026 Stress in America survey.



Photo: "Woman Working" by Kristin Hardwick, CC0

The survey was conducted online by The Harris Poll for the APA among 3,132 U.S. adults ages 18 and older. It ran from July 29 to August 24, 2026. It also included extra samples of Black, Latino/a/e and Asian adults. The findings are self-reported opinions from one survey, not measurements of health.

Money and the national outlook were the two stressors the APA highlighted. According to the APA, 77% of adults cited the cost of living as a significant source of stress, including rent or mortgage, groceries and childcare. Another 74% cited the future of the nation.

The more striking finding is how people have come to see that stress. About 72% agreed with the statement "stress is just something I have to live with." The same share (72%) said bad news no longer shocks them the way it used to. And 68% said they have become accustomed to living with uncertainty.

APA CEO Arthur C. Evans Jr., Ph.D., drew a line between getting used to stress and coping well with it. "Becoming accustomed to chronic stress is not the same as adapting to it in a healthy way," he said. He added that chronic stress can take a serious toll on physical and psychological well-being.

The survey did not test how to tell the two apart. But its results show what accepting stress can look like in daily life. Nearly half of respondents (47%) said they had pulled back from at least one form of social engagement over the past year because of stress, uncertainty or feeling overwhelmed. Nearly three in five (59%) felt they were doing everything "right" but still falling behind. More than half (56%) said they had lowered their expectations for what they could achieve in life.

Some people may also be changing where they turn for support. Among surveyed AI users, 49% said they had conversations with AI as a friend, and 47% said they used it in a role comparable to a mental health professional. One in 10 said they relied on AI more than friends and family for advice.

Evans cautioned against reading too much into that convenience. "Accessibility, however, should not be confused with expertise," he said. In his view, AI tools may play a supportive role. But they cannot replace the clinical judgment of a psychologist or other qualified mental health professional, or the human connection of family and friends.

There are limits to what this survey can say. It captures what people reported at one point in time. It does not show whether stress led to withdrawal or the reverse. It does not link either to health outcomes such as illness or lifespan. The Carrier Management report does not describe how respondents defined social withdrawal or what kinds of activities they dropped.

FOR YOU

For readers interested in healthspan, the survey raises a question rather than answering it. When stress feels normal, does it stop being noticed? The APA's position, as stated by Evans, is that healthy coping strategies, meaningful connections and accessible support can help protect health, relationships and the ability to pursue goals, even when stressful circumstances persist.

WHAT TO WATCH NEXT

Whether future Stress in America surveys show the share of adults who accept stress and pull back from others rising or falling, and whether researchers test how those habits relate to long-term health.

Source: Carrier Management (reporting APA Stress in America 2026)

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. **Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use**
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics

26 Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk
27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

NATURE COMMUNICATIONS · 2 SOURCES

Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use

Arteries can slowly fill with mineral deposits that make them stiff, and a new study in mice points to a cell-level energy switch that may drive the process.




Photo: "Black-mouse-in-gloved-hands" by Commissioned by Understanding Animal Research, CC BY-SA 4.0

The work is preclinical. According to the paper in Nature Communications (2026), the researchers tested a small protein fragment in cell experiments and in mouse models of vascular calcification. Only the abstract was available to us, and it does not give the number of mice or the size of any effect. No people were treated.

Vascular calcification is the build-up of calcium deposits in artery walls. It is a major cause of death in people with chronic kidney disease, the study notes. Fight Aging!, which covered the paper, adds that it also becomes more common with age and can raise blood pressure. Calcification of heart structures such as the aortic valves is ultimately fatal, it says.

The study centers on a micropeptide, a protein fragment only 40 amino acids long. The authors named it PKM2 AP. It is made from a stretch of the genome that does not code for ordinary proteins. It sits in both the mitochondria, the cell's power units, and the surrounding cytoplasm.

PKM2 AP binds an enzyme called PKM2, which helps cells burn sugar without using oxygen. This process is called aerobic glycolysis, and it produces lactate. According to the abstract, PKM2 AP acts as a "molecular glue". It brings a cellular tagging enzyme, STUB1, to PKM2. The tag marks PKM2 for breakdown.

With less PKM2, the abstract reports, sugar burning and lactate production fall. That in turn dampens the shift of artery cells toward a bone-like state, which the authors link to calcification. The abstract states that giving PKM2 AP to mice, or genetically editing mice to carry the gene's second reading frame, alleviated calcification features in mouse models.

Fight Aging! quotes the paper's introduction on two further points. Experiments in human aortic smooth muscle cells showed the same drop in sugar burning and lactate. And PKM2 AP was found at high levels in patients with kidney-disease-related calcification. That last finding is an association. It does not show the peptide is the cause, and it is unclear from the available text whether high levels reflect a protective response.

For people living with kidney disease, the context is a lack of options. The paper's introduction, as quoted by Fight Aging!, says that intensified dialysis regimens and phosphate binders have not been enough to halt calcification. Fight Aging! itself adds that EDTA chelation has shown modest benefit at best, and cautions that slowing calcification is not the same as reversing it.

Much remains unknown. Mouse results often fail to carry over to people. The abstract does not report dosing, safety, how a peptide would be delivered, or how long any benefit lasts.

WHAT TO WATCH NEXT

Whether the effect is confirmed in other labs and animal models, and whether safety data appear before any human trial. Readers should not start or stop any treatment without talking to their own clinician.

Sources: Nature Communications (2026), Fight Aging! (reporting a Nature Communications paper)

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. **Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause**
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics

26 Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk
27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 3 MIN

THE MENOPAUSE SOCIETY

Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause

Women who use hormone therapy after menopause may have migraines that come more often and last longer, according to The Menopause Society's report of a new analysis. But the same report says the findings may not mean the therapy is the cause.

This article is based on The Menopause Society's report of the study. The paper itself was not reviewed. The work will be presented at the society's 2026 Annual Meeting in San Diego, October 20–24, so it is a conference presentation.

According to the report, researchers set out to look at how hormone therapy relates to migraine in postmenopausal women. They looked at how often migraines occur, how severe they are, how often they happen, how long they last and how much pain medicine is used. They did this regardless of how the hormone therapy was taken.

The Menopause Society says the analysis was a systematic review and meta-analysis. That means it combined results from earlier studies. According to the report, it drew on five studies that together included nearly 24,000 women. The pooled analysis showed an average migraine incidence of 18.94%.

The Menopause Society reports that hormone therapy was linked to more frequent migraine attacks and longer migraine episodes. It also reports that the researchers found no significant differences in the number of pain relievers used per month or in migraine severity scores.

Context matters here. According to the report, migraines are estimated to affect 10% to 29% of women during the menopause transition. They often worsen and become more frequent then, especially in perimenopause. The society attributes this to unpredictable drops in estrogen. Hormone therapy is described as effective for bothersome menopause symptoms, especially hot flashes. A challenge is that changes in estrogen levels may influence migraine.

The report urges caution on cause. Dr. Stephanie Faubion, medical director for The Menopause Society, says women with migraine may be more likely to seek treatment for menopause symptoms. The findings, she says, may reflect underlying differences between women who use hormone therapy and those who do not. In other words, the link could run in either direction, or come from something else. She adds that more research is needed before conclusions are drawn about the effect of hormone therapy on migraine burden.

Faubion also says hormone therapy remains the most effective treatment for bothersome vasomotor symptoms, such as hot flashes, and can be used safely in many women with migraine.

Dr. Flavia Fairbanks Ruano of the University of Miami Miller School of Medicine, the lead author, says more research is needed to understand the relationship and to help guide individualized treatment decisions. The report says further clinical trials are needed to understand the biology and to guide more effective treatments.

What this means for personal decisions is not yet settled. The report does not offer a list of questions for women with migraine. It does point to one open issue: whether any added migraine burden comes from the therapy itself or from who chooses it. Those are questions for a woman and her own clinician to weigh together.

On a related topic, The Arising reported on October 21 that FIGO and the International Menopause Society urge long-term hormone therapy for women with early menopause. That is a separate matter from this analysis, which looks at migraine in postmenopausal women, so the two add different pieces to the wider picture of hormone therapy.

Watch for the full presentation and any peer-reviewed paper, which would show how the studies were chosen and how strong the findings are, along with the clinical trials the researchers say are needed. Readers should not start or stop any treatment without talking to their own clinician.

Source: The Menopause Society

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. **Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults**
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 1 MIN

JOURNAL OF EXERCISE SCIENCE AND FITNESS

Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults

A new systematic review asks a practical question for people past midlife who sleep badly: which kind of exercise helps, and how much?

The paper is titled "Comparative effects of exercise modalities on sleep quality in middle-aged and older adults with sleep disorders: A systematic review with pairwise, network, and dose-response meta-analyses." It appears in the Journal of Exercise Science & Fitness.

The title points to three ways of pooling earlier studies. A pairwise analysis compares two approaches head to head. A network analysis ranks several approaches against one another. A dose-response analysis looks at how results change with the amount of exercise.

This article is based on the journal's listing of the study. The paper itself was not reviewed. The listing page did not show any results, so the findings, the number of trials and participants, and any amount of exercise linked to better sleep could not be confirmed.

The question still matters. If certain types or amounts of exercise stand out, that could shape how clinicians and older adults think about managing sleep disorders. If no clear pattern emerges, that would be useful to know too.

WHAT TO WATCH NEXT

The full text, which should show which exercise types were compared, what amounts were examined, and how strong the underlying trials were. Anyone considering a change in exercise, especially with a sleep disorder, should talk to their own clinician before starting or stopping anything.

Source: Journal of Exercise Science and Fitness

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. **2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70**
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

MEDRXIV PREPRINT, NOT PEER REVIEWED · 2 SOURCES

2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70

Among 2,711 people whose brains were examined after death in São Paulo, Alzheimer's-type changes at levels a current biomarker test can detect were uncommon before age 70, and brain disease that those tests do not detect was linked to cognitive impairment about as often as advanced Alzheimer's changes were.

The evidence is an observational autopsy study in people, posted as a preprint on medRxiv. A preprint has not been peer reviewed, and only the abstract was available to us, so details beyond it are unverified.

The researchers used the Biobank for Aging Studies of the University of Sao Paulo. Decedents were sampled through the city's centralized autopsy service, which performs about 15,000 autopsies a year and verifies about 16% of deaths in the city. The cohort covered 2004 through 2025. It included adults with complete amyloid, tau, dementia-rating and coexisting-pathology assessments. Mean age was 73.4 years, the range was 23 to 111, and 1,340 (49.4%) were female.

Amyloid and tau are two proteins that build up in Alzheimer's disease. The team staged each using standard tissue measures: Thal phase for amyloid and Braak stage for tau tangles. They defined the range a biomarker could detect as Thal phase 3 to 5 together with Braak stage IV to VI.

Of the 2,711 decedents, 531 (19.6%) met both thresholds. Another 270 (10.0%) met the amyloid threshold only, 207 (7.6%) the tau threshold only, and 1,703 (62.8%) neither. So the two markers disagreed in 17.6% of cases, according to the authors.

Age mattered a great deal. The combined state was found in 0% of those aged 23 to 50. It rose to 5.5% at ages 61 to 70, 14.5% at 71 to 80, 36.5% at 81 to 90, and 45.9% at 91 to 111.

Cognitive impairment, defined here as a Clinical Dementia Rating above 0, tracked tau stage. It was present in 88 of 541 people (16.3%) at Braak stage 0 and 155 of 179 (86.6%) at stage VI.

The second finding concerns other causes. The authors counted contributing coexisting brain disease, which amyloid and tau tests do not detect. Impairment was present in 225 of 1,467 people (15.3%) with neither type of pathology. It was present in 204 of 349 (58.5%) with coexisting disease alone, 216 of 339 (63.7%) with amyloid-tau pathology alone, and 165 of 192 (85.9%) with both.

In a statistical model of dementia severity, coexisting disease had the largest unique contribution (partial R2 0.088). Braak stage accounted for the largest share of total explained variance. These are associations in a cross-sectional study. They do not show that either pathology caused the impairment.

For reading a test result, the authors conclude that these tissue-based frequencies can help interpret positive and negative biomarker results. In plain terms, a positive result is less common in younger people. Impairment in someone with a negative result, or a positive one, may still involve other brain disease. The abstract does not say how individual patients should act on this.

This adds a different angle to our October 20 report on a mouse study of brain immune cells and sleep in Alzheimer's. That work was in animals. This one looks at human brain tissue and suggests Alzheimer's is often not the only factor.

Next to watch: peer review of this preprint, and whether other autopsy cohorts with different populations find the same age pattern and the same role for coexisting disease.

Sources: medRxiv preprint, not peer reviewed (2026), medRxiv

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. **Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing**
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN SCIENCE ADVANCES · 2 SOURCES

Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing

Childbirth leaves a measurable mark on the body, and for many measures it takes months to fade. A large analysis of routine lab tests found that about half of 76 tests needed between three months and a year after delivery to return to baseline. Whether recovery time shapes long-term aging is a hypothesis proposed by a recent review, not an established finding.



Photo: by nenadstojkovicart, CC BY 2.0

The work was published in Science Advances in 2025 by Bar, Alon and colleagues. It is an observational, cross-sectional analysis of existing lab records, not a trial. It covers 44 million measurements from more than 300,000 pregnancies. A cross-sectional design compares many women at different points in time rather than following the same women throughout.

The team looked at each test week by week, from 20 weeks before conception to 80 weeks after delivery. That gave a detailed timeline for each measure. According to the study's abstract, the slow return to baseline highlights the physiological load of childbirth.

The abstract reports several other findings. The precise timing showed effects of supplements taken before conception. It also showed overshoots after delivery, where a measure swings past its baseline before settling. And it showed complex responses to changes in blood volume and in the kidneys' filtration rate. Three complications, gestational diabetes, preeclampsia and postpartum hemorrhage, each showed distinct patterns over time.

What the study does not say matters too. Based on the abstract, which was the only part available to us, it does not measure biological age or use aging clocks. It does not follow long-term health, and it does not test whether the gap between pregnancies changes anything. The abstract does not give details on which tests recovered slowly, so we do not report them.

The aging link comes from other work. Longevity.Technology reported on a new review in Trends in Endocrinology & Metabolism by Stephen Albright and Jesse Poganik of Brigham and Women's Hospital, funded by Hevolution. They propose a "recovery period hypothesis": the time between delivery and the next conception may decide how fully a mother's biological age returns to its earlier course. According to the coverage, the review presents this as a hypothesis. It does not claim that pregnancy permanently ages women or that any particular interval guarantees recovery.

The coverage also cites a study of 130 women followed for nearly four years after birth. Those who conceived again showed a disrupted postpartum slowing in DunedinPACE, a measure of the pace of aging. That is a small study. The coverage notes a further caveat from the review's authors: most aging clocks were trained outside pregnancy and may read normal adaptation as damage.

The large lab-test study and the aging hypothesis are separate pieces of evidence, and the coverage joins them more tightly than the study does. Slow lab recovery shows the body is under load after birth. It does not show that this load speeds aging for life. Poganik told Longevity.Technology that factors affecting the clocks are likely multiple, not one lever.

For now, the open question is whether the length of recovery changes long-term health, and the evidence cannot yet say. The weakest point in the argument is that the lab study and the aging-clock work measure different things. Watch for studies that apply aging clocks across the postpartum period, since the review sets out the study designs it says are needed to test its predictions, and Poganik said applying clocks in this kind of study would be "super interesting."

Sources: Science Advances (2025), Longevity.Technology

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. **Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics**
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

BMC GERIATRICS · 2 SOURCES

Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics

In a small randomised trial of adults aged 65 and older with type 2 diabetes, a Mediterranean-style diet, resistance exercise and the drug empagliflozin all improved blood sugar control, and the differences between them were not statistically significant.



Photo: "Fitness programming Greenville Aquatics &", CC0

The findings come from a secondary analysis of the CEV-65 randomised controlled trial, published in BMC Geriatrics in 2026. The trial enrolled 100 older adults with type 2 diabetes. A secondary analysis looks again at data from a completed trial, this time with a new question. Here, the question was about cost and value as well as clinical results. The authors describe their findings as exploratory.

The trial compared three approaches. One was a Mediterranean diet, called VegMedD in the paper. One was empagliflozin, a drug in the SGLT2 inhibitor class. One was circuit resistance training, a form of exercise built around strength work. The researchers tracked HbA1c, a common measure of average blood sugar over recent weeks. They also tracked frailty, a state of increased vulnerability that comes with age and raises the risk of falls, hospital stays and disability.

All three interventions improved glycemic control, according to the abstract. Frailty improvements were modest. The abstract does not give the size of the changes, so this article does not either.

The drug did best on one measure. The researchers defined a "responder" as someone who improved on both HbA1c and frailty. Empagliflozin had the highest responder rate. The diet and exercise arms were substantially less costly. On a cost-effectiveness analysis built around the responder measure, the lifestyle arms cost less but were less effective.

A second analysis gave a different picture. It used quality-adjusted life years, or QALYs, which combine length of life and quality of life into one number. The team estimated QALYs from SF-12 questionnaire data, using a validated mapping method. On this measure, both the diet and the exercise interventions were "economically dominant". That means they cost less and produced more QALYs than the drug under current pricing. The diet had the highest probability of being cost-effective across conventional willingness-to-pay thresholds.

The authors tested how sturdy these conclusions were. The responder-based results were sensitive to assumptions about drug pricing. The QALY-based results held up comparatively well. The study team used adjusted regression models, propensity score weighting and probabilistic sensitivity analyses.

The limits matter. The follow-up lasted only 10 weeks, and the sample was small. The authors say the results should not be extrapolated to long-term comparative effectiveness. They point in particular to the established long-term heart and kidney benefits of SGLT2 inhibitors, which a 10-week study cannot capture. The abstract also does not say how the cost figures were built beyond the pricing scenarios, so the economic results rest on the trial's own assumptions.

The authors conclude that treatments with similar short-term clinical results can differ in economic and population health value. In the short term, they say, lifestyle strategies had more favourable cost–utility profiles. That is a statement about value

over 10 weeks. It is not a finding that lifestyle changes are better than medication over the long run.

WHAT TO WATCH NEXT

Longer trials that follow older adults with diabetes for years, and that track heart, kidney and frailty outcomes alongside costs, would show whether the short-term value seen here lasts. Readers should not start or stop any diet, exercise programme or medication without talking to their own clinician.

Sources: BMC Geriatrics (2026), BMC Geriatrics

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. **Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk**

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 3 MIN

BMC MEDICINE · 2 SOURCES

Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

Ultra-processed food is often discussed as one thing, but a new review in BMC Medicine finds that its subtypes may not move type 2 diabetes risk in the same direction.



Photo: by Zhungon Yaue SZLIJ Poau, CC BY-SA 4.0

The paper is a systematic review of observational studies, combined with a new analysis of one large cohort. The review covered 6 cohort studies with 635,332 adults who did not have type 2 diabetes at the start. Follow-up ranged from 6 to 26.1 years. The authors screened 222 articles to find those six. Observational studies can show links. They cannot show cause.

The authors sorted ultra-processed foods into eight subtypes: breads and cereals; sauces, spreads and condiments; sweets, snacks and confectionery; dairy products; packaged snacks; artificially and sugar-sweetened beverages; meat-based products;

and ready-to-eat dishes. They did not pool the results into one number. The studies measured intake in different units and adjusted for different factors, so the team looked at the direction of each association instead.

According to the review, most studies found that ultra-processed ready-to-eat dishes, meat-based products, and artificially and sugar-sweetened beverages were positively associated with type 2 diabetes. Ultra-processed dairy products, and sweets, snacks and confectionery, were generally inversely associated, although results varied. An inverse association means higher intake was linked to lower diabetes risk. It does not show that those foods protect against the disease.

The authors also caution about the evidence itself. They rated the overall risk of bias as moderate to high in all included studies. That means the individual findings should be read with care.

Their central argument concerns definitions. In causal reasoning, a question about an intervention should be clearly defined. If one label covers foods with different effects, results are hard to interpret and hard to apply elsewhere. The authors give an example from earlier research: a higher intake of total potatoes was linked to higher diabetes risk, but when split up, the higher risk appeared only for French fries, not for boiled, baked or mashed potatoes.

To show how grouping can hide patterns, the team ran a post-hoc analysis in the Danish Diet, Cancer and Health cohort, which included 52,201 participants. They built a fictive group called the "terrible five": sugar-sweetened beverages, processed meat, red meat, refined grains and vegetables. The first four have been linked to higher diabetes risk in earlier cohorts, and vegetables to lower risk. The combined group was positively associated with type 2 diabetes, while vegetables on their own were inversely associated. The authors stress that this group is not meant to represent ultra-processed food. It is an extreme example of how mixing very different foods can mask individual associations.

For personal choices, the study suggests that the category label may say less than what is actually in the food. For policy, the authors conclude that broad groupings like ultra-processed food could have unintended consequences and may hamper policies built on them unless the definition or the mechanistic understanding improves. The study does not test any diet and does not recommend one.

This adds to The Arising's October 20 report on a review of 46 studies, which found ultra-processed food and heart disease research methodologically weak. That was a different review on a different outcome. Both point to limits in the evidence, and this

one adds a question about whether the category is defined well enough to study.

WHAT TO WATCH NEXT

Studies that measure specific ultra-processed subtypes with better methods, and any work that clarifies the mechanisms behind the differences. Nobody should start or stop any food or eating pattern without talking to their own clinician.

Sources: BMC medicine (2026), BMC Medicine

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 **AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing**
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

LONGEVITY.TECHNOLOGY

AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing

A molecule just nine amino acids long may be the next test of whether the immune system can be taught to clear out aging cells, but so far the evidence comes from the company that made it.



Photo: “Monoclonal antibodies (8)” by Linda Bartlett (Photographer), Public domain

According to Longevity.Technology's report of a company announcement, Immorta Bio of Miami says it has finished its planned preclinical studies of SenoMune-0257. That is a synthetic peptide, a short chain of amino acids, designed to help the immune system recognize and remove senescent cells. This article is based on that report. The company's data and the underlying paper were not reviewed.

Senescent cells are often called "zombie cells." They have stopped dividing but have not died. According to the report, the company says they contribute to chronic inflammation, tissue deterioration and the progression of many diseases. The report says the company also points to benefits from removing them in experimental models of conditions including cardiovascular disease, fibrosis, neurodegeneration and cancer, and to improved physical function and longer lifespan in mice.

Drugs that kill senescent cells directly are called senolytics. Per Longevity.Technology, Immorta cites two limits: possible off-target toxicity and the inability to build lasting immune memory. Its approach is different. The peptide is meant to prompt the body's own T cells to find and remove senescent cells.

According to the report, the company says AI helped find the peptide. Thomas Ichim, president and chief scientific officer, is quoted saying the team identified dozens of candidates and narrowed them through computational analysis and laboratory experiments to SenoMune-0257.

In laboratory studies, the report says, the peptide stimulated cytotoxic T cells, the immune cells that kill targets. These cells selectively eliminated senescent cells while sparing healthy ones, "under the conditions tested," in the company's words. The report does not give numbers, sample sizes or published data for those results.

The company describes the candidate as a potentially universal, off-the-shelf product. That would be a simpler design than the complex cellular immunotherapy it built earlier, called SenoVax. The company says the peptide is designed to offer durable immune memory, fewer off-target effects and lower manufacturing costs than personalized cell therapies. Those are design goals. They have not been shown in people.

The timeline is short. According to the report, Immorta is preparing for clinical entry in 2026, with initial human evaluation expected before year-end. The report notes the company does not say whether a regulatory application has been filed, where a trial would be held or how many people would take part. Chairman and CEO Boris Reznik called senolytic immunotherapy "a fundamental breakthrough." That is a statement of belief, not a result.

For anyone thinking about healthspan, the reality check is plain. The idea of clearing senescent cells is widely discussed. This particular approach rests on company-reported lab work, with no human data yet. Whether a peptide that worked in the lab will behave the same way in people is unknown. Nothing here is something a person can use.

WHAT TO WATCH NEXT

Whether the first human dosing happens by year-end as the company expects, and whether Immorta releases detailed data or peer-reviewed results alongside it. Do not start or stop any treatment without talking to your own clinician.

Source: Longevity.Technology

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 **Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study**
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

NATURE COMMUNICATIONS · 2 SOURCES

Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study

Eggs age, and so far scientists have understood that process mainly through the RNA messages inside them. A new study in Nature Communications looked at the proteins instead, and found a possible metabolic lever: a protein called MCT4, which moves lactate out of the cell.



Photo: by David McClenaghan, CSIRO, CC BY 3.0

This is laboratory research on individual egg cells (oocytes) from mice and humans. It is not a clinical trial, and nothing in the available text describes a treatment given to people. Only the paper's abstract and introduction were available for this article, so some details are not reported here.

Falling egg quality is a major risk factor for female infertility. According to the paper, human fertility declines significantly after age 35. Aged eggs can show irregular maturation, mitochondrial defects and reduced fertilization capacity. The authors also note that not all aged eggs are affected: eggs from similarly aged females can differ in how well they mature and get fertilized.

Earlier work mostly measured RNA. Proteins are the molecules that carry out most cell functions, and the authors say they track poorly with RNA levels in eggs. Studying proteins in single eggs has been hard, because older methods needed many eggs at once.

The team used a platform it had developed earlier, which measures RNA and protein from the same single egg. It profiled 205 eggs from mice and humans: 103 aged and 102 young. The authors report about 4,000 proteins in mouse eggs and about 6,800 in human eggs.

The first finding is a mismatch. Changes in protein levels in aged eggs were not closely matched by changes in RNA. According to the authors, this indicates that protein changes in aged eggs are not primarily driven by RNA levels. The changes also differed by species and by stage of egg development.

The second finding is variety. The profiling captured molecular differences between aged eggs, which fits the observation that aging does not hit every egg equally. From this, the authors identified MCT4 as a candidate marker of egg aging. A candidate marker is a signal worth testing further, not a proven test.

The third finding comes from functional experiments. The authors write that MCT4 appears to contribute to aging-associated egg defects through its role in exporting lactate, and that inhibiting it improves the quality of aged eggs. The abstract uses the word "suggest" for the mechanism, so this is evidence of involvement, not a full explanation. The authors describe altered lactate metabolism as a candidate marker and intervention target.

The limits are clear. The work is preclinical. The abstract does not say how egg quality was measured in the inhibition experiments or how large the effect was. It does not say whether MCT4 can be safely blocked in a living ovary, and it does not show that blocking MCT4 would help anyone conceive.

WHAT TO WATCH NEXT

Whether other groups confirm MCT4 as a marker in larger sets of human eggs, and whether any approach to blocking it is tested for safety and benefit in animals and then in people. Nobody should start or stop any treatment, supplement or fertility plan because of this early research without first talking to their own clinician.

Sources: Nature Communications (2026), Nature Communications

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 **Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women**
30 Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

LONGEVITY & HEALTHSPAN · STANDARD READ · 1 MIN

JOURNAL OF OBESITY & METABOLIC SYNDROME · 2 SOURCES

Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women

Twelve weeks of aquatic or dance-based aerobic exercise went along with less body fat, lower levels of an inflammation marker and better scores on a thinking test in older women with obesity, according to a new randomized trial.



Photo: “Pool Aerobics” by Kirt Edblom, CC BY-SA 2.0

The study appeared in the Journal of Obesity & Metabolic Syndrome. It is a randomized trial of 54 women aged 65 and older. They were assigned to one of four groups: a control group, aerobic aquatic exercise, aerobic dance exercise, or combined aerobic and resistance exercise. Only the study's abstract was available for this report, so details beyond it are not covered here.

The researchers found that groups changed differently over time in body weight, body fat percentage, interleukin-6 (IL-6) and scores on the Korean version of the Mini-Mental State Examination (MMSE-K), a screening test of thinking and memory. IL-6 is a signalling protein linked to inflammation. The aquatic and dance groups both showed significant reductions in body weight and body fat percentage. Fat-free mass, which is everything in the body that is not fat, increased only in the aquatic group.

The authors also report increases in brain-derived neurotrophic factor (BDNF), a protein that supports nerve cells. They conclude that moderate-intensity aquatic and dance-based aerobic exercise over 12 weeks improved both metabolic health and cognitive function in these women. They say it was accompanied by reductions in IL-6 and increases in BDNF.

The word "accompanied" matters. The abstract does not show that the changes in IL-6 or BDNF caused the cognitive gains. The trial is small. The abstract available does not give the size of each change, how the combined aerobic and resistance group fared, or whether the effects last after the programs end. It also does not address joint comfort or how easy each activity is to keep up.

WHAT TO WATCH NEXT

Larger and longer trials, and the full paper's detail on the combined exercise group and on how much each measure changed. Anyone thinking about starting or changing an exercise program should first talk with their own clinician.

Sources: Journal of obesity & metabolic syndrome (2026), Journal of Obesity & Metabolic Syndrome

IN THIS EDITION · LONGEVITY & HEALTHSPAN

1. Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds
2. Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds
3. Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed
4. FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment
5. Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk
6. Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia
7. Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial
8. Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness
9. NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice
10. Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells
11. Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial
12. Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness
13. Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients
14. Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes
15. Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds
16. Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers
17. Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics
18. AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's
19. APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially
20. Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use
21. Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause
22. Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults
23. 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70
24. Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing
25. Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics
26. Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk

27 AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing
28 Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study
29 Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women
30 **Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory**

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

BIORXIV PREPRINT, NOT PEER REVIEWED · 2 SOURCES

Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory

A common idea in aging science says that as we get older, our cells slowly lose track of what they are. A new mouse study suggests that, in the brain at least, this is not what happens.




Photo: "Habenula mouse" by National Institutes of Health (NIH), Public domain

The work is a preprint posted on bioRxiv. That means it has not been peer reviewed. It was done in mice, not people. The abstract available to us does not give the number of animals, so we cannot report it.

The study looked at epigenetic marks. These are chemical tags added directly to DNA. They help control which genes are switched on or off. According to the authors, such marks let a cell keep its identity while still adapting to changes around it.

Aging is often thought to disrupt this control, so that cells lose their identities and decline in function. The authors note that this idea has been hard to test. Most studies use tissue with many cell types mixed together. Many also fail to tell apart the two most common DNA tags: 5-methylcytosine (methylation) and 5-hydroxymethylcytosine (hydroxymethylation). These two often have opposite links to gene activity.

The team looked at major cell types in the mouse hippocampus, a brain region involved in memory. According to the abstract, cell identity and the logic of gene regulation were preserved during aging. What changed with age was cell-type specific. The changes appeared at regions that govern each cell's specialised functions.

The authors also report that the link between DNA tags and gene activity is not governed by one rule. It depended on the type of tag, the genomic context, the specific DNA sequence and the length of the gene.

From this, the authors conclude that aging reshapes epigenetic control rather than dismantling it. That is their interpretation of the findings in mice. The abstract does not test any treatment.

Why it matters: claims about reversing epigenetic aging often treat it as one general drift that can be wound back. This study points to something more specific. Changes differ by cell type and by gene. It also suggests that methods which blend tissues, or merge the two DNA tags, may miss this detail. The abstract does not say how this affects any approach to reversal, and that question remains open.

Key limits: this is a preprint, it covers mice only, and only the abstract was available for this report. Details of methods, sample sizes and the size of the changes could not be checked.

WHAT TO WATCH NEXT

Peer review of the work, and whether other groups find the same pattern in other brain regions and in human tissue.

Sources: bioRxiv preprint, not peer reviewed (2026), bioRxiv

The Arising

HEALTH INTELLIGENCE

SATURDAY, OCTOBER 24, 2026 · MARKETS & STRATEGY DESK

IN THIS EDITION · MARKETS & STRATEGY

1. **Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies**
2. Fractyl Cuts 45% of Staff to Focus on Revita After Pivotal Win
3. CMS and States Launch $275M Program to Recruit Nursing Home Nurses
4. Insurers Split on How the Pandemic Should Shape Future Mortality Assumptions
5. Owners Reportedly Explore $1 Billion Sale of Largest US Senior Living Operator

MARKETS & STRATEGY · STANDARD READ · 2 MIN

CAPITAL MARKETS AND COMPETITIVE LANDSCAPE · LONGEVITY.TECHNOLOGY

Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies

Money flowing into longevity biotech has grown sharply, but it is going to fewer companies at later stages. According to Longevity.Technology's Longevity Biotech Report, investment rose from $4.7 billion in 2024 to $18.4 billion in 2025, and $12.1 billion is already in for 2026.




Photo: "ALE4218" by Alessiocoser, CC BY 4.0

The report says about 44% of 2025's disclosed total went into larger rounds for a smaller group of companies. It describes these firms as capitalized with enough reserve to pivot to another asset if the first one stalls. Founders seeking true seed money, under $5 million, face a harder market, according to the report.

The likely driver is the buyer. Longevity.Technology has argued that Big Pharma tends to buy proven science rather than build it. If so, venture investors have reason to fund proven science too. The report is careful on this point. It calls the pattern consistent with "reverse capture" rather than proven by it. Longevity.Technology's own commentary stresses that the data show capital relocating, not vanishing.

Fund economics add pressure. Hugh Rienhoff, a biotech entrepreneur and investor, argues in the Financial Times that many biotech venture investors have become bankers who chase deals and exits. That is one investor's argument, not a finding. He points to PitchBook data showing general biotech fundraising fell from a $152.3 billion peak in 2018 to $12 billion in 2024. Drug development still takes more than 15 years. Faster returns therefore tend to mean backing assets that are already validated.

Cellular reprogramming is the exception. The report calls it the hot category across specialist, generalist and pharma-linked investors. NewLimit raised $610 million across three rounds. Retro Biosciences raised roughly $1 billion in a single Series A. Crossover and tech-native funds, including Founders Fund, Thrive, a16z, General Catalyst and Accel, now write the largest checks. Lilly Ventures also sits in NewLimit's rounds.

The report describes a relay. Specialist funds such as Apollo Health Ventures, age1, Kizoo and Hevolution originate seed and Series A deals. For example, age1 co-led a $21 million seed round in Aerska, then co-led a $39 million Series A four months later. Generalists lead at scale. Pharma venture arms come in once risk has fallen. Hevolution's more than $400 million in grant commitments now sits alongside a growing run of lead equity positions.

NewLimit, Aeovian, Juvena and TRIMTECH each drew money from two or all three investor groups. The report reads this as the strongest early sign that pharma uses corporate venture as a scouting tool. That is the report's interpretation. The evidence is deal data, and the report was sponsored by MuseCell Innovations.

For the market, the implication is a gap at the earliest and riskiest stage, with fewer hands holding seed risk. Founders may need to plan early for who takes the next handoff. Watch whether 2026 totals keep rising while seed-stage rounds stay scarce, and whether more pharma venture arms appear in early deals.

Source: Longevity.Technology

IN THIS EDITION · MARKETS & STRATEGY

1. Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies
2. **Fractyl Cuts 45% of Staff to Focus on Revita After Pivotal Win**
3. CMS and States Launch $275M Program to Recruit Nursing Home Nurses
4. Insurers Split on How the Pandemic Should Shape Future Mortality Assumptions
5. Owners Reportedly Explore $1 Billion Sale of Largest US Senior Living Operator

MARKETS & STRATEGY · STANDARD READ · 2 MIN

COMPETITIVE LANDSCAPE · LONGEVITY.TECHNOLOGY

Fractyl Cuts 45% of Staff to Focus on Revita After Pivotal Win

Fractyl is cutting about 45% of its workforce and putting what is left of its money behind one product: Revita, a procedure it hopes will help people keep weight off after they stop GLP-1 drugs. Revita is not FDA-authorized in the U.S.; it holds Breakthrough Device designation only, so it is not currently available to U.S. patients outside trials.



Photo: “Computer Office” by Lukas, CC0

The decision follows positive six-month topline results from the REMAIN-1 pivotal cohort. According to Longevity.Technology, which cites the company's announcement, the cohort met its prespecified six-month co-primary endpoint with a p-value of 0.0023. The company claims Revita could become the first durable procedural therapy for weight maintenance after GLP-1 treatment ends. That is the company's claim, not an established fact.

The trade-off is stark. Fractyl will stop internal development of its Rejuva gene therapy program and will seek strategic alternatives for it. The company says the cuts should reduce quarterly cash burn by about 50%, to roughly $8 million. Even so, cash is expected to last only into the second quarter of 2027.

That timing shapes the strategy. Fractyl plans to file an FDA de novo submission in late Q4 2026. It expects topline 12-month pivotal data in Q1 2027. The company sees possible FDA marketing authorization in late 2027 and a possible U.S. launch in early 2028. On those dates, the money would run out well before any approval. The source does not say how the company would fund the gap, so that question remains open.

On regulatory position, Revita has FDA Breakthrough Device designation for weight maintenance after GLP-1 discontinuation. It is also CE-marked in the EU and UK. A de novo pathway is used for new devices with no existing equivalent. The source does not detail the review process or what the FDA will require.

For the competitive landscape, the focus is a specific niche: the source frames Revita as aimed at what happens after GLP-1 drugs are stopped. The source does not provide market size, pricing, or comparisons with other products, so any view on how large this niche is or who competes in it would be speculation. The six-month result is also an interim readout. The 12-month data will show more about durability. This is where the argument is weakest: we cannot size the market or name rivals from the evidence at hand.

Leadership is changing too. Co-founder Jay Caplan will retire from executive roles effective 30 October 2026 and remain as a senior advisor.

WHAT TO WATCH NEXT

The late Q4 2026 de novo submission, the Q1 2027 12-month readout, and whether Fractyl secures funding or a partner before its cash runs short in Q2 2027. Readers should not start or stop any medication or treatment, including GLP-1 drugs, without consulting their clinician.

Source: Longevity.Technology

IN THIS EDITION · MARKETS & STRATEGY

1. Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies
2. Fractyl Cuts 45% of Staff to Focus on Revita After Pivotal Win
3. **CMS and States Launch $275M Program to Recruit Nursing Home Nurses**
4. Insurers Split on How the Pandemic Should Shape Future Mortality Assumptions
5. Owners Reportedly Explore $1 Billion Sale of Largest US Senior Living Operator

MARKETS & STRATEGY · STANDARD READ · 2 MIN

REGULATORY CHANGE · SKILLED NURSING NEWS

CMS and States Launch $275M Program to Recruit Nursing Home Nurses

The federal government and the states have put $275 million behind a plan to bring nurses into nursing homes, and the money comes from fines the industry has already paid.

The Centers for Medicare and Medicaid Services (CMS) and states launched the Nurses for Nursing Homes initiative this week. Students and licensed nurses can qualify for up to $40,000 in student loan repayment, a $10,000 stipend, or both if they meet the requirements for each. In return, nurses must serve three years in a qualifying nursing home. According to CMS, the program is expected to support more than 4,000 nurses.

CMS has committed $100 million. States are committing at least $175 million more. The funding comes from civil monetary penalties that states and CMS have collected from nursing homes. CMS Administrator Dr. Mehmet Oz said the program works "without taking a dime from taxpayers."

Eligibility for facilities is narrower than it might appear. Qualifying homes are Medicare-, Medicaid- or dually certified. CMS set eligibility using each state's available funds and the number of nurses it expects to recruit, and it made all rural nursing homes eligible. It asked states for input, then ranked the remaining areas by

the ratio of population to registered nurses. CMS said it left some homes out because applicants might otherwise favor more attractive areas, leaving the highest-shortage communities without help. The method relies on geographic data, not facility staffing data, because CMS could not determine why a given home was short-staffed. CMS says it will monitor results and may change the method.

For operators, that design matters. Eligible homes may have a recruiting tool that nearby ineligible competitors lack. That is our reading, not a finding in the source. The source does not say how many homes qualify.

The nurse-side rules are specific. Nurses must hold an active RN or LPN/LVN license when they start, and work at least 30 hours a week at a qualifying home. The stipend requires eligible student loan debt or a graduation within the past two years. Payments are taxable and arrive quarterly, after CMS verifies an average of 30 hours a week over the quarter. Nurses must apply the money to their own loans. Eligible loans include federal direct, Stafford, Perkins and consolidation loans (if the original loans were for nursing education), plus private and institutional nursing school loans. A limited number of state nursing home inspector roles also qualify.

Timing also shapes who benefits. Nurses generally cannot have worked in a nursing home in the 60 days before opening an application account. During the first 90 days, Oct. 26, 2026 to Jan. 24, 2027, an exemption covers RNs and LPNs/LVNs who started at an eligible home between July 28 and Oct. 25, 2026.

Industry groups welcomed the launch. Katie Smith Sloan of LeadingAge said resources are being directed to communities facing the most significant workforce shortages. LeadingAge expects to highlight opportunities to expand eligibility as participation begins. Clif Porter of AHCA/NCAL called it a meaningful investment in rural and underserved communities. Amy Stewart of the American Association of Post-Acute Care Nursing cautioned that nursing home work needs specialized skills beyond traditional nursing education. "The goal should be more than filling vacancies," she said.

Whether the program keeps nurses past the three-year commitment is not addressed in the source. Watch for how CMS adjusts which facilities qualify once early results arrive, and whether advocates win a broader eligibility list.

Source: Skilled Nursing News

IN THIS EDITION · MARKETS & STRATEGY

1. Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies
2. Fractyl Cuts 45% of Staff to Focus on Revita After Pivotal Win
3. CMS and States Launch $275M Program to Recruit Nursing Home Nurses
4. **Insurers Split on How the Pandemic Should Shape Future Mortality Assumptions**
5. Owners Reportedly Explore $1 Billion Sale of Largest US Senior Living Operator

MARKETS & STRATEGY · STANDARD READ · 2 MIN

SOCIETY OF ACTUARIES RESEARCH INSTITUTE

Insurers Split on How the Pandemic Should Shape Future Mortality Assumptions

Insurers that price life policies and annuities still do not agree on what the pandemic means for how long people will live. That is the central finding of a new industry survey, and it matters because those assumptions sit underneath the price of every long-dated promise.

The Society of Actuaries Research Institute published its 2025 Mortality Improvement Survey Report on October 15, 2026. Kara Clark, FSA, wrote the report. It draws on responses from 47 company-country respondents.

According to the report, there is no clear industry consensus on how post-pandemic mortality experience should affect future mortality improvement assumptions. Assumptions vary by company, product, business function, attained age and projection horizon. Mortality improvement means the expected rate at which death rates fall over time.

The results do not point in one direction. The report says the data do not support a broad conclusion that improvement assumptions have uniformly risen or fallen. Some short-term results suggest caution. Longer-term medians are stable or higher in several life and annuity categories, depending on product, function and attained age.

For competitive positioning, that spread is the key point. Two insurers can look at the same recent experience and set different long-run assumptions. The survey does not say how those differences feed into specific prices. That link is an inference for readers to test, not a finding of the report.

The framework behind the numbers looks steadier than the numbers themselves. According to the report, the level of assumptions changed for some companies, but the underlying structure stayed remarkably consistent. Companies continue to vary assumptions mainly by attained age and gender.

Durational mortality improvement assumptions remain widely used, but not universally. These assumptions change with the time since the projection start. Use is highest for life products and somewhat lower for annuity products.

COVID-19 is no longer seen as the dominant long-term driver of mortality change, the report says, but its effect has not disappeared. Fewer than half of respondents who answered the question apply explicit COVID-19 or post-pandemic adjustments to underlying mortality rates. The report also says companies are still incorporating post-pandemic experience into forward-looking assumptions.

On what drives improvement, respondents continue to name cancer and cardiovascular disease. Longer-term expectations give more attention to medical and technological advances. The report lists personalized medicine, artificial intelligence, genetics and aging research. These are views from survey respondents. The report does not show that such advances will deliver gains.

Respondents also flagged risks on the other side. The drivers of deterioration they named most often were obesity, mental health or depression, and socioeconomic inequality.

The survey reflects what insurers say they do, not how their assumptions have performed. Readers weighing life, annuity or pension risk transfer pricing should treat it as a map of current practice. It is not a forecast of mortality.

WHAT TO WATCH NEXT

Whether the gap between cautious short-term views and steadier long-term medians narrows in future survey rounds, and whether more companies adopt or drop explicit post-pandemic adjustments.

Source: Society of Actuaries Research Institute

IN THIS EDITION · MARKETS & STRATEGY

1. Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies
2. Fractyl Cuts 45% of Staff to Focus on Revita After Pivotal Win
3. CMS and States Launch $275M Program to Recruit Nursing Home Nurses
4. Insurers Split on How the Pandemic Should Shape Future Mortality Assumptions
5. **Owners Reportedly Explore $1 Billion Sale of Largest US Senior Living Operator**

MARKETS & STRATEGY · STANDARD READ · 2 MIN SENIOR HOUSING NEWS

Owners Reportedly Explore $1 Billion Sale of Largest US Senior Living Operator

The investors behind the largest senior living operator in the United States are reportedly looking for a buyer, and the price being discussed is about $1 billion.

According to an Oct. 20 Reuters report, which relied on one unnamed source, the companies that back Discovery Senior Living have hired the investment bank William Blair to find a buyer. Senior Housing News, which relayed the report, says a sale could value the company at $1 billion. No deal has been announced. A representative for Coastwood declined to comment on Wednesday. Discovery did not immediately respond to a request for comment.

The numbers give a sense of the price. Discovery's annual earnings before interest, taxes, depreciation and amortization (EBITDA) are about $65 million, according to the report. By our own arithmetic, $1 billion would be roughly 15 times that figure. The source does not say what the valuation includes, such as debt, so that multiple is a rough guide only.

Lee Equity Partners and Coastwood Senior Housing Partners invested in the Bonita Springs, Florida-based company in 2022. Since then, Discovery has grown to manage about 450 communities across the country. Its approach is to build regional

platforms with their own brands and operations, all under the Discovery name. This year its total unit count passed that of Brookdale Senior Living, making it the nation's largest operator.

Growth is continuing. Earlier this week, Discovery announced it is acquiring Sunshine Retirement Living, an Oregon-based operator with 33 communities under management.

The timing fits a wider pattern. Earlier in October, Sunrise Senior Living changed hands in a $1 billion deal that gave majority ownership to BDT & MSD Partners. Its executive team owns the rest. Sunrise also announced a $7.5 billion development pipeline. Our October 15 coverage of that deal looked at what a new generalist buyer could mean for competition among operators. This report adds a second large operator that may be for sale, this time with the sellers being financial backers rather than a long-held owner.

If Discovery sells, it would be the latest top-five operator to change hands in a sizable deal this year, according to Senior Housing News. For investors, a completed sale near $1 billion would show what buyers will pay for scale built through acquisitions and regional brands. For competitors, it could mean a new owner with fresh capital. The source does not discuss regulatory review or any effect on residents or staff.

Watch for whether Discovery or its owners confirm a sale process, who emerges as a bidder, and whether any final price lands near the reported $1 billion.

Source: Senior Housing News (citing Reuters)

The Arising

HEALTH INTELLIGENCE

SATURDAY, OCTOBER 24, 2026 · LONGEVITY & HEALTHSPAN · LONG READS DESK

IN THIS EDITION · LONGEVITY & HEALTHSPAN · LONG READS

1. **A 6.3-Million-Cell Brain Atlas Finds Alzheimer's Is Not Just Faster Aging**
2. Does Annual Flu Vaccination Blunt the Next Shot? A Korean Trial Is Testing It
3. Does Where Stem Cells Fail Matter as Much as How Many?
4. Does Fading Nitric Oxide Silence Cell Recycling in Aging Arteries? Evidence Points the Other Way

LONGEVITY & HEALTHSPAN · LONG READS · 3 MIN

NEWS · VERIFIED · 1 SOURCE

A 6.3-Million-Cell Brain Atlas Finds Alzheimer's Is Not Just Faster Aging

A Nature study of brain tissue from 1,494 donors maps gene activity across eight brain disorders. Severe Alzheimer's shows fewer neurons and more immune and vascular cells, in a pattern distinct from healthy aging. It is a map, not a treatment.

Is Alzheimer's disease simply brain aging on fast-forward? A new atlas of more than six million brain cells says no, at least not entirely. That matters, because the answer decides whether we chase aging itself or the specific changes that make disease different.

WHAT WAS REPORTED

Our research desk flagged the study, and we confirmed it in Nature, published September 23, 2026. A team led by Donghoon Lee and Panos Roussos at the Icahn School of Medicine at Mount Sinai used brain specimens from 1,494 donors to build a single-cell gene-activity atlas of the dorsolateral prefrontal cortex, a region involved in planning and judgment. It covers more than 6.3 million individual cell nuclei.

Tissue came from several brain banks, with collaborators at the National Institute of Mental Health and Rush University. The cohort includes healthy controls and people with eight conditions: Alzheimer's disease, diffuse Lewy body disease, vascular dementia, Parkinson's disease, tauopathy, frontotemporal dementia, schizophrenia and bipolar disorder.

WHAT THE EVIDENCE SAYS

Four findings stand out in the paper's summary.

- People differ a lot. Variation between individuals accounted for a substantial portion of gene-activity differences, which means small studies can easily mislead.
- Some changes are shared. Several disorders showed common signatures in basic housekeeping functions, such as processing genetic messages and routing proteins.
- Four dementias cluster. After setting those shared signatures aside, Alzheimer's, Lewy body disease, vascular dementia and Parkinson's showed stronger genetic and gene-activity overlap with each other.
- Severe Alzheimer's looks different from aging. More severe disease was associated with fewer neurons and more immune and vascular cells, a pattern the authors describe as distinct from healthy aging.

The team also linked the psychiatric symptoms that often accompany Alzheimer's, such as agitation or depression, to a higher abundance of deep-layer excitatory neurons. And they built trajectories suggesting different cell types respond at early and late stages.

Our research desk's summary was accurate. Its headline, however, slightly overstates the paper's focus. The atlas is mainly a cross-disease map; the Alzheimer's-versus-aging comparison is one part of it.

WHY IT MATTERS FOR A LONGER, HEALTHIER LIFE

Longevity medicine often assumes that slowing aging will slow every age-related disease. This atlas supports a more careful view. Some brain changes are shared across diseases and may reflect common aging biology. Others, such as the immune and vascular shift in severe Alzheimer's, appear disease-specific and may need their own targets.

The clustering of four dementias is also practical. Many older adults have mixed brain pathology. Shared biology across Alzheimer's, Lewy body and vascular disease reinforces why protecting blood vessels is one of the most reliable brain-health strategies we have.

WHAT DOESN'T HOLD UP, OR REMAINS OPEN

This is post-mortem tissue from one brain region. It captures a snapshot at death, not change over time within a person, so the 'trajectories' are reconstructed rather than observed. Cell-count differences may reflect neurons dying rather than causing decline.

Above all, these are associations. The study does not show which changes drive disease and which are consequences, and it tests no treatment.

WHAT TO DO

- Keep focusing on the vascular basics that protect the brain: blood pressure, blood sugar, cholesterol, physical activity and not smoking.
- If you notice new memory, mood or behavior changes, raise them with your doctor; psychiatric symptoms can be early signs of neurodegenerative disease.
- Be skeptical of products claiming to reverse 'brain aging' based on studies like this one. It is a research map, not a therapy.

WHAT TO WATCH NEXT

- Whether the immune and vascular cell shifts replicate in other brain regions and in living patients through imaging or blood markers.
- Drug programs that target disease-specific cell changes rather than aging in general.
- Use of the atlas by other groups to test candidate treatment targets.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

CLAIM	WHAT WE FOUND	TIER
Atlas of 1,494 donors and 6.3 million nuclei in Nature	Confirmed in the published paper	VERIFIED
Alzheimer's, Lewy body, vascular dementia and Parkinson's share biology	Reported after removing cross-disease signatures	MODERATE
Severe Alzheimer's differs from healthy aging	Observed in tissue; association only	MODERATE
These changes cause Alzheimer's	Not tested	UNSUPPORTED

Source
Lee D, et al. Single-cell atlas of transcriptomic vulnerability across brain disorders. Nature 2026;657:988-1002. doi:10.1038/s41586-025-09573-z
From The Arising library: prepared for the research desk of September 26.

IN THIS EDITION · LONGEVITY & HEALTHSPAN · LONG READS

1. A 6.3-Million-Cell Brain Atlas Finds Alzheimer's Is Not Just Faster Aging
2. **Does Annual Flu Vaccination Blunt the Next Shot? A Korean Trial Is Testing It**
3. Does Where Stem Cells Fail Matter as Much as How Many?
4. Does Fading Nitric Oxide Silence Cell Recycling in Aging Arteries? Evidence Points the Other Way

LONGEVITY & HEALTHSPAN · LONG READS · 3 MIN

NEWS · PARTLY VERIFIED · 4 SOURCES

Does Annual Flu Vaccination Blunt the Next Shot? A Korean Trial Is Testing It

A registered Phase 4 trial compares standard-dose, adjuvanted and high-dose flu vaccines in adults 65 and older, with a younger reference group, over up to three years of annual shots. We read the full registry record: it started (estimated) on 21 September 2026 and is recruiting. It measures immune responses only, not infections or hospitalizations.

Many older adults get a flu shot every fall, often for years. A nagging question is whether repeated doses make each new one work a little less well. A trial registered in Korea is designed to measure exactly that.

WHAT THE REGISTRY SHOWS

The trial is registered as NCT07838298, sponsored by Korea University Guro Hospital, with the National Research Foundation of Korea as collaborator and a site in Seoul. It plans to enroll 180 participants, including older adults (65+) and a younger adult reference group aged 19 to 49 who receive standard dose.

It has four arms: three older-adult arms (standard-dose as the active comparator, MF59-adjuvanted, which adds an immune booster, and high-dose) plus the younger standard-dose reference arm. Its questions are whether the vaccines produce different immune responses, how immune aging shapes them, and whether responses change with repeated annual vaccination. Primary outcomes are antibody

measures and fold-rise at one month, yearly for up to three years. Secondary outcomes include B and T cells, nasal IgA and molecular profiling. Primary completion is estimated for December 2028.

One point is easy to misread. The registry sets no requirement for prior flu vaccination history; it excludes only vaccines given in the four weeks before enrollment. Here, 'repeated vaccination' means the annual doses given during the study, not years of shots beforehand.

WHAT THE EVIDENCE SAYS

The scientific question is well founded. The landmark comparison came in 2014, when a randomized trial of nearly 32,000 adults 65 and older, published in the New England Journal of Medicine, found that a high-dose vaccine produced higher antibody levels and about 24 percent fewer laboratory-confirmed flu cases than standard dose (1.4 versus 1.9 percent of participants).

The repeat-vaccination concern is real but unsettled. A 2026 observational study of older adults in China found that people vaccinated in consecutive seasons started with higher antibody levels but had smaller fold-rises after the new shot. Antibody levels did not differ between groups at 30, 90 or 180 days, and the authors concluded protection was comparable. Earlier Hong Kong studies of adults 75 and older also found lower fold-rises with repeat vaccination but similar seroprotection, so the Chinese cohort is not the only evidence.

A 2026 review in Frontiers in Immunology argues that serial vaccination may activate regulatory T cells that reduce antibody titers, and that aging memory T cells may worsen this. That is a hypothesis-building review, not settled evidence.

WHY IT MATTERS FOR A LONGER, HEALTHIER LIFE

Flu remains a major cause of hospitalization and functional decline in older adults, and a serious illness can permanently set back strength and independence. If repeated vaccination does blunt response, stronger formulations might seem to matter more for long-time vaccinees. If it does not, the reassuring message is to keep vaccinating every year.

WHAT DOESN'T HOLD UP, OR REMAINS OPEN

The 'stronger formulations' idea is the weakest part of this argument. A 2025 analysis of the PIVOT trial found that effects of prior vaccination persisted even with enhanced (adjuvanted or recombinant) vaccines in older adults. A better vaccine may therefore not erase the repeat-vaccination effect.

This is also an immune-response trial. Antibody levels are a stand-in for protection, not the same thing. All registered outcomes are immunologic; none covers infections, hospitalizations or survival. A difference between vaccine types would not, by itself, explain the role of repeated vaccination. Those are separate questions.

With 180 participants split across four groups, three of them older adults, each older-adult arm will have fewer than 60 people, so the trial can detect only fairly large differences. Results are years away.

WHAT TO DO

- If you are 65 or older, keep getting an annual flu vaccine; nothing here suggests skipping it.
- Ask your doctor or pharmacist whether a high-dose or adjuvanted vaccine is right for you; these are designed for older adults.
- If you have a weakened immune system or a history of vaccine reactions, review your options with your doctor.

WHAT TO WATCH NEXT

- Recruitment progress and any changes to the registry record.
- Results, estimated for after December 2028, ideally broken down by year of vaccination.
- Larger studies that link repeated vaccination to infections and hospitalizations, not just antibody levels.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

Sources

ClinicalTrials.gov. Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults (official title: Immunogenicity of Different Influenza Vaccine Strategies in Older Adults in a Repeated Vaccination Setting). NCT07838298. clinicaltrials.gov

DiazGranados CA, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014. doi:10.1056/NEJMoa1315727

Wang R, et al. Repeated annual influenza vaccination in older adults induces comparable seroprotection despite reduced antibody fold rise. Vaccines 2026. doi:10.3390/vaccines14040338

Gupta RK, et al. Low effectiveness of influenza vaccines vis-à-vis mechanism of protection by vaccines. Front Immunol 2026. doi:10.3389/fimmu.2026.1816148

From The Arising library: prepared for the research desk of September 26.

IN THIS EDITION · LONGEVITY & HEALTHSPAN · LONG READS

1. A 6.3-Million-Cell Brain Atlas Finds Alzheimer's Is Not Just Faster Aging
2. Does Annual Flu Vaccination Blunt the Next Shot? A Korean Trial Is Testing It
3. **Does Where Stem Cells Fail Matter as Much as How Many?**
4. Does Fading Nitric Oxide Silence Cell Recycling in Aging Arteries? Evidence Points the Other Way

LONGEVITY & HEALTHSPAN · LONG READS · 3 MIN HYPOTHESIS, NOT YET TESTED · 3 SOURCES

Does Where Stem Cells Fail Matter as Much as How Many?

Our research desk borrows from mine engineering to propose, as an untested hypothesis it rates at 60 percent, that clustered stem-cell loss overloads neighbors and speeds telomere failure, while the same loss scattered does not. Recent skin biology makes the premise more plausible than it first sounds.

In an underground mine, one weakened pillar is rarely the problem. The danger is what its neighbors inherit when it stops carrying weight. Our research desk asks whether aging tissues fail the same way: not because of how many stem cells stop dividing, but because of where.

WHAT WAS PROPOSED

Start with simple arithmetic. If a tissue needs a fixed number of new cells each week and one-fifth of its dividing cells stop, each survivor must, on average, work one-quarter harder. But if replacement is mostly local, cells bordering a damaged patch could inherit far more than that average.

Extra divisions wear down telomeres, the protective caps on chromosome ends. Some neighbors then stop dividing, concentrating demand on even fewer cells. The desk proposes that this feedback means clustered loss accelerates telomere-related aging, independently of the total amount of initial damage.

The test uses lab-grown human skin from primary keratinocytes, with matched short-telomere and longer-telomere cultures. An inducible switch arrests the same fraction of basal stem cells, either in one patch or scattered. The prediction: in short-telomere tissue, clustered arrest causes at least 25 percent more new telomere-linked arrests among initially healthy cells over eight weeks than scattered arrest, after subtracting the same comparison in longer-telomere cultures. The desk gives it 60 percent, conditional on a well-powered experiment.

WHAT THE EVIDENCE SAYS

The local-replacement premise has direct support in mice. In 2018, Valentina Greco's lab at Yale tracked every epidermal stem cell in large regions of living mouse skin, imaged in the paw. Differentiation of one stem cell was followed, within one to two days, by division of a direct neighbor. Self-renewal responds locally to tissue demand, which is the condition the desk needs. It has not yet been shown in human or cultured epidermis, which is where the proposed test would run.

The telomere premise is also strong. Carol Greider's lab showed in 2001 that it is the shortest telomere, not the average length, that triggers dysfunction and limits cell survival. That supports the desk's point that average telomere measurements discard the information that matters.

And telomeres are favored sites of lasting damage. A 2012 study from Newcastle University found that persistent DNA-damage foci in senescent cells sit at telomeres, and that telomere-associated foci increase with age in mouse gut and liver, regardless of telomere length. This is early, cell-culture and mouse evidence. We found no retraction, correction or reversal of the three studies cited here.

WHY IT MATTERS FOR A LONGER, HEALTHIER LIFE

If spatial clustering matters, two people with the same average telomere length or the same number of senescent cells could age very differently. It would also suggest a research target: preserving the distribution of regenerative capacity, not just its total. That could reshape how we think about clearing senescent cells, which removes cells but may leave holes their neighbors must fill.

WHAT DOES NOT HOLD UP YET

The desk's weakest assumption is that demand stays local. In skin culture, cells migrate, and if they spread the load quickly, the feedback loop never starts. Eight weeks may also be too short for extra divisions to exhaust telomeres, and damage signals may lower tissue output before neighbors become overworked.

Clustering could impair renewal through inflammation or altered tissue shape alone. The longer-telomere control is designed to subtract that effect, which is the experiment's best feature. The mining analogy is a source of questions, not evidence; cells, unlike rock, can change their capacity.

WHAT TO WATCH NEXT

- A lineage-tracked skin-culture experiment comparing clustered and scattered arrest at two telomere reserves.
- Spatial maps of senescent cells in aging human tissue, testing whether they cluster.
- Senescent-cell-clearing studies that report what happens to neighboring cells afterward.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

Sources

Mesa KR, et al. Homeostatic epidermal stem cell self-renewal is driven by local differentiation. Cell Stem Cell 2018. doi:10.1016/j.stem.2018.09.005
Hemann MT, et al. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001. doi:10.1016/s0092-8674(01)00504-9
Hewitt G, et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun 2012. doi:10.1038/ncomms1708
From The Arising library: prepared for the research desk of September 26.

IN THIS EDITION · LONGEVITY & HEALTHSPAN · LONG READS

1. A 6.3-Million-Cell Brain Atlas Finds Alzheimer's Is Not Just Faster Aging
2. Does Annual Flu Vaccination Blunt the Next Shot? A Korean Trial Is Testing It
3. Does Where Stem Cells Fail Matter as Much as How Many?
4. **Does Fading Nitric Oxide Silence Cell Recycling in Aging Arteries? Evidence Points the Other Way**

LONGEVITY & HEALTHSPAN · LONG READS · 4 MIN

HYPOTHESIS, NOT YET TESTED · 4 SOURCES

Does Fading Nitric Oxide Silence Cell Recycling in Aging Arteries? Evidence Points the Other Way

Our research desk proposes that falling nitric oxide in blood vessels switches off TFEB, the master switch for cellular recycling, tying two hallmarks of aging together. Published studies support a connection, but mostly show recycling protecting nitric oxide, not the reverse. We found no study showing that nitric oxide or eNOS regulates TFEB, so the key link remains unconfirmed, and that is the weakest point of the argument.

Arteries stiffen with age, and cells everywhere get worse at clearing out their own junk. These two changes sit on separate lines of the standard list of aging hallmarks. Our research desk proposes a single upstream cause, and the idea is testable in mice within weeks.

THE IDEA IN PLAIN TERMS

The cells lining your arteries make nitric oxide using an enzyme called eNOS. Nitric oxide relaxes vessels and keeps them healthy. Its output falls with age.

Autophagy is the cell's recycling program. A protein called TFEB acts as its master switch, turning on genes that build lysosomes, the cell's recycling centers. Autophagy also declines with age, and boosting it extends lifespan in animals.

The desk's proposal: nitric oxide from eNOS keeps TFEB active in vessel cells. As eNOS fades, TFEB goes quiet, lysosomes work poorly, and damaged parts pile up. That pushes vessel cells toward an inflamed, stiff state. The same loss in lymphatic vessels would weaken fluid drainage. One fading signal, two hallmarks. This is a proposal, not a finding.

The desk gives the broad claim about 55 percent odds. It gives 75 percent to a narrower one: that TFEB activity can be measured in aged vessel walls and shifts with exercise.

WHAT THE EVIDENCE SAYS

Nitric oxide and autophagy are linked in aging arteries. In 2013, Thomas LaRocca, Douglas Seals and colleagues at the University of Colorado compared old and young mice. Old mice had about 20 percent stiffer aortas and about 25 percent worse endothelial dilation, driven by lower nitric oxide. Spermidine, an autophagy enhancer, restored nitric-oxide-dependent dilation and normalized stiffness. In cell experiments, the benefit depended on autophagy; that dependence was not shown in the mice themselves.

But the arrow points the other way in the best mechanistic data. In a 2022 Diabetes paper, a Hong Kong team found that blocking autophagy caused eNOS to fall apart into inactive single units and lowered nitric oxide. Boosting TFEB restored eNOS pairing and improved vessel relaxation in diabetic mice. Calorie restriction did the same. Here TFEB protects eNOS, not the reverse.

We could not find the cell-culture studies the desk cites showing that nitric oxide stabilizes TFEB, and our search found no such study published since the desk date either. That piece may exist, but it is the link the whole hypothesis depends on, and it is the one we could not confirm. Published reviews describe TFEB as regulated by other pathways, including mTORC1, AMPK and calcineurin.

TFEB protects vessels. Mice engineered to lack TFEB in endothelial cells handle glucose worse, and mice with extra endothelial TFEB handle it better, according to a 2020 University of Michigan study. TFEB is broadly considered protective against vascular inflammation and atherosclerosis, though this rests on mouse and cell work.

Lymphatics are messier. The desk says lymphatic vessels rely on nitric oxide to pump. A 2011 study in rats found that aged lymphatic vessels pumped far less, but blocking nitric oxide actually brought their pumping back toward young levels. In old lymphatics, nitric oxide may be part of the problem, not the missing ingredient.

WHAT WOULD SETTLE IT

- Compare young mice, old sedentary mice, and old mice given four weeks of wheel running.
- Isolate aortic endothelial cells and measure TFEB in the nucleus, autophagy markers, and how much eNOS is in its active paired form.
- Add a key check: block eNOS in young mice and see whether TFEB drops. Also boost TFEB in old mice and see whether eNOS recovers. Running both directions would show which way the arrow points.

WHY IT MATTERS FOR A LONGER, HEALTHIER LIFE

If either direction holds, it supports something we already recommend: protect your endothelium. Exercise, not smoking, and controlling blood pressure, glucose and cholesterol all improve nitric oxide signalling. The mouse data hint that they may help vessel cells clear damage too.

It also tempers the excitement around autophagy supplements. Spermidine helped old mouse arteries, but human trial data on vascular aging are limited. We do not recommend it as a vascular treatment outside a study.

WHAT TO DO

- Make regular aerobic exercise the foundation; it is the most reliable way to support endothelial function.
- Know your blood pressure, fasting glucose or A1c, and LDL cholesterol, and treat them if they are high.
- Do not start autophagy-targeted supplements for heart or vessel health without talking to your doctor, especially if you take other medications.

WHAT TO WATCH NEXT

- Mouse studies that measure endothelial TFEB and eNOS together across age, with and without exercise.
- Experiments testing both directions of the link, eNOS to TFEB and TFEB to eNOS.
- Human trials of autophagy-targeted interventions with arterial stiffness or endothelial function as outcomes.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

Sources

LaRocca TJ, Gioscia-Ryan RA, Hearon CM, Seals DR. The autophagy enhancer spermidine reverses arterial aging. Mech Ageing Dev 2013;134:314-20. doi:10.1016/j.mad.2013.04.004 (via PubMed)

Zhao L, Zhang CL, He L, et al. Restoration of Autophagic Flux Improves Endothelial Function in Diabetes Through Lowering Mitochondrial ROS-Mediated eNOS Monomerization. Diabetes 2022;71:1099-1114. doi:10.2337/db21-0660 (via PubMed)
Sun J, Lu H, Liang W, et al. Endothelial TFEB Improves Glucose Tolerance via Upregulation of IRS1 and IRS2. Arterioscler Thromb Vasc Biol 2021;41:783-795. doi:10.1161/ATVBAHA.120.315310 (via PubMed)
Akl TJ, Nagai T, Coté GL, Gashev AA. Mesenteric lymph flow in adult and aged rats. Am J Physiol Heart Circ Physiol 2011;301:H1828-40. doi:10.1152/ajpheart.00538.2011 (via PubMed)
From The Arising library: prepared for the research desk of September 27.

The Arising

HEALTH INTELLIGENCE

SATURDAY, OCTOBER 24, 2026 · MARKETS & STRATEGY · LONG READS DESK

IN THIS EDITION · MARKETS & STRATEGY · LONG READS

1. **C2N, Cambridge Cognition and a New Alzheimer's Trust Bundle UK Dementia Testing Into One Pathway**
2. Refiner Stocks Have Doubled in 2026 as the World Runs Short of Diesel

MARKETS & STRATEGY · LONG READS · 2 MIN

NEWS · VERIFIED · 1 SOURCE

C2N, Cambridge Cognition and a New Alzheimer's Trust Bundle UK Dementia Testing Into One Pathway

The UK partnership links a blood test, a digital cognitive assessment and imaging infrastructure. It is an organized service, not yet proof that it shortens the road to diagnosis.

Three organizations have joined to pull several parts of Alzheimer's assessment into a single UK pathway. The move bundles a blood test, a digital cognitive test and scanning infrastructure, so a patient can move through them as one route rather than several disconnected steps.

For a reader watching the longevity economy, the interesting question is not the announcement. It is whether bundling actually lowers the time to diagnosis.

WHAT WAS CLAIMED

Our research desk flagged a C2N Diagnostics partnership combining blood testing and cognitive assessment in the UK. We confirmed it against the original announcement, dated September 21, 2026.

The partners are C2N Diagnostics, Cambridge Cognition and The Alzheimer's Trust, a newly formed subsidiary of The Cancer Screening Trust. The pathway combines C2N's MHRA-registered PrecivityAD2 blood test, Cambridge Cognition's CANTAB

Pathway digital cognitive assessments, and The Alzheimer's Trust's national phlebotomy and MRI infrastructure. UK clinicians can now order the blood test and the cognitive test through the Trust.

WHAT THE EVIDENCE SAYS

The announcement is real and the components are established products. The business development is the combination itself, not a new clinical result. It does not report a trial comparing this pathway against existing care.

The partners cite supporting evidence for the underlying tests. In a Swedish primary-care study, a digital cognitive test plus a blood biomarker reached about 90 percent accuracy versus roughly 70 percent for standard GP care. A JAMA study of more than 1,200 patients reported high negative and positive predictive values for PrecivityAD2. Those numbers describe the tests, not this bundled service.

WHY IT MATTERS FOR THIS READER

Diagnosis in UK dementia care is slow: the partners cite an average of about 3.5 years from first symptoms. A route that reliably compresses that delay would be valuable, and it signals where private, organized longevity services are heading. Facts and context only here, not investment guidance. Not financial advice.

WHAT DOES NOT HOLD UP YET

The most interesting question stays open: will the partnership actually shorten the road to diagnosis and improve care? The announcement gives no patient numbers, no waiting-time results and no comparison with current care. It also discloses no pricing or funding figures.

For now, this is an organized effort to arrange diagnostic services around a shared pathway. Evidence of practical benefit will require results beyond the announcement.

WHAT TO WATCH NEXT

- Any published waiting-time or accuracy data from the pathway itself, not just its component tests.
- Pricing, funding and how widely UK clinicians adopt it.
- Whether the NHS integrates or runs its own comparison against this private route.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

CLAIM	WHAT WE FOUND	TIER
C2N, Cambridge Cognition and The Alzheimer's Trust formed a UK pathway	Confirmed in Sep 21, 2026 announcement	VERIFIED
Pathway bundles PrecivityAD2, CANTAB Pathway and MRI/phlebotomy	Confirmed	VERIFIED
The combined service shortens time to diagnosis	Not shown; no comparative data	UNSUPPORTED
Pricing or funding disclosed	Not disclosed	UNVERIFIED

Source

C2N Diagnostics, Cambridge Cognition and The Alzheimer's Trust announce UK Alzheimer's diagnostic partnership. City AM, Sep 21, 2026.

From The Arising library: prepared for the research desk of September 24.

IN THIS EDITION · MARKETS & STRATEGY · LONG READS

1. C2N, Cambridge Cognition and a New Alzheimer's Trust Bundle UK Dementia Testing Into One Pathway
2. **Refiner Stocks Have Doubled in 2026 as the World Runs Short of Diesel**

MARKETS & STRATEGY · LONG READS · 4 MIN NEWS · VERIFIED · 2 SOURCES

Refiner Stocks Have Doubled in 2026 as the World Runs Short of Diesel

The shortage is in refined fuel, not crude oil. War damage to refineries in the Middle East and Russia has left the world short of diesel, gasoline and jet fuel. Three large U.S. refiners have more than doubled this year. Here is what is driving it, and why it may not last.

Diesel crossed $6 a gallon in the United States for the first time in mid-September, and it kept climbing, reaching roughly $6.31 to $6.49 by September 20 and 21 according to AAA and GasBuddy. That price moves everything that rides on a truck, from groceries to hospital supplies. It has also made American oil refiners some of the best-performing large stocks of the year.

WHAT WAS REPORTED

On September 14, OilPrice.com reported that Phillips 66, Valero and Marathon Petroleum had each more than doubled in 2026. ExxonMobil and Chevron, by comparison, were up about 40%. Traders Union, writing the same day, described the refiners' rally as margin-driven, with diesel and jet fuel tightness lifting the cash-flow outlook.

The reason is the gap between what refiners pay for crude oil and what they get for gasoline, diesel and jet fuel. Traders call that gap the crack spread. OilPrice.com described product margins at record highs.

WHY FUEL IS SHORT

The cause is not mainly a lack of crude. It is a lack of refining. OilPrice.com, citing the International Energy Agency, reported global refinery throughput of 81.4 million barrels a day in August. That was 4.2 million barrels a day below a year earlier.

More than 7 million barrels a day of refined product flows were offline in the Middle East and Russia, according to the same report. The wars involving Iran and Ukraine are the main reasons. Ukraine has targeted Russian refineries for months. Lost refining capacity cannot be replaced quickly.

Inventories show the strain. U.S. distillate stocks in August were on track for their lowest end-of-month level since April 2005, according to RBN Energy as cited by OilPrice.com. Traders Union put distillate stocks about 14% below the five-year average. Phillips 66 chief executive Mark Lashier called it more of a supply shock than a demand shock.

WHERE OUR RESEARCH DESK WAS OFF

The desk's summary blamed refinery outages, maintenance turnarounds and higher freight costs. Those play a part. The reporting we found puts war damage to foreign refining capacity at the center, which the desk did not mention.

The desk also said the margin had widened without a big move in crude. That is only partly true. Crude was also rising as Middle East tensions escalated. Product prices simply rose faster, which is why the cracks reached records. We could not confirm a specific weekly crude figure, so we do not give one.

WHY IT MATTERS TO THIS READER

Fuel shocks plausibly reach health care quickly. Hospitals run on deliveries, generators and ambulances. This is our own reasoning, not something the sources measured, and it is the weakest part of the argument here. We have no data on how long diesel costs take to show up in the price of supplies, food and medications, or on which patients are hit hardest. Patients on fixed incomes and rural patients who drive long distances to see specialists are the likeliest to feel it.

For anyone holding energy stocks, the lesson is about what a company actually earns. A refiner's profit rides on the spread, not on the oil price. That makes it a different bet from owning a producer, with different risks.

WHAT COULD REVERSE IT

- Margins swing fast. Morningstar DBRS has called the current margins a likely temporary tailwind that could weaken when tensions ease. Valero's chief operating officer said cracks had pulled back from their third-quarter peaks but should recover. Spreads can fall as quickly as they rose.
- Analysts are cautious. OilPrice.com reported that average 12-month price targets for Valero, Marathon and Phillips 66 trailed their share prices.

- Peace or repairs. Any restoration of Russian or Middle Eastern refining would ease the shortage. Lashier said he expects normalization to take longer than it did after 2022.
- Demand. Prices this high eventually reduce fuel use, especially in freight.
- Policy. Talk of a U.S. diesel export ban surfaced in October and widened the WTI–Brent discount to about $12 a barrel. Wood Mackenzie says a ban could cut U.S. crude runs by more than 2 million barrels a day, a new risk for refiners.

Not financial advice. This article reports facts and context only.

WHAT TO WATCH NEXT

- Weekly U.S. distillate inventory data against the five-year average.
- Any repair of Russian refineries or easing in the Middle East.
- Further refiner earnings calls. Third-quarter results are now arriving: Valero reported on October 22 a record quarterly profit of about $6.8 billion, with a refining margin of $39.24 a barrel against $13.14 a year earlier.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

Sources

Paraskova T. Global Fuel Squeeze Triggers U.S. Refiners Stocks Rally. OilPrice.com, September 14, 2026. oilprice.com
Volkova A. U.S. refiners extend margin-driven rally as diesel and jet fuel tightness boosts cash flow outlook. Traders Union, September 14, 2026. tradersunion.com
From The Arising library: prepared for the research desk of September 25.

The Arising

HEALTH INTELLIGENCE

SATURDAY, OCTOBER 24, 2026 · MEASUREMENT & AI DESK

IN THIS EDITION · MEASUREMENT & AI

1. **Cloudflare Plans a Post-Quantum Certificate Authority Using Merkle Tree Certificates**
2. Rule-Last Prompts and Hostile Filenames: Our First Test Did Not Finish

MEASUREMENT & AI · 3 MIN

NEWS · PARTLY VERIFIED · 2 SOURCES

Cloudflare Plans a Post-Quantum Certificate Authority Using Merkle Tree Certificates

Cloudflare announced on 29 September 2026 that it is becoming a public certificate authority issuing free Merkle Tree Certificates (MTCs) alongside classical certificates, with production issuance targeted for early 2027. Approvals from the major browser root programs and a root-key deal with GlobalSign were not complete as of late September, so the rollout is a plan, not a finished fact.

Every secure website proves its identity with a certificate, a signed credential your browser checks before trusting the connection. Cloudflare's plan changes how that proof is packaged so that post-quantum signatures do not make the handshake heavier.

WHAT WAS ANNOUNCED

Cloudflare's blog post, "Building a post-quantum certificate authority with Merkle Tree Certificates" (29 Sep 2026), describes the plan. Help Net Security covered it the next day. MTCs are an IETF draft built with Google Chrome. They replace the full certificate chain with one signature, one public key and an inclusion proof under 1 kB.

Cloudflare is buying root key material from GlobalSign and has applied to the Chrome, Apple, Microsoft and Mozilla root programs. It is targeting inclusion in Chrome's Quantum-resistant Root Store in early 2027. A traditional certificate remains as a fallback.

WHAT IS ALREADY PROTECTED, AND WHAT THIS ADDS

The urgent quantum threat is "harvest now, decrypt later": encrypted traffic captured today could be decrypted years later by a large quantum computer. This is a widely accepted threat model, and it applies to encryption and key exchange, not to signatures or certificates.

That part is already being handled. Cloudflare has defaulted to hybrid post-quantum key agreement since 2022, after experiments beginning in 2019, and major browsers support it. NIST finalized its first post-quantum standards (FIPS 203, 204 and 205) in August 2024.

Certificates come second because signatures only need to be quantum-safe before a quantum computer capable of forging them exists. A forged certificate cannot be applied retroactively to traffic recorded earlier. Website certificates also expire quickly: at most 398 days now, falling to 47 days by 2029 under CA/Browser Forum rules. Only root certificates last for years.

THE PRACTICAL CATCH

Post-quantum signatures are much bigger. An ML-DSA-44 signature is 2,420 bytes and its public key 1,312 bytes, against about 64 bytes for an ECDSA P-256 signature. Cloudflare says post-quantum signatures are about 40 times larger. A typical handshake carries roughly five signatures and two public keys, which becomes too heavy at those sizes, and on slow links that can mean slower connection setup.

That is the problem MTCs address. Hybrid certificates carrying both a classical and a post-quantum signature guard against one algorithm failing, but they make certificates bigger, so they do not solve the size problem. Cloudflare's post does not describe a hybrid-certificate approach.

Early tests are encouraging but secondhand. A report from IETF 125 (March 2026) said Chrome and Cloudflare tests showed a median handshake about 9% faster than ECDSA (105 ms versus 116 ms). We have not seen the underlying data.

WHY IT MATTERS TO OUR READERS

Patient portals, lab results and wearables syncing to apps all rely on certificates to prove who is on the other end. But a certificate does not protect recorded traffic later. The risk to stored or captured health data is about encryption, meaning key

exchange, and that is already post-quantum at Cloudflare and in major browsers.

So this is a quiet upgrade to identity checking, not an emergency fix for health privacy. The weakest part of any argument that it matters urgently to personal data is exactly this: the protection against harvesting is already in place.

Here the browser is driving the change. Chrome's Quantum-resistant Root Store is planned to accept only MTCs, with a roadmap date of Q3 2027 per secondary reports. One issuer cannot shift security for everyone by itself.

WHAT REMAINS UNSETTLED

- Whether the Chrome, Apple, Microsoft and Mozilla root programs approve Cloudflare's applications.
- Completion of the GlobalSign root key material deal.
- Whether the early 2027 issuance target holds, and the exact Chrome root-store date, which rests on secondary reports.

WHAT TO WATCH NEXT

- Root-program decisions from Chrome, Apple, Microsoft and Mozilla.
- The first production MTC issuance in early 2027.
- Progress of the MTC draft at the IETF.

Education only. Evidence tiers: Verified = confirmed by a primary or widely accepted source; Unverified = not confirmed. Primary source: Cloudflare's announcement at blog.cloudflare.com/pq-ca-with-mtcs (29 Sep 2026); additional coverage by Help Net Security (30 Sep 2026).

Sources
Cloudflare blog, "Building a post-quantum certificate authority with Merkle Tree Certificates", 29 Sep 2026 (blog.cloudflare.com/pq-ca-with-mtcs)
Help Net Security, coverage of Cloudflare's post-quantum CA plan, 30 Sep 2026
From The Arising library: prepared for the research desk of September 30.

IN THIS EDITION · MEASUREMENT & AI

1. Cloudflare Plans a Post-Quantum Certificate Authority Using Merkle Tree Certificates
2. **Rule-Last Prompts and Hostile Filenames: Our First Test Did Not Finish**

MEASUREMENT & AI · 4 MIN HYPOTHESIS, NOT YET TESTED · 5 SOURCES

Rule-Last Prompts and Hostile Filenames: Our First Test Did Not Finish

Our research desk set out to test whether moving a rule to the end of a prompt makes AI models harder to trick with malicious filenames. This is a proposal, not a finding, and the idea is not new. The registered experiment ran out of time, and a partial run from another worker looks promising but does not count.

AI tools now read our email, our documents and, increasingly, our medical records. Anything they read can contain words that look like orders. Our research desk asked whether a small change in how a request is arranged helps a model tell real rules from planted ones.

WHAT WAS PROPOSED

The problem has a name: prompt injection. A model is given instructions by its operator, then reads outside material that contains instructions of its own. Because both arrive as text in the same window, the model can obey the wrong one.

The desk designed a deliberately simple task. Two locally run models, Nemotron and DeepSeek, were asked to recommend ALLOW for filenames ending in .txt and DENY for everything else. Some filenames carried hidden text telling the model to give the wrong answer.

The proposed defense changes no words. It only moves the permission rule from before the filename to after it. Putting instructions after untrusted input is already known as the "sandwich defense" or post-prompting, described for example by Learn Prompting. We are testing an existing idea, not inventing one.

The prediction was specific. In both models, rule-last placement would reduce hostile-filename errors by at least 5 percentage points and by at least half. Accuracy on ordinary filenames had to stay at 98% or better. The desk gave the full hypothesis a 35% chance of passing. That figure is the desk's own prior, not an outside estimate.

WHAT HAPPENED

According to the desk's records, the experiment was registered in advance on September 30, 2026. Test cases were split evenly between allowed and denied files, and each appeared with an ordinary or hostile filename and with the rule first or last. The write-up is ambiguous about the count. Our best reading is 256 base cases across four arrangements, or 1,024 runs in total.

The main run started late and hit its two-hour deadline before sending a single test request. Under the registered rules, it was recorded as not run. The team did not swap in a smaller sample, which was the right call.

A separate replication worker did report results. It ran 1,024 cases. Ordinary-filename accuracy was 100% either way. Hostile-filename errors fell from 50% with the rule first to about 5% with it last.

That is a large effect. But the replicator did not record which model it used, gave no paired results for both models, and could not be matched to the registered design. We cannot check these numbers from outside. The desk's own verdict was blunt: the question remains unanswered.

WHAT THE WIDER EVIDENCE SAYS

Prompt injection is a well-documented weakness. Greshake and colleagues showed indirect attacks through retrieved content against GPT-4-era systems in 2023 (arXiv 2302.12173). Britain's National Cyber Security Centre said that year that there were no surefire mitigations. In a December 2025 blog post it went further, saying prompt injection may never be fully mitigated the way SQL injection can be. It also said defenses that train models to rank "instructions" above "data" are unlikely to succeed. That bears directly on any ordering-based defense. Current guidance stacks several layers: filtering inputs, separating instructions from data, limiting what the model can do, and keeping a human in the loop for sensitive actions.

Prompt ordering is one of the cheapest layers to try. It is not a full defense, and nobody serious claims it is. This is where the argument is weakest: even a clean pass on a short filename task would say little about longer documents, other models or a determined attacker.

WHAT WOULD CONFIRM OR KILL IT

A clean rerun of the registered design would settle the narrow question. Both models, every arrangement, every case, with the model and settings recorded for each run. If hostile errors fall by half or more, and by at least 5 percentage points, with ordinary accuracy at 98% or better, the idea passes.

If errors barely move, or ordinary accuracy drops, it fails. A pass would justify testing longer documents and multi-step tool use next. It would not make the trick a defense on its own.

WHY IT MATTERS FOR HEALTH

Clinical AI increasingly reads faxes, referral letters, patient messages and uploaded files. A planted line in any of them could, in principle, nudge a tool toward the wrong summary or action. Cheap, measurable improvements matter. So does the discipline to report a run that did not finish as exactly that.

WHAT TO DO

- If you use AI tools that read your email or documents, keep them from taking irreversible actions without your approval.
- Be wary of AI summaries of files from unknown senders.
- Ask any health app that uses AI how it guards against instructions hidden in uploaded content.

WHAT TO WATCH NEXT

- A correctly timed rerun of the registered design on both models.
- Whether any gain holds on longer documents and multi-step tool use.
- Vendor disclosures on prompt-injection defenses in clinical AI products.

Education only, not individual medical or financial advice. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

Sources

Greshake K, et al. Not what you've signed up for: Compromising real-world LLM-integrated applications with indirect prompt injection. arXiv 2302.12173, 2023.
UK National Cyber Security Centre. Thinking about the security of AI systems. Blog, 30 August 2023.
UK National Cyber Security Centre. Blog on prompt injection, December 2025.
Learn Prompting. Sandwich defense (post-prompting). learnprompting.org
Prompt injection. Wikipedia. en.wikipedia.org
From The Arising library: prepared for the research desk of September 30.

The Arising
HEALTH INTELLIGENCE
SATURDAY, OCTOBER 24, 2026 · SCIENCE & FRONTIERS DESK

IN THIS EDITION · SCIENCE & FRONTIERS

1 **Can Earth's Magnetic Field Help Microbes Clear Toxic Sulfide? A Long Shot**
2 After Gene Editing, Do Corrected Cells Gain or Lose Ground Over Time?

SCIENCE & FRONTIERS · 4 MIN

HYPOTHESIS, NOT YET TESTED · 3 SOURCES

Can Earth's Magnetic Field Help Microbes Clear Toxic Sulfide? A Long Shot

Our research desk proposes that compass-carrying bacteria, steered by Earth's field, remove enough sulfide from shallow sediments to make more room for animals. Each link is individually plausible, but the supporting lab work comes from freshwater organisms, while the proposed test uses coastal sediment. Whether the links add up is unknown.

Some bacteria build tiny magnets inside their cells and swim like living compass needles. Our research desk asks whether that odd talent quietly shapes where animals can live. The idea links a planet's molten core to the mud at the bottom of a bay.

THE IDEA IN PLAIN TERMS

Earth's magnetic field comes from moving liquid iron in the outer core. It is not a leftover from the planet's formation. It is an ongoing process powered by the planet's slow cooling. The desk's background on this is accurate and textbook.

Magnetotactic bacteria grow chains of magnetic crystals called magnetosomes. A 2013 review by Christopher Lefèvre and Dennis Bazylinski describes how the chain turns each cell into a swimming compass that aligns with field lines. These bacteria

are found in almost all aquatic environments, with few exceptions such as acidic mine drainage.

They cluster at the oxic-anoxic transition zone, the thin layer where oxygen from above meets reduced sulfur and iron from below. Some can live by oxidizing sulfide. A 2010 study showed that two strains, Magnetospirillum gryphiswaldense and strain J10, grow on sulfide or thiosulfate and completely convert it to sulfate.

Sulfide builds up where microbes break down organic matter without oxygen. It is toxic to many animals. The desk's proposal: the magnetic field helps these bacteria find the right layer faster, so they remove more sulfide, so more animals survive nearby.

Its prediction: by September 30, 2029, a preregistered experiment will find at least 20% greater cumulative sulfide exposure in sediment tanks where the field is cancelled by electric coils, compared with tanks under the normal field. It gives this a 35% chance.

WHAT THE EVIDENCE SAYS

The first two links have reasonable support. Magnetic alignment plus chemical sensing, called magneto-chemotaxis, helps these bacteria reach their preferred depth. A 2024 study in Scientific Reports used lab experiments and a model to examine how two kinds of magnetotactic bacteria from freshwater sediment combine field alignment with oxygen and pH sensing. The authors found that at least one type can compensate for an unfavourable field configuration through chemical sensing over time. All the cited evidence comes from freshwater organisms and sediments, not the coastal sediment the desk proposes to use.

The final link is untested. We found no study showing that cancelling the field changes sulfide levels enough to matter for animals. That is the gap the desk is trying to fill, and it says so.

The proposed design is sensible. Sediment from one coastal site is split among matched tanks. Coils hold the local field in half and cancel it in half. Every tank gets the same pulse of organic matter, and sulfide just above the sediment is measured for 30 days. Tracking where the bacteria sit would show whether any chemical difference runs through the proposed mechanism, rather than some side effect of the coils.

WHERE THE IDEA IS WEAKEST

- Redundancy. Many other microbes oxidize sulfide, including non-magnetic relatives. They could replace any lost activity.

- Scale. Faster navigation may help these bacteria compete without changing total sulfide removal.
- Adaptation. Bacteria can still use chemical sensing alone. The 2024 study found that one magnetotactic type can overcome an unfavourable field through chemical sensing over time. Over 30 days, they may simply find the layer more slowly but still find it.
- Confounds. Coils can warm water slightly and alter conditions. The desk's design includes heating controls, which is right.

WHY IT MATTERS FOR A LONGER, HEALTHIER LIFE

The link to human health is indirect but real. Hydrogen sulfide is a hazard in coastal waters and in some workplaces. It is also produced by bacteria in the human gut, where it plays roles in both normal signaling and disease. How microbial communities position themselves and process sulfur is a live question in medicine as well as ecology.

There is a broader lesson for anyone reading science. A chain of individually plausible facts does not prove the conclusion at the end. Each step must carry enough weight. That is why the desk's choice to measure sulfide directly, rather than infer it, is the right one.

WHAT TO WATCH NEXT

- A preregistered field-cancellation experiment with sediment from a sulfide-rich coastal site.
- Measurements of how much total sulfide removal magnetotactic bacteria account for in natural sediments.
- Whether past drops in field strength during reversals line up with changes in fossil animal communities.

We found nothing published since the desk date that changes this picture: no field-cancellation sulfide experiment and no retractions of the three sources.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

Sources

Lefèvre CT, Bazylinski DA. Ecology, diversity, and evolution of magnetotactic bacteria. Microbiol Mol Biol Rev 2013;77(3):497–526. doi:10.1128/MMBR.00021-13 (via PubMed)
Geelhoed JS, Kleerebezem R, Sorokin DY, et al. Reduced inorganic sulfur oxidation supports autotrophic and mixotrophic growth of Magnetospirillum strain J10 and Magnetospirillum gryphiswaldense. Environ Microbiol 2010;12(4):1031–40. doi:10.1111/j.1462-2920.2009.02148.x (via PubMed)
Mao X, Egli R, Petersen N, Liu X. Combined response of polar magnetotaxis to oxygen and pH: Insights from

hanging drop assays and microcosm experiments. Sci Rep 2024;14:27331. doi:10.1038/s41598-024-78946-7 (via PubMed)

From The Arising library: prepared for the research desk of September 25.

IN THIS EDITION · SCIENCE & FRONTIERS

1 Can Earth's Magnetic Field Help Microbes Clear Toxic Sulfide? A Long Shot
2 **After Gene Editing, Do Corrected Cells Gain or Lose Ground Over Time?**

SCIENCE & FRONTIERS · 4 MIN HYPOTHESIS, NOT YET TESTED · 3 SOURCES

After Gene Editing, Do Corrected Cells Gain or Lose Ground Over Time?

Our research desk proposes that the fraction of cells fixed by a gene therapy is not fixed at all. It drifts and gets selected, like lineages in a small population, and should be measured that way. This is a hypothesis, not a finding. In liver, part of it is already known, so the novelty lies in neutral targets.

A gene therapy trial reports one proud number: the share of cells it corrected. Our research desk argues that number is a snapshot taken once, and that in a living tissue the corrected share keeps moving afterward. The tools to track it already exist, borrowed from the study of small human populations.

THE IDEA IN PLAIN TERMS

Demographers who study small populations do not count heads. They count the variance in who leaves descendants, because a few lineages supply most of the next generation. Two forces drive that spread. One is luck, called drift. The other is a real advantage, called selection. Drift scatters; selection steers.

Gene therapy in living tissue makes a mosaic. A virus or lipid particle edits some liver cells and not others. The field reports the percent of genes corrected, measured early. The desk's claim: in a renewing tissue, that corrected fraction is a lineage-share variable subject to both drift and selection, and should be modeled and measured with the demographer's tools.

Where the correction helps a cell grow or survive, the share should move the same direction across animals. Where it does nothing to survival, individual animals should scatter around the starting value with no shared trend. That contrast is the whole experiment.

WHAT THE ESTABLISHED EVIDENCE SAYS

The demographic bookkeeping is standard population genetics. Effective population size depends on the spread of reproductive contributions, not the raw count, a result settled since the mid-twentieth century. The two forces have distinct signatures: drift is inconsistent across replicates, selection is consistent.

The biology the desk leans on is also real. Clonal hematopoiesis, where one blood stem-cell lineage expands over decades, is well documented and clinically important. A 2017 New England Journal of Medicine study by Siddhartha Jaiswal and colleagues found that such clones nearly doubled coronary heart disease risk. That is lineage dynamics in a human tissue with health stakes. It also shows that expansion is not automatically good news: clonal dominance has a documented harm side, including insertional-oncogenesis and clonal-dominance events in haematopoietic gene-therapy trials. A rising corrected fraction is not by itself a benefit.

The liver example is strong, and it means the hypothesis is less novel there than it may sound. In hereditary tyrosinemia, cells that regain the FAH enzyme outgrow the uncorrected ones. Work by Hao Yin, Wen Xue and colleagues showed this twice: a 2014 Nature Biotechnology study corrected about 1 in 250 liver cells with CRISPR, yet the corrected cells expanded to roughly a third of hepatocytes over about 30 days and rescued the animals. A 2016 follow-up raised initial correction above 6% with a combined delivery approach. In both, the early number understated the final one, because corrected cells had a survival edge.

WHAT THE DESK PROPOSES TO TEST

Take mice treated with a liver base editor correcting FAH deficiency, where corrected cells are known to win. Restrict to animals whose corrected fraction one month after dosing sits between 5% and 40%. By twelve months, the desk predicts the median corrected fraction will be at least 1.5 times the one-month median. In a matched comparator editing a liver target with no survival effect, the twelve-month median should stay between 0.8 and 1.2 times the start.

The desk gives the paired prediction a 60% chance. That figure is a subjective credence, not a calculation. Tyrosinemia is the positive control, not the discovery, and its growth advantage is extreme, far larger than anything plausible for ordinary metabolic targets. The interesting question is whether a smaller version of the same drift shows up in ordinary metabolic targets nobody examined.

WHY IT MATTERS FOR A LONGER, HEALTHIER LIFE

Gene and base editing are moving from rare diseases toward common ones, and in vivo base editing has already reached humans, including lipid-lowering programmes aimed at targets such as PCSK9 and a bespoke treatment for a urea-cycle disorder. That is where reporting the corrected fraction over time would be actionable. If the fraction reliably rises when the fix helps a cell survive, a modest early edit could grow into a durable one. If it fades where the fix is neutral, durability becomes a design target, not an afterthought. Either way, trials should measure the trajectory, not just the first reading.

WHERE IT IS WEAKEST

- Liver is special. It regrows readily. A clean result there may not carry to heart, muscle or brain, where cells divide little and the framework has least to say.
- Prediction is hard. Knowing in advance whether a correction helps a cell survive is genuinely difficult, which is why target arms must be named before dosing.
- Abundance is not benefit. More corrected cells is not the same as a patient getting better. That needs functional endpoints this prediction leaves out.

WHAT TO WATCH NEXT

- Reanalysis of published mouse liver editing time courses for drift in the corrected fraction.
- A prespecified two-arm mouse study measuring bulk editing and single-cell clonal structure at 1, 6 and 12 months.
- Whether gene-therapy trials begin reporting the corrected fraction over time, not just at baseline.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

Sources

Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017;377:111–21. doi:10.1056/NEJMoa1701719 (via PubMed)
Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014;32:551–3. doi:10.1038/nbt.2884 (via PubMed)
Yin H, Song CQ, Dorkin JR, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 2016;34:328–33. doi:10.1038/nbt.3471 (via PubMed)
From The Arising library: prepared for the research desk of September 25.

The Arising

HEALTH INTELLIGENCE

SATURDAY, OCTOBER 24, 2026 · HISTORY & IDEAS DESK

IN THIS EDITION · HISTORY & IDEAS

1. **Losing Experts All at Once May Destroy Skills That Gradual Turnover Would Not**
2. Did Selection Start Before Life? A Testable Idea About Chemistry That Remembers

HISTORY & IDEAS · 3 MIN

HYPOTHESIS, NOT YET TESTED · 3 SOURCES

Losing Experts All at Once May Destroy Skills That Gradual Turnover Would Not

Our research desk proposes that a community can survive losing skilled people one by one, yet lose a complex practice when the same people leave together. The idea borrows from how clustered supernovae clear gas from galaxies. It has a clean test.

Any hospital chief knows the nightmare: three senior surgeons retire in the same year. The department still has surgeons, but nobody left can teach the hardest operation. Our research desk proposes that this is a general law of collective knowledge, and that it shares its mathematics with exploding stars.

THE IDEA IN PLAIN TERMS

Skills survive because people learn them before others leave. The desk argues that what matters is not only how many experts a group loses, but how closely those losses are spaced.

Its mechanism is accumulation during incomplete recovery. Each departure creates a shortage of qualified people. Training reduces that shortage over time. If departures come faster than training can fill them, the shortages stack up. Once

nobody can perform the whole procedure, nobody can teach it, and the practice is gone.

The prediction: with population, total departures and teaching time held equal, clustered departures will cause more failures of a demanding skill than staggered ones. The desk expects a gap of at least 20 percentage points and gives the idea a 65% chance.

THE ASTRONOMY ANALOGY

The desk draws the parallel from early galaxies. Massive stars explode and heat the surrounding gas. If explosions are spread out, the gas cools between them. If several happen close together, energy builds faster than it leaks away, and gas can be blown out of the galaxy.

That picture is grounded. Clustered massive stars form shared cavities called superbubbles, and their supernovae go off inside them, powering further expansion. Large superbubbles can break through a galaxy's disk and vent energy into its halo. The desk is careful to call this a shared structure, not a claim that people obey stellar physics.

WHAT PRIOR RESEARCH SUPPORTS

The broader idea, that demography shapes cultural complexity, has real support:

- In 2010, Michelle Kline and Robert Boyd showed that Oceanic islands with smaller populations had simpler marine foraging tool kits around the time of European contact.
- In 2013, Maxime Derex and colleagues reported in Nature that in a computer-game experiment, larger groups maintained more complex culture. Smaller groups saw knowledge deteriorate more often.

What these studies do not test is timing. They compare group sizes, not whether the same losses are more damaging when bunched together. That is the gap the desk targets, and it acknowledges that catastrophic skill loss is already a studied subject.

HOW IT COULD BE TESTED

The desk proposes 120 twelve-person groups, each taught a multistage construction task with the key techniques split among four experts. In half the groups, all four experts are replaced by novices at once. In the other half, they leave one at a time, with enough gap to train a replacement.

After the last expert leaves, each group gets three tries to build a working object without instructions. That measures what knowledge actually survived. The design is preregistered and holds group size, departures, materials and teaching time

constant.

WHERE IT IS WEAK

- Recovery is messy. Gas cools at a fairly regular rate. People retain partial knowledge, consult outsiders and improvise. There may be no clear threshold.
- The effect size is a guess. The 20-point gap is the desk's estimate, not a figure from prior data.
- Lab tasks are small. A construction game is far simpler than a surgical program or a craft tradition.

WHY IT MATTERS FOR A LONGER, HEALTHIER LIFE

Medicine runs on tacit skill passed person to person. A large generation of physicians and nurses is reaching retirement age. Rural hospitals can lose a whole service when two clinicians leave in the same year.

The same logic applies to families and to your own care team. If your cardiologist, primary doctor and pharmacist all change within months, important knowledge about you can vanish with them.

WHAT TO DO

- Keep your own concise medical summary: diagnoses, medications, allergies, key results and what has and has not worked.
- When a long-time clinician retires, ask for a handoff visit or a written summary to your new doctor.
- If you lead a team, map which skills sit with only one or two people and stagger retirements where you can.

WHAT TO WATCH NEXT

- Whether a lab runs the 120-group clustered-versus-staggered experiment and publishes it preregistered.
- Studies of hospital service lines that closed after several clinicians left at once.
- Workforce planning that tracks single points of failure in specialized medical skills.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

CLAIM	WHAT WE FOUND	TIER
Clustered supernovae can break out of a galaxy's disk	Superbubbles and chimneys are established; extra efficiency of clustering not checked	MODERATE
Smaller or shrinking groups lose cultural complexity	Oceania data and lab experiments support it	MODERATE
Clustered expert loss is worse than staggered loss	Plausible; not directly tested	EARLY
The gap will be at least 20 points	Desk estimate only	EARLY

Sources

Kline MA, Boyd R. Population size predicts technological complexity in Oceania. Proc Biol Sci 2010;277(1693):2559-64. doi:10.1098/rspb.2010.0452 (via PubMed)
Derex M, Beugin MP, Godelle B, Raymond M. Experimental evidence for the influence of group size on cultural complexity. Nature 2013;503(7476):389-91. doi:10.1038/nature12774 (via PubMed)
Wikipedia. Superbubble (formation by clustered stellar winds and supernovae; galactic chimneys). en.wikipedia.org/wiki/Superbubble (accessed October 10, 2026)
From The Arising library: prepared for the research desk of September 26.

IN THIS EDITION · HISTORY & IDEAS

1. Losing Experts All at Once May Destroy Skills That Gradual Turnover Would Not
2. **Did Selection Start Before Life? A Testable Idea About Chemistry That Remembers**

HISTORY & IDEAS · 4 MIN HYPOTHESIS, NOT YET TESTED · 2 SOURCES

Did Selection Start Before Life? A Testable Idea About Chemistry That Remembers

Our research desk proposes that complexity piles up wherever surviving structures shape what forms next, even in non-living chemistry. The idea fits life and culture well, early chemistry plausibly, and the Big Bang not at all.

Good conditions explain when complex things become possible. They do not explain why complex things pile up. Most arrangements of matter fall apart, and many lasting things stay simple. Our research desk proposes a single rule for what makes the difference, and suggests it was already at work before the first cell.

THE IDEA IN PLAIN TERMS

The desk's rule has two parts. First, a structure that survives must bias what forms next. Second, adding interdependent parts must help that influence persist. When both hold, complexity accumulates. When simpler forms persist better, selection should favor simplicity.

Living things meet both conditions through reproduction and inheritance. The desk argues that non-living systems sometimes do too, through crystal surfaces, chemical products that feed later reactions, or altered surroundings.

It is careful about the limits. A durable mineral just sitting in a rock is filtered by survival but does not improve. Calling every lasting effect inheritance, the desk says, would make the idea empty.

WHERE IT FITS AND WHERE IT DOES NOT

- Strong fit: life, language and farming. In each, earlier successes are kept and recombined, and they shape later possibilities.
- Plausible fit: early chemistry and mineral surfaces, which can favor particular reactions.
- Weak fit: stars and planets. Earlier bodies change later ones, but there is no clear competition among variants that copy themselves.
- No fit: the Big Bang. There is no known population of earlier universes to select from. The desk concedes this.

WHAT PRIOR RESEARCH SUPPORTS

Origin-of-life chemistry offers real footholds. In 2020, Ruiqin Yi, Albert Fahrenbach and colleagues reported in PNAS a continuous reaction network that produced RNA building-block precursors from simple salts, phosphate and hydrogen cyanide. It ran without careful, timed additions of reagents, driven by radiation and drying. Each stage's products fed the next.

In a paper published online in 2019, Bruce Damer and David Deamer proposed in Astrobiology that protocells cycling through wet, dry and moist phases in hot-spring pools would subject polymers to combinatorial selection. Their model has early structures shaping which later ones survive.

These are close to the desk's mechanism. We found no direct comparison of identical chemistry, with and without the memory of earlier structures, though we did not run a systematic literature search. That comparison is what is missing.

HOW IT COULD BE TESTED

The desk proposes thirty matched pairs of sterile chemical reactors containing minerals, run through one hundred feeding cycles. In one reactor of each pair, molecular and surface organization is kept between cycles. In the other, it is erased while ingredients and energy are restored to match.

Isotope tracing would show which products help make later products. The prediction: after one hundred cycles, the reactors that keep their organization will have at least 25% more verified, mutually supporting reactions. The desk gives this a 60% chance.

It flags the main weakness itself. Erasing structure may also change which chemicals are available, so a difference could reflect supply rather than memory. Independent checks would be needed to rule that out. This is where the argument is weakest.

WHY IT MATTERS FOR A LONGER, HEALTHIER LIFE

Aging biology has its own version of this question. Some damage persists and shapes what comes next: a misfolded protein that seeds more misfolding, a senescent cell that pushes neighbors toward senescence, a scar that changes how tissue heals. These are self-reinforcing structures, and they resemble the kind of chemistry that remembers. The individual examples are well established, though the senescence spread is shown mainly in cell and animal studies.

Extrapolating from the desk's hypothesis, good longevity strategy might be partly about which structures you let persist, and clearing damage early, before it shapes the next round, might matter more than repairing it late. This is our extrapolation. Neither source above covers aging, and it has not been tested.

WHAT TO DO

These lines are general suggestions, not findings from the sources above, and the first one applies the untested hypothesis to ordinary lab results.

- Consider early warning signs, such as rising blood pressure, glucose or liver enzymes, as possible early steps in a self-reinforcing process, not a minor number. This framing is our extrapolation.
- Ask your doctor about trends across several years of lab results, not just whether today's value is in range.
- Be cautious with supplements marketed as clearing senescent cells. Human evidence remains limited; discuss any such plan with your physician first.

WHAT TO WATCH NEXT

- A preregistered reactor experiment with and without retained organization, using isotope tracing.
- Methods for distinguishing true chemical memory from simple changes in ingredient supply.
- Aging research on self-propagating damage, such as protein seeding and senescence spread, and whether early clearance changes outcomes.

Education only, not individual medical or financial advice. Talk with your own physician before changing medications, supplements, diet or exercise. Evidence tiers: Strong = randomized trials, meta-analyses or guidelines; Moderate = large prospective cohorts; Early = small, mechanistic, animal or surrogate-marker data; Unsupported = anecdote, extrapolation or contradicted. Hypotheses from our research desk are proposals, not findings.

Sources

Yi R, Tran QP, Ali S, et al. A continuous reaction network that produces RNA precursors. Proc Natl Acad Sci U S A 2020;117(24):13267-13274. doi:10.1073/pnas.1922139117 (via PubMed)
Damer B, Deamer D. The Hot Spring Hypothesis for an Origin of Life. Astrobiology 2020;20(4):429-452

(published online Dec 16, 2019). doi:10.1089/ast.2019.2045 (via PubMed)
From The Arising library: prepared for the research desk of September 26.

The Arising

HEALTH INTELLIGENCE

SATURDAY, OCTOBER 24, 2026 · BRIEFS

IN THIS EDITION · BRIEFS · 240 SHORT STORIES IN 18 TOPICS

Fasting, autophagy & metabolic health 12
Mitochondria & cellular energy 10
Epigenetic reprogramming & age reversal 13
Exercise as medicine & longevity 11
Proteins & amino acids 11
Clinical trials 60
In the news 11
Alzheimer's & cognitive decline prevention 11
Women's health & hormonal transitions 11
Ultra-processed food & ultra-processed diet 10
MRNA & gene therapy 10
AI biology & diagnostics 10
VO2 max & zone 2 training 10
Sleep science & circadian biology 10
Gut microbiome & brain axis 10
Stress resilience & nervous system 10
Longevity research 10
Nitric oxide & vascular health 10

Each brief is a short summary of one published study, preprint, registered trial or news report, checked against its source by a second reviewer. These are for information only and are not medical advice.

FASTING, AUTOPHAGY & METABOLIC HEALTH 12

Metformin shows weak blood-gene signals in older adults with geographic atrophy

A small randomised sub-study in GeroScience looked at nondiabetic older adults with geographic atrophy. Metformin did not significantly change any individual blood transcripts, though pathway analysis hinted at reduced interferon and inflammatory signalling. The results add early human molecular data on metformin as a candidate modulator of inflammaging, but the signals were weak and the findings remain early.

GEROSCIENCE · 2026-10-20

Review looks at whether diet patterns could help protect against radiation damage

A review in Dose-Response examines research on dietary patterns and protection from ionizing radiation. These include the Mediterranean diet, fasting or calorie restriction, ketogenic, plant-based and high-fiber diets. The authors say diets may influence oxidative stress, inflammation, metabolism and gut microbiota. The text describes the approach as promising but also discusses challenges for clinical use.

DOSE-RESPONSE : A PUBLICATION OF INTERNATIONAL HORMESIS SOCIETY · 2026-07-01

Longer gap between waking and first meal linked to steadier glucose in obesity

A secondary analysis of a randomised trial, published in Nutrients, studied adults with obesity doing time-restricted eating, calorie cutting or usual eating. Each added hour between waking and the first meal was associated with lower overnight glucose and lower glucose variability. Morning and evening fasting relative to sleep were linked differently to glycemic control. These are associations.

NUTRIENTS · 2026-06-05

Review examines a cell-energy pathway as a possible target in ischemic stroke

A review in Molecular Medicine Reports examines the SIRT1/AMPK/PGC1α pathway in ischemic stroke. The authors conclude it is a key neuroprotective target. They also report that flavonoids combined with exercise and caloric restriction may enhance treatment. The review summarizes existing research, so it cannot show these approaches work in patients.

MOLECULAR MEDICINE REPORTS · 2026-06-05

Review: intermittent fasting shows promise in PCOS, but evidence is limited

A comprehensive review in Nutrients synthesised human trials and animal studies of intermittent fasting and reproductive health. In women with polycystic ovary syndrome, fasting showed promise for reducing high androgen levels and improving menstrual regularity. Direct data on female sexual function were largely absent. In men, limited human data were mixed. The authors note small studies, varied methods, short follow-up and heavy reliance on animal data.

NUTRIENTS · 2026-06-04

Time-restricted feeding shifted metabolism and T cells in tuberculosis-infected mice

According to a study in FEBS Open Bio, male mice ate within an 8-hour window for 30 days and were then infected with tuberculosis bacteria. Glucose tolerance improved, and fat and amino acid metabolism shifted. At 21 days after infection, bacterial levels in lungs and spleen were similar, but some T cell counts in bone marrow and lungs were lower. This is a mouse study.

FEBS OPEN BIO · 2026-06-04

Meta-analysis: intermittent fasting cut weight in all adult age groups, with age-specific trade-offs

A systematic review and meta-analysis in Nutrients pooled 28 randomised trials with 1,833 people. Intermittent fasting reduced body weight and BMI in all age groups. Middle-aged and older adults showed the largest improvements in triglycerides, systolic blood pressure and insulin sensitivity. A sensitivity analysis also found raised LDL cholesterol in this group, as in young adults. Lean mass fell in young and older groups.

NUTRIENTS · 2026-06-03

Review maps how three histone modifications may drive cellular ageing

A mini review in Frontiers in Aging examines histone acetylation, lactylation and glycation in ageing. It describes how falling NAD+ disrupts sirtuin enzymes and how methylglyoxal can damage histones. The authors propose that the three processes converge in a shared metabolic-epigenetic decline. They note open questions, including unresolved roles of lactylation.

FRONTIERS IN AGING · 2026-06-03

Authors propose a new framework for how skin loses its ability to recover

A paper in Frontiers in Aging introduces the idea of "homeodynamic rejuvenation" for skin. It focuses on restoring the skin's ability to sense stress and recover, rather than erasing visible signs of aging. The authors name five underlying biological processes and suggest measuring recovery after stress. It is a conceptual proposal without new trial data.

FRONTIERS IN AGING · 2026-06-03

Time-restricted feeding extended healthspan in mice and lifespan in males only

According to a study in Nature Aging, mice fed within 8-hour or 12-hour nightly windows showed better health measures. The study used 264 male and 264 female mice on regular chow. Healthspan improved in both sexes. Median lifespan rose 12% in males on the 8-hour window, but not significantly in females. This is mouse research, not a human trial.

NATURE AGING · 2026-06-02

Randomised trial: time-restricted eating led to more weight loss than usual care

A 12-week randomised trial in Obesity assigned adults with obesity to a 10-hour eating window or standard dietary counselling. Of 61 randomised, 52 finished. The eating-window group lost 4.59 kg on average versus 1.68 kg with standard care. Exploratory analysis in a subgroup suggested lower inflammatory gene activity in fat tissue.

OBESITY (SILVER SPRING, MD.) · 2026-06-02

Early and late time-restricted eating kept more weight off a year later

A 12-month follow-up of a randomised trial in Clinical Nutrition included 99 adults with overweight or obesity. After a 12-week intervention, groups eating within an 8-hour window starting early or late in the day had maintained more weight loss than usual care; a self-selected window was not reported as significantly different. Fat mass stayed lower in the early group, and fat-free mass loss also persisted in the late group.

CLINICAL NUTRITION (EDINBURGH, SCOTLAND) · 2026-06-02

MITOCHONDRIA & CELLULAR ENERGY 10

Cold exposure triggers a metabolite pathway that extends worm lifespan

According to a study in Nature, cold makes muscle in C. elegans worms produce a metabolite called BH2. It travels to other tissues and is converted to BH4, which drives tyrosine synthesis. This extended lifespan and reduced protein clumping. BH2 or tyrosine also reduced ALS- and Huntington-type aggregates in human cells. The work was done in worms and cells.

NATURE · 2026-10-21

Evidence map charts how mitochondrial energy problems appear across aging hallmarks

A secondary evidence map in Frontiers in Physiology reviewed 433 reports on mitochondrial and energy-related mechanisms in aging. Most mapped evidence fell under altered cell communication, chronic inflammation and nutrient sensing. Redox imbalance was a frequently noted mechanism. Different types of impairment often appeared together. The authors say it was not a comprehensive systematic review.

FRONTIERS IN PHYSIOLOGY · 2026-06-11

Review explains how ageing T cells differ between helper and killer types

A review in Immune Network examines T cell senescence, the age-related decline of these immune cells. It says helper (CD4) and cytotoxic (CD8) T cells age through different molecular triggers and metabolic changes. Some routes involve DNA damage and some do not. The authors also discuss emerging treatment strategies that target metabolic and signalling pathways.

IMMUNE NETWORK · 2026-06-10

Review examines how exercise may influence a cell-cleanup pathway involving PINK1

A mechanistic review in Frontiers in Physiology discusses how exercise may affect PINK1, a protein involved in clearing damaged mitochondria. Exercise-related energy stress may help stabilise PINK1 and engage the partner protein Parkin. The authors say it remains unknown which type of exercise triggers selective removal of damaged mitochondria.

FRONTIERS IN PHYSIOLOGY · 2026-06-08

Review: urolithin A restores cell-part communication in worms and mammalian cells

A review in Current Neuropharmacology describes how mitophagy, the clearing of worn mitochondria, helps keep cell compartments in contact. It reports that urolithin A acts through a calcium-dependent mechanism in nematodes and mammalian cells. It also restored lysosome activity. The authors say these mechanisms still need validation in human tissues.

CURRENT NEUROPHARMACOLOGY · 2026-06-08

Review examines mitochondria as a target in age-related diseases and the obstacles

A review in MedComm summarises how faulty mitochondria, the cell's energy units, contribute to aging-related conditions. These include muscle, bone, brain, heart and metabolic diseases. It covers treatment strategies, including mitochondrial transplantation and DNA base editing. It also stresses hurdles before clinical use, such as differences in mitochondria between tissues.

MEDCOMM · 2026-06-04

Review links faulty cell-recycling to glaucoma damage in the eye's drainage and nerve cells

A review in Frontiers in Cell and Developmental Biology argues glaucoma is best seen as a nerve-degenerating disease, not just high eye pressure. It draws on lab, animal and human stem cell studies. These suggest cell-recycling processes, including mitochondrial clean-up, may protect early but fail during chronic injury. The model is a proposal, not proven.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY · 2026-06-04

Review finds protein and collagen with resistance training linked to better muscle in older adults

A review in Current Nutrition Reports examined 32 human studies on supplements for healthy aging. Protein and collagen, especially alongside resistance training, consistently improved muscle mass and physical function. Antioxidants, glycine, N-acetylcysteine and NAD+ precursors showed possible benefits, but results varied across populations and doses. The authors call for more research.

CURRENT NUTRITION REPORTS · 2026-06-03

Review proposes energy shortfall may disrupt cell cleanup in Parkinson's disease

A review in Frontiers in Aging Neuroscience examines how falling cell energy relates to failing autophagy, the cell's clean-up process, in Parkinson's disease. It describes evidence that mild energy decline may boost autophagy, while severe loss may stop it. The authors suggest this could create a reinforcing cycle. The causal relationship remains unclear.

FRONTIERS IN AGING NEUROSCIENCE · 2026-06-03

Review: clearing damaged mitochondria may protect neurons, but clinical evidence is lacking

A review in npj Aging examines mitophagy, the process that removes damaged mitochondria from cells. Impaired mitophagy is common in diseases such as Alzheimer's and Parkinson's. The authors say drugs, gene therapies and dietary approaches that target it show promise. They also note that turning these findings into effective clinical treatments remains a challenge.

NPJ AGING · 2026-06-03

New method flags unusual control groups in mouse lifespan studies

A preprint on bioRxiv, not yet peer reviewed, analysed 10,757 control mice from 18 years of the NIA Interventions Testing Program. The authors built a framework to flag anomalous control cohorts. Removing one newly flagged male cohort changed statistical significance for two rapamycin regimens. This may affect how rapamycin results are interpreted in these mouse studies.

BIORXIV · 2026-10-22

Pregnancy cardiometabolic complications show mixed links to offspring ageing markers

A systematic review and meta-analysis in Paediatric and Perinatal Epidemiology pooled 123 studies. Gestational diabetes and hypertensive disorders did not shorten offspring telomeres. Higher maternal BMI was linked to slightly shorter telomeres. These exposures were also tied to altered methylation of cardiometabolic genes. The findings show associations, not proven causes.

PAEDIATRIC AND PERINATAL EPIDEMIOLOGY · 2026-10-21

Brain DNA methylation changes in aging overlap with those seen in Alzheimer's

According to a study in Genome Medicine, researchers analysed DNA methylation in postmortem brain tissue from two cohorts. They found 3264 sites linked to age. Nearly all sites shared with Alzheimer's changes moved in the same direction. Brain epigenetic age was higher in people with clinical Alzheimer's. This is an observational analysis, so it shows links, not causes.

GENOME MEDICINE · 2026-06-16

Review links extremely premature birth to later chronic disease and faster ageing

A review in The Journal of Physiology covers babies born at or before 28 weeks. It describes how early oxidative stress may damage developing organs and activate cellular senescence and epigenetic changes. Former extremely premature infants face higher risks of lung, heart, kidney and metabolic disease. These diseases are associated with accelerated ageing and higher mortality.

THE JOURNAL OF PHYSIOLOGY · 2026-06-16

Review: single-cell studies show prostate cancer progression involves shifting cell states

A review in the American Journal of Clinical and Experimental Urology summarizes single-cell and spatial studies of prostate cancer. It says progression to castration-resistant disease reflects cells changing identity and epigenetic reprogramming, not just genetic steps. The authors also discuss immune-suppressing niches, drug resistance and technical challenges such as standardization and reproducibility.

AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY · 2026-06-15

Review links microplastic exposure to disrupted blood sugar control

A review in the Journal of Basic and Clinical Physiology and Pharmacology gathers biochemical evidence linking microplastics to impaired glucose metabolism. The authors describe possible routes, including hormone disruption, inflammation, oxidative stress and insulin resistance. The text describes an association and proposed mechanisms, not proof that microplastics cause type 2 diabetes.

JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY · 2026-06-15

BPA exposure in fish linked to lower fertility across generations

A study in Environmental Epigenetics exposed medaka fish to bisphenol A, an environmental chemical. Reduced male fertility appeared in the first and third generations. It came with higher DNA methylation on the androgen receptor gene promoter and lower gene activity. The authors say this suggests a transgenerational effect. This is fish research, not human data.

ENVIRONMENTAL EPIGENETICS · 2026-06-13

Lab study: inflammatory signals reshape human neutrophils' gene activity and germ-fighting traits

A study in the journal Tuberculosis grew neutrophils from healthy donors in the lab under two opposing inflammatory conditions. One mix changed the cells' size, gene activity and DNA methylation. These cells made more inflammatory signals and more extracellular traps when exposed to tuberculosis bacteria. This was cell-culture work, not a trial in people.

TUBERCULOSIS (EDINBURGH, SCOTLAND) · 2026-06-13

Adults with moderate or complex congenital heart disease show faster epigenetic ageing

An observational study in the European Heart Journal compared 120 adults with congenital heart disease with 120 matched healthy controls. Those with moderate and complex disease had accelerated epigenetic ageing on the PhenoAge clock, by 3.0 and 5.5 years. People with simple disease looked similar to healthy peers. The design shows a link, not a cause.

EUROPEAN HEART JOURNAL · 2026-06-11

Food insecurity linked to higher depression risk in older adults

A longitudinal cohort study in Frontiers in Nutrition followed 5,547 middle-aged and older adults in the US Health and Retirement Study. Over 7.9 years, 1,320 developed depression. Those with lower food security had higher risk than those with high food security. Epigenetic age acceleration explained only a small part of the link. This shows association, not cause.

FRONTIERS IN NUTRITION · 2026-06-10

Review explains how mammals keep jumping genes silenced, especially in germ cells

A review in Epigenomics covers transposable elements, DNA sequences that can become active and harm genome stability. It describes layered silencing systems, especially in germ cells. Outside the germline, the review says these elements can switch on in early development and in aging, with effects including inflammation and genome instability. It synthesises existing research rather than reporting new data.

EPIGENOMICS · 2026-06-10

Partial reprogramming of neurons improved cognition in Alzheimer's-model mice

A study in Molecular Biomedicine used intermittent, neuron-specific expression of Yamanaka factors in the hippocampus for six months in mice modelling tau-related Alzheimer's disease. The mice showed sex-dependent improvements in cognitive and emotional behaviour, less tau pathology and rescued hippocampal neural synchrony. This was mouse research. The authors do not report any results in people.

MOLECULAR BIOMEDICINE · 2026-06-10

Cloned multi-gene pigs for transplant research died with heart bleeding

A case report in Frontiers in Veterinary Science describes cloned pigs engineered with several human genes for xenotransplantation research. All piglets died within 48 hours of birth. Necropsy found bleeding in the heart muscle of the left ventricle. The authors propose incomplete epigenetic reprogramming and gene burden as possible causes. This is animal research, and the cause is not proven.

FRONTIERS IN VETERINARY SCIENCE · 2026-06-10

Reversing frailty linked to lower cardiovascular risk in large UK study

An observational study in npj Aging followed about 469,000 UK Biobank adults. People whose frailty reversed had lower cardiovascular risk. A 309-protein frailty signature, led by inflammatory proteins, accounted for roughly half of the link between frailty and cardiovascular disease. Because the study is observational, it shows an association, not proof of cause.

NPJ AGING · 2026-10-21

Graded exercise program reversed frailty in some older adults in Chinese trial

A randomised trial in BMC Geriatrics enrolled 111 community-dwelling adults aged 60 and over with pre-frailty or frailty in Beijing. A five-month graded exercise program beat weekly health education on frailty scores. In the exercise group, 21.2% reached a robust state. Gains were significant in pre-frail people but not in the frail subgroup.

BMC GERIATRICS · 2026-05-29

Review explores how exercise type and intensity may change heart-related gene regulation

A review in Clinical Epigenetics examines how aerobic and resistance exercise may alter gene regulation in ways that affect heart health. It contrasts these with ultra-endurance exercise, which may cause harmful changes in susceptible people. The authors note limits: incomplete causal evidence, heavy reliance on experimental models and elite athletes, and few long-term population studies.

CLINICAL EPIGENETICS · 2026-05-28

Survey in China links social prescribing, activity and wellbeing to healthy-ageing attitudes

A cross-sectional survey of 5,600 people across China, published in the Journal of Multidisciplinary Healthcare, examined social prescription, health-conscious behaviour, physical activity and mental wellbeing. The authors conclude that these factors combined are linked to better perspectives and attitudes toward healthy ageing. As a snapshot survey, it cannot show cause and effect.

JOURNAL OF MULTIDISCIPLINARY HEALTHCARE · 2026-05-27

Stakeholders identify barriers to running a strength program in community centres

A mixed methods study in JBI Evidence Implementation involved 8 managers and 11 exercise instructors in Greater Manchester, UK. It examined delivering STRONGER with AGE, a strength training program for healthy aging. Managers cited staffing, finances and organizational priorities. Instructors cited gaps in knowledge and skills. The study mapped 19 implementation strategies.

JBI EVIDENCE IMPLEMENTATION · 2026-05-26

In aged diabetic rats, exercise plus ursolic acid altered muscle growth proteins

A study in rats, published in Aging Medicine, used 50 aged rats, including a healthy control group; the rest had induced type 2 diabetes. Eight weeks of resistance training, ursolic acid, or both maintained phosphorylated mTORC1, which fell in untreated diabetic rats. Only the combination also preserved PI3K. The authors suggest a combined benefit against diabetes-related muscle loss. This is animal work, not a human trial.

AGING MEDICINE (MILTON (N.S.W)) · 2026-05-25

Review examines lifestyle's role alongside semaglutide and tirzepatide obesity drugs

A narrative review in Current Atherosclerosis Reports discusses lifestyle measures before, during and after newer obesity drugs such as semaglutide and tirzepatide. Recent trials showed weight losses of around 15-20%. The authors note concerns about muscle loss, nutrition and weight regain after stopping. They say the best timing and content of lifestyle programs remain unclear.

CURRENT ATHEROSCLEROSIS REPORTS · 2026-05-25

Pooled trials link several exercise types to lower blood sugar markers in type 2 diabetes

A network meta-analysis in Frontiers in Public Health pooled 29 randomised trials with 1,301 middle-aged and older adults with type 2 diabetes. It compared exercise types and intensities. High-intensity resistance training had moderate-certainty evidence of lowering HbA1c. Several other aerobic and resistance programmes showed lower-certainty evidence of similar reductions compared with usual care.

FRONTIERS IN PUBLIC HEALTH · 2026-05-25

Paper argues muscle loss with obesity is overlooked in Nordic primary care

A discussion paper in Frontiers in Aging says sarcopenic obesity, low muscle mass alongside excess body fat, is under-recognised in Nordic general practice. The authors cite limited prevalence data, inconsistent diagnostic criteria and mostly cross-sectional studies. They propose a simple case-finding approach combining basic function tests, nutritional risk assessment and body measures alongside BMI.

FRONTIERS IN AGING · 2026-05-22

Review examines collagen, vitamin C and vitamin E for ageing muscle and brain

A review in Frontiers in Nutrition summarised randomised trials and preclinical studies on collagen, vitamin C and vitamin E alongside exercise in older people. The authors say the three may work together. They also note that most evidence tests each nutrient alone, not the combination, which limits what can be concluded about how they interact.

FRONTIERS IN NUTRITION · 2026-05-21

Isometric-based exercise program lowered blood pressure more in older adults with heart disease

A small randomised trial in the Journal of Sports Sciences enrolled 30 older adults with stable cardiovascular disease. Two 24-week exercise programmes, one with isometric exercises, both improved heart rate, blood pressure, fitness and quality of life versus controls. The isometric version produced larger blood pressure reductions. Only ten people were in each group.

JOURNAL OF SPORTS SCIENCES · 2026-05-21

PROTEINS & AMINO ACIDS 11

Resistance training may modestly improve strength in frail older adults

A systematic review and meta-analysis in Frontiers in Public Health pooled nine randomised trials with 566 frail or pre-frail adults aged 60 and over. Resistance training improved knee-extensor strength and possibly grip strength and gait speed. Certainty was low to very low. Effects on frailty scores were unclear, so the evidence base remains weak.

FRONTIERS IN PUBLIC HEALTH · 2026-10-22

Closer Mediterranean diet adherence linked to lower odds of sarcopenia

A systematic review and meta-analysis in BMC Nutrition pooled seven observational studies with 9,709 participants. High Mediterranean diet adherence was associated with about 19% lower odds of sarcopenia, the age-related loss of muscle. The link rose in a linear dose-response pattern. Because the studies are observational, the result shows association, not cause.

BMC NUTRITION · 2026-07-25

Review describes how poor nutrition and muscle loss reinforce each other in older adults

A review in the EXCLI Journal discusses Malnutrition-Sarcopenia Syndrome in older adults. It notes debate over whether this is a distinct condition. The review describes a cycle in which poor nutrition and muscle loss worsen each other. It links the combination to longer hospital stays and higher mortality than either problem alone.

EXCLI JOURNAL · 2026-06-10

Review: bone and muscle loss together affect about one in five older adults

A narrative review in Health Science Reports looks at osteosarcopenia, the combination of osteoporosis and sarcopenia. It reports that about 18% to 20% of older adults are affected, more often women. The condition is linked to falls, fractures, disability and death. The authors say diagnosis lacks standard criteria, and no single treatment targets both bone and muscle.

HEALTH SCIENCE REPORTS · 2026-06-10

Trunk muscle fat may relate to protein intake in older women

A small cross-sectional study in Nutrients involved 24 women aged 18 to 23 and 25 women aged 66 to 77. MRI measured fat within trunk muscle, and questionnaires assessed diet and eating behavior. The authors say this muscle fat may be related to protein intake and eating behavior in the older group. A cross-sectional design shows associations, not causes.

NUTRIENTS · 2026-06-10

Frailty and low muscle mass linked to slower early recovery after spinal fracture

A retrospective cohort study in Frontiers in Nutrition looked at 120 patients aged 60 and over with osteoporotic vertebral compression fractures. Frail patients had lower function scores at discharge, longer hospital stays and more complications. Frailty and sarcopenia were independently associated with reduced early recovery. The study did not assess long-term outcomes.

FRONTIERS IN NUTRITION · 2026-06-09

Review links food insecurity and financial hardship to poorer health in older adults

A narrative review in Frontiers in Nutrition examines how money and food access relate to ageing. Food insecurity and hardship are consistently associated with poorer diet quality, frailty, sarcopenia and cognitive decline. Food-insecure older adults were also more likely to have overweight or obesity. The authors argue for systemic rather than individual-level solutions.

FRONTIERS IN NUTRITION · 2026-06-08

One long overnight fast did not improve muscle's response to protein

A small randomised crossover study in The Journal of Nutrition tested nine healthy young adults, average age about 23, after a 16-hour and a 10-hour overnight fast. The longer fast did not change how much dietary protein was built into muscle protein. Forearm glucose and amino acid uptake were also similar. Insulin levels after the meal were lower after the longer fast.

THE JOURNAL OF NUTRITION · 2026-06-07

Review finds promising but limited evidence for plant compounds in age-related muscle loss

A review in Pharmaceuticals looks at plant-derived compounds for sarcopenia, the age-related loss of muscle. Experimental and early clinical evidence suggests they affect pathways involved in muscle aging. Clinical use is limited by poor absorption, varied dosing and a lack of long-term randomised trials. The authors say the compounds appear most useful alongside resistance exercise and nutrition support.

PHARMACEUTICALS (BASEL, SWITZERLAND) · 2026-06-07

Review finds limited evidence on metabolic markers linking diet and frailty

A systematic review in The Journal of Frailty & Aging searched three databases and found 1661 studies, of which five met the criteria. They covered fruit and vegetable intake, plant and animal protein intake, and Mediterranean diet adherence. Metabolites such as hippuric acid, amino acids and lipid-derived compounds may point to a frailty signature. The authors say evidence is limited and the direction of associations is unclear.

THE JOURNAL OF FRAILTY & AGING · 2026-06-06

Experts propose guidance for managing metabolic crises in maple syrup urine disease

Eight expert physicians met in February 2025 and reviewed four guidelines and 20 other articles. Their recommendations, published in the Orphanet Journal of Rare Diseases, cover maple syrup urine disease, a rare inherited metabolic disorder. They say crises need prompt multidisciplinary treatment to lower leucine safely. This is expert consensus, not a trial. The disease is not tied to aging in the text.

ORPHANET JOURNAL OF RARE DISEASES · 2026-06-06

CLINICAL TRIALS

60

Study of 61 children with cerebral palsy examines sleep and caregiver burden

A trial registry entry on ClinicalTrials.gov describes a completed observational, cross-sectional study. It included 61 children with cerebral palsy and their main caregivers. Researchers used questionnaires to look at children's sleep, caregiver sleep, caregiver burden and anxiety or depression symptoms. The study was designed to examine links among these, and no results are given in the entry.

CLINICALTRIALS.GOV (NCT07168577) · 2026-10-23

Planned Chinese study will track fitness and health in 8,960 older adults

A registry entry on ClinicalTrials.gov describes an observational study that has not yet begun recruiting. It plans to enrol about 8,960 people aged 60 to 79 across China. Participants will complete questionnaires, fitness tests and blood tests, then be followed over time. The aim is to examine how activity and fitness are associated with health. No results exist yet.

CLINICALTRIALS.GOV (NCT07881094) · 2026-10-23

Trial to test virtual reality training for thinking skills in metabolic syndrome

A registry entry on ClinicalTrials.gov describes a trial that is recruiting. It will test whether a virtual reality programme combining cognitive training and exercise improves cognitive function. Participants are middle-aged adults with metabolic syndrome and subjective cognitive complaints. The programme runs in group sessions over 12 weeks. The trial is registered only, so there are no results yet.

CLINICALTRIALS.GOV (NCT07040748) · 2026-10-23

Planned trial tests magnetic brain stimulation for small vessel disease cognitive decline

A registry entry on ClinicalTrials.gov describes a randomised trial that has not yet begun recruiting. It will enrol 160 adults aged 45 to 85 with mild cognitive impairment or mild vascular dementia linked to small vessel disease. Participants will get real or sham magnetic stimulation for 24 weeks. The main outcome is change in a cognitive test score. No results exist yet.

CLINICALTRIALS.GOV (NCT07891650) · 2026-10-23

Trial compares two robot training settings in children with spinal muscular atrophy

A registry entry on ClinicalTrials.gov describes a randomised trial that is recruiting. At least 13 children aged 6 to 12 with spinal muscular atrophy will take part. One leg gets a compliant setting on a knee training robot and the other a rigid setting, for up to 8 weeks. The main outcome is knee-extension torque. No results exist yet.

CLINICALTRIALS.GOV (NCT07822711) · 2026-10-23

Chinese hospital recruiting older adults for long-term Alzheimer's observational study

A registered observational study in Fujian Province, China, is now recruiting, according to ClinicalTrials.gov. Sponsored by Fujian Medical University Union Hospital, it will follow people from the general population and those with cognitive impairment. It aims to study Alzheimer's risk factors, genes and digital screening tools, and to develop blood and PET imaging tests. There are no results yet.

CLINICALTRIALS.GOV (NCT07891429) · 2026-10-23

UK study planned on how hospitals deliver elranatamab for myeloma

A registered study, listed on ClinicalTrials.gov, will review how NHS hospitals deliver elranatamab to people with relapsed or refractory multiple myeloma. It is retrospective and observational, across 20 hospitals. It will look at managing step-up dosing side effects, infection care and resource use. The study is not yet recruiting and has no results.

CLINICALTRIALS.GOV (NCT07891871) · 2026-10-23

Completed study examines lung dead space and survival in ventilated ICU patients

A study registered on ClinicalTrials.gov and now marked completed, from Karadeniz Technical University, looks at physiological dead space in adults on mechanical ventilation in intensive care. It examines how this measure relates to death and discharge status. The registry entry gives no results, so any link to outcomes is not yet known.

CLINICALTRIALS.GOV (NCT06963944) · 2026-10-23

Early trial testing experimental flu vaccine with and without adjuvant

A Phase 1 trial run by the National Institute of Allergy and Infectious Diseases is recruiting healthy adults aged 18 to 50, according to ClinicalTrials.gov. It tests the experimental flu vaccine FluMos-v2 with and without the experimental adjuvant ALFQ. Participants get two shots about four months apart, keep symptom diaries and give blood, saliva and nasal samples over 15 months. No results are available.

CLINICALTRIALS.GOV (NCT06863142) · 2026-10-23

Planned trial compares two vitamin D doses alongside iron for anaemic children

A randomised controlled trial registered on ClinicalTrials.gov, not yet recruiting, will test two vitamin D3 doses added to oral iron. It involves children aged 6 to 60 months with iron deficiency anaemia and vitamin D deficiency. Over 12 weeks, researchers will compare changes in haemoglobin between groups. The sponsor is AlFayhaa General Hospital. There are no results yet.

CLINICALTRIALS.GOV (NCT07892170) · 2026-10-23

Registered study will map tonsil cells in children with sleep apnoea

A trial registry entry from the Chinese University of Hong Kong lists a completed study of tonsil tissue in children with obstructive sleep apnoea. Researchers planned single-cell sequencing to look at immune cells and gene activity in enlarged tonsils. They hope to understand why some children's tissue enlarges. No results are given in the entry.

CLINICALTRIALS.GOV (NCT05115968) · 2026-10-23

AstraZeneca safety trial of two obesity drugs is under way

A trial registry entry from AstraZeneca describes an early-phase study of AZD9550, alone and with AZD6234, in adults with overweight or obesity, with or without type 2 diabetes. It tests safety, tolerability and how the body handles the drugs. The study is active but no longer recruiting. No results are listed.

CLINICALTRIALS.GOV (NCT06151964) · 2026-10-23

Planned trial will test whether meals affect Immulina's immune effects

A trial registry entry from the University of Mississippi Medical Center describes a phase 2 study that has not yet begun recruiting. It will explore whether eating alters how the supplement Immulina acts on immune markers. An earlier study showed strong natural killer cell responses in only a minority of participants. No results exist yet.

CLINICALTRIALS.GOV (NCT07893314) · 2026-10-23

Phase 3 trial tests mibavademab for obesity caused by leptin gene mutations

A trial registry entry from Regeneron lists a recruiting phase 3 study of the experimental drug mibavademab. It involves people with obesity caused by changes in the leptin gene. Researchers will assess how well it controls body weight and how safe it is. The entry reports no results.

CLINICALTRIALS.GOV (NCT07220772) · 2026-10-22

Trial compares magnetic-field therapy with exercise for enlarged prostate in older men

A trial listed on ClinicalTrials.gov, sponsored by Cairo University, compares electromagnetic field therapy with aerobic exercise. It involves 75 men aged 60 to 75 with benign prostatic hyperplasia, a non-cancerous enlargement of the prostate. The entry is marked completed, but the text gives no results, so it is unknown which approach worked better.

CLINICALTRIALS.GOV (NCT07357168) · 2026-10-22

Trial tests herbal decoction for fatigue in lung cancer patients on standard treatment

A registered trial from the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, tests an herbal decoction for cancer-related fatigue. Patients with untreated lung adenocarcinoma receive standard therapy plus either the decoction or a placebo for 21 days. The entry is listed as completed, but no results are given, so any benefit is unknown.

CLINICALTRIALS.GOV (NCT07890051) · 2026-10-22

Italian study to examine fractures and bone health in adults with Duchenne

An Italian study sponsored by Istituto Giannina Gaslini is recruiting about 200 adults with Duchenne muscular dystrophy from 15 referral centres, plus healthy adult male controls who will give only a blood sample. Researchers aim to estimate how common fragility fractures are, identify childhood risk and protective factors, measure bone-related blood markers and look for genetic modifiers. No results are reported yet.

CLINICALTRIALS.GOV (NCT07890883) · 2026-10-22

Trial tests whether WhatsApp reminders raise pneumonia vaccination in 65-year-olds in Chile

A randomised trial registered on ClinicalTrials.gov is testing WhatsApp reminders for the pneumococcal vaccine in adults turning 65 in Chile. One group gets reminders and the other gets usual care. Vaccination status is checked over six weeks. The trial is enrolling by invitation and has reported no results yet.

CLINICALTRIALS.GOV (NCT07659470) · 2026-10-22

Dutch study evaluates effects of reducing tobacco retail outlets on smoking

A policy evaluation registered by Maastricht University Medical Center looks at Dutch rules to cut the number and types of tobacco outlets, including a ban on supermarket sales. It uses monitoring data, surveys and interviews to assess effects on adult smokers and non-smoking youth. The entry is marked completed, but the text reports no findings.

CLINICALTRIALS.GOV (NCT05554120) · 2026-10-22

Brazilian study will test blood markers against bone marrow stem cell quality

A registered observational study at a Brazilian university hospital is recruiting adults aged 40 to 80 having foot or ankle surgery, according to ClinicalTrials.gov. Researchers will check whether routine blood tests are associated with how well stem cells from bone marrow function. It has no results yet. It will not guide individual treatment.

CLINICALTRIALS.GOV (NCT07802106) · 2026-10-22

Trial will test an online Mediterranean diet programme for people with Parkinson's

A randomised pilot trial from Queen's University Belfast is recruiting 120 UK adults with Parkinson's disease, according to ClinicalTrials.gov. It will test whether the MediPD online programme is practical and helps people shift toward a Mediterranean-style diet over 24 weeks. Quality of life and cognition will also be examined. The trial has no results yet.

CLINICALTRIALS.GOV (NCT07838675) · 2026-10-21

Trial compares flecainide safety with standard drugs in atrial fibrillation and heart disease

A registered phase 4 randomised trial led by KU Leuven is recruiting adults with atrial fibrillation and stable coronary artery disease, according to ClinicalTrials.gov. It will compare flecainide with sotalol or amiodarone to see whether flecainide is not worse on safety. Patients will be followed for at least one year. No results have been posted.

CLINICALTRIALS.GOV (NCT07405671) · 2026-10-21

Trial compares two massage methods added to physiotherapy for shoulder impingement

A registered randomised controlled trial, listed on ClinicalTrials.gov, involves 48 people aged 40 to 60 with subacromial impingement syndrome. Groups receive standard physiotherapy alone, or with percussion massage, or with instrument-assisted soft tissue mobilisation, for four weeks. The main outcome is shoulder joint position sense. The entry reports no results.

CLINICALTRIALS.GOV (NCT07756203) · 2026-10-21

Oxford malaria vaccine candidates tested in a trial in Burkina Faso children

A registered trial run by the University of Oxford is testing two malaria vaccine candidates. They are R78C and a combination of RH5.1 with R21, each with the Matrix-M ingredient. It is a Phase IIb randomised controlled trial in children aged 5 to 36 months in Burkina Faso. The entry lists it as active, not recruiting. No results are reported.

CLINICALTRIALS.GOV (NCT07183371) · 2026-10-21

Early trial tests YTS109 cell therapy in hard-to-treat autoimmune disease

A registered Phase 1 trial is testing YTS109 cells in adults with relapsed or treatment-resistant autoimmune diseases, including lupus and Sjogren's syndrome. Sponsored by China Immunotech, it is single-arm and open-label. About 18 patients will receive one infusion. The main goal is safety. The trial is recruiting and has no results yet.

CLINICALTRIALS.GOV (NCT07104721) · 2026-10-21

Norwegian trial tests whether machine learning can predict migraine drug response

A registered study from the Norwegian University of Science and Technology asks whether machine learning can predict who responds to migraine preventive drugs. Models will use patient features recorded before treatment. Predictions will be compared with actual results, with success defined as a 50% or greater drop in monthly headache days. The entry lists it as completed. No results are given.

CLINICALTRIALS.GOV (NCT06893874) · 2026-10-21

Planned Cairo trial will test virtual reality exercise in COPD

A registered randomised trial from Cairo University plans to compare 12 weeks of virtual reality breathing and cycling training with conventional pulmonary rehabilitation. Participants are patients aged 45 to 55 with stable COPD. The main outcomes are diaphragm movement and FEV_1, a lung function measure. The trial has not yet started recruiting, so there are no results.

CLINICALTRIALS.GOV (NCT07885995) · 2026-10-21

Hong Kong study used ultrasound to look for enlarged aortas in hypertensive patients

A registered study from the Chinese University of Hong Kong recruited hypertensive patients in an emergency department. Doctors used point-of-care ultrasound to measure the aorta. The main outcome is how many patients had a markedly enlarged aorta, defined by set size thresholds. The entry lists the study as completed. No results are reported.

CLINICALTRIALS.GOV (NCT06854588) · 2026-10-21

Trial tests exercise-based care for fatigue in teens with leukemia

A completed randomised trial is listed on ClinicalTrials.gov. It enrolled 70 adolescents aged 13 to 16 with acute lymphoblastic leukemia. One group followed a six-week programme combining individual physical activity with psychosocial support. The other received usual care. The registry entry reports no results, so it is unclear whether the programme eased fatigue or improved hope and resilience.

CLINICALTRIALS.GOV (NCT07882069) · 2026-10-20

Planned pilot study will compare graphic and text-only alcohol cancer warnings

A pilot study registered on ClinicalTrials.gov has not yet started recruiting. It plans to enrol 50 adults who drink regularly. Researchers will compare graphic alcohol cancer warning labels with the current text-only U.S. Surgeon General label. They will track eye movements and stated intentions. There are no results yet.

CLINICALTRIALS.GOV (NCT07852013) · 2026-10-20

Completed trial tests feasibility of mindfulness therapy for university students

A completed trial registered on ClinicalTrials.gov, sponsored by Universidad de los Andes, Chile, explored whether an adapted eight-week mindfulness-based cognitive therapy programme is acceptable and feasible for university students. It involves weekly 90-minute group sessions led by a certified instructor, plus audiovisual material guiding daily self-applied exercises, and targets depressive and anxiety symptoms. The registry entry reports no results.

CLINICALTRIALS.GOV (NCT05114824) · 2026-10-20

Registry lists trial of ear acupuncture add-on for arthritic low back pain

This entry comes from a trial registry; the trial is marked completed, but no results are posted. Sixty adults in Ho Chi Minh City with chronic low back pain from lumbar spine osteoarthritis were randomly assigned. All had 10 electroacupuncture sessions over 3 weeks. One group also had Battlefield Acupuncture, the other sham ear acupuncture. Pain, daily interference and side effects were measured.

CLINICALTRIALS.GOV (NCT06874959) · 2026-10-20

Phase 1 trial of MTX325 for Parkinson's disease is recruiting

A registry entry shows Mission Therapeutics is running a phase 1 trial of MTX325, which is recruiting. The aim is to learn whether it could be developed as a potential disease-modifying Parkinson's treatment. Parts 1 to 4 are complete. Part 5, testing multiple doses in patients with Parkinson's, is in progress. No results are listed.

CLINICALTRIALS.GOV (NCT07630545) · 2026-10-20

Registered study will test whether pre-surgery CT scans predict heart recovery after bypass

This is an observational study listed in a trial registry. It is recruiting, and no results are posted. Researchers will use photon-counting CT scans of heart muscle before coronary artery bypass surgery. They want to know if the scans can predict heart structure changes three months later, measured by left ventricular end-systolic volume index.

CLINICALTRIALS.GOV (NCT07883499) · 2026-10-20

Registered pilot study tests a powered leg brace for walking after stroke

A registry entry from the VA Office of Research and Development describes a pilot study in Veterans with weakness on one side after stroke. It tests a brace combining muscle stimulation and motorized knee assistance. Researchers will build and tune the device first. They will then test whether it improves walking speed, distance and energy use. No results are posted.

CLINICALTRIALS.GOV (NCT04116671) · 2026-10-19

Completed observational study checks if frailty screens flag chemotherapy side-effect risk in older adults

This observational study, listed in a trial registry, is marked completed, but no results are shown. It involved adults aged 65 or older receiving chemotherapy after surgery for gastrointestinal cancer. Researchers examined whether the FRAIL scale and FiND questionnaire, given beforehand, were associated with severe side effects over the following 180 days.

CLINICALTRIALS.GOV (NCT07272538) · 2026-10-19

NIH registers completed study of blood sequencing to spot infections after stem cell transplant

This is a registered trial entry from the NIH Clinical Center. It says the study is completed, but no results are listed. Researchers tested whether sequencing genetic material in blood plasma can detect bacteria, fungi, protozoa or viruses in transplant patients. They also planned to compare findings with fever and suspected infection over six months.

CLINICALTRIALS.GOV (NCT06904053) · 2026-10-16

NIH registers completed brain imaging study of how people retain new motor skills

This is a registry entry from the National Institute of Neurological Disorders and Stroke. The study is listed as completed, with no results given. Healthy adults aged 18 to 50 did typing and tapping tasks and may have had MRI scans. Researchers aimed to learn how different brain layers help people retain a new movement skill.

CLINICALTRIALS.GOV (NCT04431011) · 2026-10-16

Registered trial tests four-drug combination for advanced bile duct cancer; no results yet

This is a registry entry from the National Cancer Institute for a phase 1 and 2 trial that is still recruiting. No results are posted. It tests a study drug, CDX-1140, with capecitabine, oxaliplatin and Keytruda. Participants are adults whose biliary tract cancer progressed after treatment and cannot be treated with surgery or transplant.

CLINICALTRIALS.GOV (NCT05849480) · 2026-10-16

Registered trial tests sacituzumab govitecan for rare urinary and genital tract cancers

This is a registry entry from the National Cancer Institute for a phase 2 trial that is still recruiting. No results are posted. It tests sacituzumab govitecan alone or with atezolizumab in adults with rare genitourinary tumors. Both drugs are already approved for other cancers. Researchers want to learn whether the combination can help.

CLINICALTRIALS.GOV (NCT06161532) · 2026-10-16

Registered trial compares two exercise programs for fall risk in people over 65

This is a registry entry from Beni-Suef University. The trial is listed as completed, with no results given. It planned to enrol 40 people over 65 who are at risk of falling. It compares Otago exercise training with high velocity resistance training. The entry states an expectation of no significant difference between them.

CLINICALTRIALS.GOV (NCT07204808) · 2026-10-16

NCI trial tests two-session focal radiation for localized prostate cancer

A phase 2 trial sponsored by the National Cancer Institute and registered on ClinicalTrials.gov is recruiting adults with untreated prostate cancer that has not spread outside the gland. It will test focal SBRT radiation in two sessions about a week apart, guided by small gold seeds. Follow-up lasts two years with scans and PSA tests, then a biopsy. No results exist yet.

CLINICALTRIALS.GOV (NCT05616650) · 2026-10-16

Registered trial compares two anesthesia types for atrial fibrillation ablation

A randomised trial registered on ClinicalTrials.gov, and still recruiting, will compare conscious sedation with general anesthesia during pulsed field ablation for paroxysmal atrial fibrillation. It plans 390 participants. The main outcome is recurrence of abnormal heart rhythm through 12 months. It will also compare complications, pain, anxiety and costs. No results exist yet.

CLINICALTRIALS.GOV (NCT07877519) · 2026-10-16

Completed registered study examines glucose swings and thinking in prediabetes

A study registered on ClinicalTrials.gov by the University of Maryland, Baltimore, and listed as completed, examines whether variability in glucose levels over a 10-day period is associated with cognitive function and Alzheimer's disease risk markers. Participants are people with prediabetes aged 50 or older. The registry description provided reports no findings, and the study looks at association, not cause.

CLINICALTRIALS.GOV (NCT04201600) · 2026-10-15

Planned study tests carotid ultrasound to predict post-spinal low blood pressure

A study registered on ClinicalTrials.gov by Tanta University has not yet begun recruiting. It will assess whether a carotid artery ultrasound measure, taken before surgery, can predict low blood pressure after spinal anesthesia in older patients having hip replacement. It will also compare this with two other measures, IVC collapsibility and echocardiography. No results exist yet.

CLINICALTRIALS.GOV (NCT07876063) · 2026-10-15

NIH is recruiting for a long-term study of RYR1-related muscle disorders

A natural history study registered on ClinicalTrials.gov by the NIH Clinical Center is recruiting people aged 7 and older with RYR1-related disorders. These genetic conditions can cause muscle weakness. Visits are yearly for 3 or 5 years, either in person or by telehealth. Participants who visit the Clinical Center will also have strength, movement, and heart and lung tests. No results exist yet.

CLINICALTRIALS.GOV (NCT06287762) · 2026-10-15

Study will test link between children's screen time and anxiety before surgery

A registered observational study is recruiting at Kanuni Sultan Suleyman Training and Research Hospital, according to ClinicalTrials.gov. It will ask whether more daily screen time is associated with higher anxiety before surgery in children aged 2 to 5. Parents will report screen time. Anxiety will be scored before anesthesia. There are no results yet.

CLINICALTRIALS.GOV (NCT07425405) · 2026-10-15

Trial will compare two exercise types after knee ligament reconstruction surgery

A randomised trial is recruiting, according to ClinicalTrials.gov. Sponsored by Cairo University, it will compare isokinetic training with plyometric training in adults aged 18 to 40 after ACL reconstruction. Both groups get 16 weeks of standard rehabilitation, then 8 weeks of one training type. It will look at strength, function and patient-reported outcomes. No results yet.

CLINICALTRIALS.GOV (NCT07862868) · 2026-10-15

Study of children in cancer treatment examines fatigue, quality of life and daily activities

A completed cross-sectional study, listed on ClinicalTrials.gov and sponsored by Medipol University, included 89 children aged 2 to 18 having cancer treatment. Researchers assessed fatigue, quality of life and functional independence using scales. They expected more fatigue to go with worse daily activity and quality of life. The entry lists no findings.

CLINICALTRIALS.GOV (NCT07606170) · 2026-10-14

Trial tests ways to cut evening light for young children's sleep

A randomised trial is recruiting, according to ClinicalTrials.gov. Sponsored by the University of Arizona, it involves children aged 5 to 6 with parent-reported trouble falling asleep. Children will be randomly assigned to home lighting changes, amber-tinted glasses or clear glasses for two weeks. Researchers will measure sleep and body clock timing. There are no results yet.

CLINICALTRIALS.GOV (NCT07391852) · 2026-10-14

Trial of school safety program for fourth graders is complete, results not listed

A completed randomised trial, listed on ClinicalTrials.gov and sponsored by Saavsus, Inc., tested an adapted radKIDS safety program in fourth-grade classrooms. Classrooms were randomly assigned to the program or usual instruction. Students completed two surveys on safety knowledge, self-efficacy and self-esteem. The entry gives no results.

CLINICALTRIALS.GOV (NCT06608173) · 2026-10-13

Completed registry study examines heart disease and ageing markers in bronchiectasis

A completed observational study listed on ClinicalTrials.gov, run by a hospital in Creteil, France, looks at bronchiectasis, a chronic lung disease. The investigators hypothesise that cardiovascular disease is more common in these patients and may relate to inflammation and ageing markers. They measure arterial stiffness, bone density and muscle mass. No results are given in the entry.

CLINICALTRIALS.GOV (NCT02804971) · 2026-06-29

Trial testing tech-based support to raise activity in isolated older adults is under way

A registered clinical trial at Arizona State University, listed on ClinicalTrials.gov, is recruiting. It will test whether websites and virtual coaching, added to basic education and goal-setting, increase physical activity in older adults who live alone and report memory concerns. It will also examine social support and stress resilience. No results exist yet.

CLINICALTRIALS.GOV (NCT06896825) · 2026-06-29

Trial of weight loss program before kidney transplant is recruiting

A trial registry entry on ClinicalTrials.gov describes OK-TRANSPLANT 2, run by Western University in Canada. It is a pilot for a larger randomised trial. People with obesity and serious kidney disease who want a transplant will join a virtual weight management program or continue usual care. The trial is still recruiting, so there are no results.

CLINICALTRIALS.GOV (NCT06396416) · 2026-06-29

Trial will test methylphenidate for fatigue in childhood brain tumor survivors

A trial registered on ClinicalTrials.gov, sponsored by Odense University Hospital, will test methylphenidate in pediatric brain tumor survivors with cancer-related fatigue. It is a phase 3 trial and is recruiting. It has no results yet. The registry says evidence-based recommendations for this fatigue are currently lacking.

CLINICALTRIALS.GOV (NCT06905587) · 2026-06-26

Registered trial tests exercise formats for active aging in older adults

A ClinicalTrials.gov entry lists a completed trial of physical activity in older adults, with no results reported. It describes two 12-week randomised studies. One compares Tai Chi, multimodal exercise and a daily-activity control. The other compares in-person group and online individual formats of the same multimodal exercise. Outcomes include physical function and self-rated active aging.

CLINICALTRIALS.GOV (NCT07670208) · 2026-06-26

Registered trial will test early palliative care alongside head and neck cancer treatment

A trial registry entry describes a planned study at the Portuguese Oncology Institute, Coimbra. It aims to add outpatient palliative care to chemoradiotherapy earlier in head and neck cancer. The trial is not yet recruiting and has no results, so it is unknown whether the approach helps.

CLINICALTRIALS.GOV (NCT07671573) · 2026-06-26

Trial will compare two blood flow restriction exercise types for athletes' knee pain

This is a registered trial with no results yet, listed on ClinicalTrials.gov and currently recruiting. It plans to randomise 60 athletes with patellofemoral pain to blood flow restriction resistance training or blood flow restriction cycling for 8 weeks. Researchers will measure pain, quadriceps strength and knee function before and after. Nothing about effectiveness is known yet.

CLINICALTRIALS.GOV (NCT07585305) · 2026-06-26

Trial recruiting to test brain stimulation for working memory in older adults

A trial listed on ClinicalTrials.gov is recruiting older adults with mild cognitive impairment. Sponsored by the University of Florida, it will study whether transcranial direct current stimulation improves working memory, compared with cognitively healthy controls. The trial is only registered. It has no results yet, so nothing is known about whether it works.

CLINICALTRIALS.GOV (NCT05998031) · 2026-06-26

Registered study will test whether saliva amino acids track gum disease and treatment

A registry entry on ClinicalTrials.gov describes a combined observational and interventional study. It will compare salivary amino acids in adults aged 20 to 50 with healthy gums, gingivitis or periodontitis. Thirty-two periodontitis patients will be re-examined after standard treatment. The entry is marked completed, but it lists no results.

CLINICALTRIALS.GOV (NCT07669233) · 2026-06-25

Company starts brain-imaging study of a neurodegenerative drug in healthy volunteers

NRG Therapeutics has begun a PET imaging study of its drug NRG5051, according to Longevity.Technology. The company says it radiolabelled the drug and started scans in healthy volunteers in London. The aim is to show the drug reaches the brain and to help choose doses for future patient trials. No results are reported yet.

LONGEVITY.TECHNOLOGY · 2026-10-23

Oral Alzheimer's drug MNA-001 reported safe in early human trial

Muna Therapeutics announced positive Phase 1 results for MNA-001, an oral drug targeting TREM2, according to Longevity.Technology. The randomised, placebo-controlled study covered younger volunteers plus an elderly group. The company reports no serious adverse events or discontinuations due to side effects. Most side effects were mild. These are company-reported results, and the text does not show whether the drug helps.

LONGEVITY.TECHNOLOGY · 2026-10-23

Immunis wins Healthy Longevity competition prize for investigational muscle and metabolic therapy

Immunis has won the Grand Prize in the National Academy of Medicine's Healthy Longevity Global Competition, according to Longevity.Technology. The award is for IMM01-STEM, an investigational biologic. The company claims it can address processes behind age-related muscle and metabolic decline. The text gives no trial data, so those claims remain untested here.

LONGEVITY.TECHNOLOGY · 2026-10-23

Cognition Therapeutics reports FDA alignment on Phase 3 plan for Lewy body dementia

Cognition Therapeutics says it has reached alignment with the U.S. Food and Drug Administration on key elements of a planned Phase 3 trial, according to Longevity.Technology. The drug is zervimesine, tested in mild-to-moderate dementia with Lewy bodies. Participants would be randomised to a daily oral dose or placebo. The trial has not reported results.

LONGEVITY.TECHNOLOGY · 2026-10-23

Gene PLA2G2F regulates compensatory responses to ageing damage in the brain

Researchers identified the gene PLA2G2F as a regulator of compensatory responses to some of the damage and dysfunction of ageing, according to a summary on Fight Aging! The work focused on memory-related hippocampal neurons but found the gene also matters in support cells such as microglia. Its expression rises with age, and artificially raising it further gave greater protection. The excerpt does not say what type of study this was.

FIGHT AGING! · 2026-10-23

APOEε4 gene variant disrupts brain insulation cells, researchers report

APOEε4 is the common APOE variant with the greatest Alzheimer's risk, according to a summary on Fight Aging!. Earlier work focused on inflammation in microglia. Here, researchers report that APOEε4 also interferes with oligodendrocytes, the cells that maintain myelin, the sheath around nerve fibres. The excerpt does not say what type of study this was.

FIGHT AGING! · 2026-10-23

CDC report: nearly half of care communities had residents with all four tracked chronic conditions

A report from the Centers for Disease Control and Prevention, covered by Senior Housing News, looked at residential care communities. It found that in 2025 almost half reported having residents diagnosed with all four chronic conditions the agency tracks. The coverage says residents are arriving with higher care needs. The text does not name the conditions.

SENIOR HOUSING NEWS · 2026-10-21

FDA approves first generic once-weekly estradiol and levonorgestrel patch for women

According to an FDA press release, the agency approved the first generic version of Climara Pro. It is a transdermal hormone therapy patch applied once a week. It is meant for women with an intact uterus. The announcement lists the dose as 0.045 mg per day of estradiol and 0.015 mg of levonorgestrel.

FDA PRESS RELEASES · 2026-10-20

FDA issues final guidance on apps used alongside prescription medicines

According to an FDA press release, the agency released final guidance on apps that accompany prescription drugs. The guidance sets out a framework for how drug companies can develop, distribute and label such apps. The short announcement gives no further detail on what the framework requires.

FDA PRESS RELEASES · 2026-10-20

FDA grants accelerated approval for immunotherapy in locally advanced rectal cancer

The U.S. Food and Drug Administration has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly), according to an FDA press release. The agency says it may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on daily life.

FDA PRESS RELEASES · 2026-10-19

FDA approves Fayuvi, first treatment for children with Sanfilippo syndrome type A

The U.S. Food and Drug Administration announced it has approved Fayuvi (rebisufligene etisparvovec-hopf), describing it as the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. The announcement excerpt does not describe how the treatment works, who can receive it, or the trial results behind the approval.

FDA PRESS RELEASES · 2026-09-17

ALZHEIMER'S & COGNITIVE DECLINE PREVENTION 11

Agitation linked to Alzheimer's markers and faster dementia progression in APOE ε4 carriers

According to a study in the Journal of Alzheimer's Disease, 491 people with mild cognitive impairment or Alzheimer's were analysed using ADNI data. Among APOE ε4 carriers, agitation was linked to higher spinal fluid GAP-43 and p-tau. These links were not seen in non-carriers. Carriers with agitation also had a higher risk of progressing to dementia. This is an observational association.

JOURNAL OF ALZHEIMER'S DISEASE : JAD · 2026-06-30

Review: plant compounds show promise against Alzheimer's in lab and animal studies

A review in Scientifica pulls together lab, animal and some clinical studies on medicinal plants and their compounds in Alzheimer's disease. It reports protective effects in experimental models. The authors say clinical trials offer further support in mild cognitive impairment, but the text provided is cut off. Most evidence described is preclinical.

SCIENTIFICA · 2026-06-30

Review offers guidance for primary care doctors on diagnosing and managing Alzheimer's

A review in the International Journal of General Medicine addresses Alzheimer's care in primary settings. It notes that specialists are limited while the number of older Americans with the disease is expected to grow. The authors say no single concise reference exists for primary care, and the review aims to provide practical recommendations for clinicians.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE · 2026-06-29

Review finds herpes viruses possibly linked to Alzheimer's, with HSV-1 most implicated

A structured narrative review in Neurology International examined studies from 2020 to 2025 on herpes viruses and Alzheimer's disease. HSV-1 was the most consistently implicated, though some findings conflicted. Some studies suggested lower dementia risk after zoster vaccination. The authors say reverse causation and uneven research limit firm conclusions.

NEUROLOGY INTERNATIONAL · 2026-06-29

Two tau tests combined sort cognitively healthy older adults into distinct risk groups

A study in Alzheimer's Research & Therapy used data from the A4 Study. It included 330 cognitively unimpaired older adults with amyloid on brain scans. Researchers combined a blood p-tau217 test with tau PET scans. They sorted people into concordant and discordant groups and followed them for about five years to compare brain and thinking changes.

ALZHEIMER'S RESEARCH & THERAPY · 2026-06-24

Review links two brain-inflammation markers to Alzheimer's progression, with a changing pattern by stage

A systematic review in Cureus covered 13 human studies of two fluid biomarkers, sTREM2 and YKL-40, in Alzheimer's disease. Spinal fluid sTREM2 followed a two-phase pattern. Early on it was linked to possible protective effects. Later it was tied to brain shrinkage and cognitive decline. The studies varied too much to combine statistically.

CUREUS · 2026-06-24

Review links ultra-processed foods, fatty liver and cognitive decline, causation unproven

A narrative review in Nutrients examines whether fatty liver disease (MASLD) connects ultra-processed food intake to cognitive ageing. Observational and mechanistic studies link higher intake with liver fat, cognitive decline, stroke and dementia-related outcomes. The authors say causality is not fully established and confounding remains important. Several possible gut-liver-brain pathways are discussed.

NUTRIENTS · 2026-06-23

Review finds exercise and multidomain programmes may aid cognition in lower-income countries

A systematic review in BMJ Global Health included 25 randomised trials with 1,304 people with mild cognitive impairment or subjective cognitive decline in low- and middle-income countries, 17 of them in China. A meta-analysis of 15 trials found positive effects on cognition. Exercise and multidomain programmes had replicated evidence of benefit. The authors found significant publication bias.

BMJ GLOBAL HEALTH · 2026-06-22

Review: hearing loss is linked to dementia risk, but cause is unproven

A narrative review in Neuro-Degenerative Diseases says hearing loss is consistently associated with higher dementia risk, with a dose-response pattern. The authors stress this is a marker, not a confirmed cause. Observational evidence suggests hearing aid use may be linked to better cognitive outcomes. The mechanisms connecting hearing and cognition are still incompletely understood.

NEURO-DEGENERATIVE DISEASES · 2026-06-20

Analysis of 2,665 people tests whether short Alzheimer's trials without placebo are feasible

A cohort analysis in Neurology used data from the Alzheimer's Disease Neuroimaging Initiative. It asked whether single-arm futility trials could work in Alzheimer's dementia and mild cognitive impairment. Among 2,665 participants, one dementia rating scale showed the most decline. At 12 months, 60.6% of people with dementia worsened by at least 1.0 points, while 6.2% improved.

NEUROLOGY · 2026-06-18

Blood test for Alzheimer's biology studied in people aged 80 and over

A retrospective cohort study in Neurology followed 167 memory-clinic patients aged 80 or older with mild cognitive impairment. About 69% showed Alzheimer's biology in spinal fluid, and these people had worse memory at baseline. The study tested a blood marker, p-Tau217, and reports excellent accuracy for detecting that biology. The rest of the results are cut off.

NEUROLOGY · 2026-06-17

WOMEN'S HEALTH & HORMONAL TRANSITIONS 11

Case report: late-onset mania in perimenopause turned out to be multiple sclerosis

A case report in PCN Reports describes a 46-year-old woman whose first manic episode was initially linked to perimenopause. Later, leg weakness and further testing revealed primary progressive multiple sclerosis as the underlying cause. The authors suggest brain MRI and autoimmune blood tests in similar cases. A single case cannot show how common this is.

PCN REPORTS : PSYCHIATRY AND CLINICAL NEUROSCIENCES · 2026-06-24

Review links menopause features and hormone therapy type to stroke risk in women

A review in Stroke summarises research linking menopause to stroke risk in women. It covers the type and timing of menopause, hormone levels, and symptoms such as hot flushes and sleep problems. Risk with menopausal hormone therapy varies by formulation, delivery route and the woman's age and health. Skin-patch types in younger midlife women looked more favourable.

STROKE · 2026-06-24

Survey across 13 countries documents symptom burden in perimenopause, menopause and after

A cross-sectional study in EClinicalMedicine, part of the MARIE project, recruited women in 13 countries from January 2024 to September 2025. It used validated scales to measure psychological, physical, pain, sleep, disability and quality-of-life symptoms. The text provided is cut off, so results are not available here.

ECLINICALMEDICINE · 2026-06-23

Review covers managing benign gynecological conditions during perimenopause

A review in Current Opinion in Obstetrics & Gynecology summarises evidence on benign gynecological problems in perimenopause, such as abnormal bleeding and fibroids. It reports that earlier loss of ovarian function, particularly before age 45 to 50, may be associated with less favourable long-term heart outcomes. The authors call for more prospective studies specific to perimenopause.

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY · 2026-06-23

Rhubarb root extract linked to fewer menopause symptoms in perimenopausal women

A paper in Frontiers in Pharmacology reports a 12-week randomised trial of 112 perimenopausal women, followed by a 52-week open-label phase. Menopause complaints fell significantly with the rhapontic rhubarb extract ERr 731 compared with placebo. Symptoms, including headache and migraine, also decreased over the year. The open-label phase had no placebo comparison.

FRONTIERS IN PHARMACOLOGY · 2026-06-23

Earlier menopause linked to more heart disease and higher death risk

An observational study in Frontiers in Cardiovascular Medicine analysed US NHANES data, with a hospital cohort as support. Women whose menopause came before age 40 had more cardiovascular disease and higher death risks than those at 50 to 51. Each year earlier was linked to about 3 to 4 percent higher risk. Cholesterol, blood pressure and blood sugar partly explained the link.

FRONTIERS IN CARDIOVASCULAR MEDICINE · 2026-06-23

Links between lifestyle habits and body health in women shifted with menopause and hormone therapy

Researchers used Canadian Longitudinal Study on Aging data from 10,165 women, followed for three years. According to a study in Menopause, the link between physical activity and fat mass grew stronger over time in all postmenopausal groups. Diet quality showed no such time-dependent pattern. This is observational, so it shows associations, not causes.

MENOPAUSE (NEW YORK, N.Y.) · 2026-06-23

Review links menopause-related hormone changes to bone and tendon injury risk

A narrative literature review in Annals of Rehabilitation Medicine examines how menopause and perimenopause relate to overuse injuries and stress fractures. It describes estrogen's roles in bone, tendon and muscle. The authors note that existing research relies heavily on observational data and fairly uniform groups, which limits how widely the findings apply.

ANNALS OF REHABILITATION MEDICINE · 2026-06-22

Central body fat measures linked to more severe menopausal symptoms

A cross-sectional study in BMC Women's Health included 638 women aged 44 to 56. Two body shape measures, the Body Roundness Index and A Body Shape Index, were both associated with higher menopausal symptom scores. A Body Shape Index showed the strongest link. Because the design is cross-sectional, the authors say prospective studies are needed to clarify causality.

BMC WOMEN'S HEALTH · 2026-06-22

Age, not menopausal status, linked to cognitive scores in Saudi women

A cross-sectional study in Healthcare looked at 220 Saudi women in Riyadh, half perimenopausal and half postmenopausal. Perimenopausal women scored slightly higher on a cognitive test. After adjusting for age, menopausal status was not a significant predictor. Age was. This design shows links only, not cause. The authors call for longitudinal studies.

HEALTHCARE (BASEL, SWITZERLAND) · 2026-06-19

Hormone levels rebounded in about half of women in menopause study

An observational cohort study in Fertility and Sterility analysed 406 women from the SWAN study. Of these, 54.2% had antimüllerian hormone become detectable again after falling below the detection limit. In 48.6% of those, estradiol also rose. Rebound was associated with younger age, lower body mass index and lower FSH. Age at final period did not differ.

FERTILITY AND STERILITY · 2026-06-19

Seven-week diet and exercise programme improved chair-stand performance in older French adults

A cluster-randomised trial in BMC Geriatrics enrolled 376 French adults aged 60 and over. A seven-week supervised diet and exercise programme improved chair-stand performance, a measure of lower-limb strength, more than the control condition. Dietary diversity rose similarly in both groups. The available text is a short summary and does not give effect sizes or further detail on the programme.

BMC GERIATRICS · 2026-07-22

Less ultra-processed food linked to better body composition in lifestyle programme

An analysis of 126 adults in a 1.5-year combined lifestyle intervention, published in Clinical Nutrition ESPEN, tracked ultra-processed food intake. It fell from 57.3% to 52.9% of intake, while unprocessed food rose from 29.0% to 36.0%. Lower ultra-processed intake was associated with beneficial changes in body composition and eating behaviour, independent of energy intake. This shows association, not cause.

CLINICAL NUTRITION ESPEN · 2026-06-26

People ate more calories on days they consumed ultra-processed foods

A cross-sectional analysis in Nutrients used Brazilian national survey data from 38,854 people. Among those who ate ultra-processed foods on only one of two days, energy intake was higher on that day: 1699 kcal versus 1530 kcal. A larger ultra-processed share of the diet was also linked to higher intake. This shows an association, not a cause.

NUTRIENTS · 2026-06-24

Selective eating found in seven in ten children at an Italian clinic

A retrospective observational study in Nutrients looked at 417 children seen at a Rome pediatric hospital. Food selectivity appeared in 70.3% of them, across all BMI categories. Low ferritin was more common in children with primary selective eating or ARFID. The design shows links, not causes.

NUTRIENTS · 2026-06-24

Higher ultra-processed food intake linked to worse memory in older Italians

A cross-sectional study in Nutrients analysed 809 community-dwelling adults aged 65 and over in Italy's NutBrain cohort. A greater share of ultra-processed food in the diet was associated with worse global cognition. The strongest associations were for episodic memory, particularly among women. The design shows only an association, not cause. The authors call for longitudinal and experimental studies.

NUTRIENTS · 2026-06-24

Commentary calls for better diet research on Indian migrant women in Auckland

A commentary in Public Health Nutrition says little is known about the eating habits of Indian migrant women in Auckland. It draws on existing evidence about diet changes after migration among South Asian groups. The authors argue for culturally grounded dietary assessment and attention to affordability, food environments and access to suitable information. This is opinion, not new data.

PUBLIC HEALTH NUTRITION · 2026-06-24

Umbrella review links ultra-processed food to higher risk across most health outcomes

An umbrella review in Nutrition Reviews pooled meta-analyses, mostly of observational studies, covering 13 outcomes. For all but one, higher ultra-processed food intake was associated with greater risk. For type 2 diabetes, risk was 10% higher per 10% increase in intake. These are associations, and certainty of evidence varied.

NUTRITION REVIEWS · 2026-06-24

Sweets, but not total ultra-processed food, linked to kidney stones in Tehran study

A case-control study in Tehran, published in Nutrition, compared 183 people with calcium oxalate kidney stones with 183 matched controls. The highest intake of sweets and confectionery was linked to higher odds of stones. The highest dairy intake was linked to lower odds. Total ultra-processed food intake showed no significant link. These are associations, not proof of cause.

NUTRITION (BURBANK, LOS ANGELES COUNTY, CALIF.) · 2026-06-23

Higher ultra-processed food intake linked to a waist-and-triglyceride phenotype

A cross-sectional study in Food & Function surveyed 528 Iranian adults. Those with the highest ultra-processed food intake had higher odds of the hypertriglyceridemic waist phenotype, with a dose-response pattern. The link was stronger in women and in people with overweight or obesity. Total intake was not tied to oxidative stress or inflammation markers. The design shows association, not cause.

FOOD & FUNCTION · 2026-06-22

Liver fat improvements tied to weight loss, less ultra-processed food

A six-month randomised controlled trial in JHEP Reports compared a Mediterranean diet, a low-carbohydrate high-protein diet and standard advice in people with fatty liver disease and overweight or obesity. Of 173 enrolled, 148 finished. Liver fat fell significantly in the low-carbohydrate and standard-advice groups. The authors conclude weight loss and lower ultra-processed food intake, rather than diet type, were the main drivers of improvement.

JHEP REPORTS : INNOVATION IN HEPATOLOGY · 2026-06-22

MRNA & GENE THERAPY 10

Falling NAT10 with age linked to weaker liver regeneration in mice

According to a study in Clinical and Molecular Hepatology, levels of the NAT10 enzyme and its RNA mark fell with age in human and mouse livers. In mice, disrupting it impaired liver regeneration, and boosting it helped. A drug that raised ATF3 restored NAT10 and regeneration in aged mouse livers. This is preclinical work, not a human treatment.

CLINICAL AND MOLECULAR HEPATOLOGY · 2026-06-18

Review: gene therapy for poor leg circulation has not shown consistent benefit

A review in Cells covers gene therapy that aims to grow new blood vessels in people with severe leg artery disease. Several studies showed biological activity and acceptable safety. However, the randomised trials RAVE and TAMARIS did not show consistent, significant clinical benefit. The authors point to a gap between promising preclinical results and human outcomes.

CELLS · 2026-06-18

Loss of a protein in brain blood vessels speeds ageing changes in mice

A mouse study in PNAS examined KLF4, a protein in blood vessel lining cells that declines with age. Mice engineered to lack it in these cells showed early blood-brain barrier leakage, inflammation, neurodegeneration, anxiety-like behaviour and cognitive deficits at middle age. The authors say this points to KLF4 loss as a driver of age-related brain decline. This is animal research.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA · 2026-06-18

Review discusses gene therapy as a way to target aging

A review in Trends in Molecular Medicine surveys gene therapies for aging and age-related diseases. It covers possible targets, delivery methods and cellular rejuvenation. The authors say single-gene therapies have eased some age-related conditions and call the approach promising. They also note that turning animal findings into clinical therapies remains challenging.

TRENDS IN MOLECULAR MEDICINE · 2026-06-17

Review maps how senescent cells may drive muscle, bone and cartilage disease

A review in Theranostics examines cellular senescence in seven musculoskeletal conditions, including sarcopenia, osteoporosis and osteoarthritis. It covers how senescent cells differ between tissues and may have both harmful and beneficial roles. The authors also discuss possible therapeutic targets and ways to identify senescent cells.

THERANOSTICS · 2026-06-17

Review: protein interaction may set a threshold for drusen formation in macular degeneration

A review in Ophthalmology Science compares healthy aging, age-related macular degeneration and a rare inherited eye disease with similar features. It suggests that binding between the proteins EFEMP1 and TIMP-3 may be a critical threshold in forming drusen, the deposits seen in the disease. This is an analysis of existing research, not a test in patients.

OPHTHALMOLOGY SCIENCE · 2026-06-16

Review surveys gene therapy approaches that might target the biology of aging

A review in Cell Reports Medicine summarises how gene therapy could act on aging pathways. These include genome editing, RNA modulation and epigenetic reprogramming. The authors call them promising and discuss safety and the steps needed to reach clinical use. As a review, it reports no new results and shows no proven benefit in people.

CELL REPORTS. MEDICINE · 2026-06-15

Review maps expanding ALS pipeline across stem-cell screening, cell and gene therapy

A review in Regenerative Therapy covers ALS research from 2020 to 2026. It notes the FDA's accelerated approval of tofersen in April 2023, the first treatment targeting a genetic cause. Drug candidates identified using stem cells, ropinirole and bosutinib, have completed early-phase trials. Regulatory T cell therapies lack efficacy proof. Company-reported interim data suggest target engagement for QRL-201, an experimental nucleic acid drug in an ongoing Phase 1/2 trial.

REGENERATIVE THERAPY · 2026-06-15

Age had little effect on a spinal-fluid gene-silencing compound, study reports

A study in Molecular Therapy tested a lipid-siRNA conjugate called L2-siRNA, a gene-silencing compound delivered via cerebrospinal fluid, for age-related changes in delivery, silencing and safety. The authors report age had minimal impact on its performance. Conjugates worked better when each lipid was paired with the siRNA design it was optimised for. The summary does not report results in people.

MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY · 2026-06-15

Review links oxidative stress to glaucoma, but clinical evidence for antioxidants lags

A narrative review in Antioxidants covers evidence published up to March 2026. It describes oxidative stress as a central contributor to glaucoma, including damage to eye drainage tissue and retinal nerve cells. It discusses antioxidant approaches such as nicotinamide and coenzyme Q10. The authors highlight gaps between preclinical promise and clinical evidence.

ANTIOXIDANTS (BASEL, SWITZERLAND) · 2026-06-14

AI BIOLOGY & DIAGNOSTICS

10

Review examines AI-guided design of lipid-polymer nanoparticles for breast cancer drugs

A review in the Journal of Nanobiotechnology looks at polymeric lipid nanoparticles as drug carriers for breast cancer. It discusses how AI tools might help prioritise designs, and how biological barriers limit delivery. The authors note that approved nanocarriers have given limited efficacy gains. The text does not report new trial results. It is not about aging.

JOURNAL OF NANOBIOTECHNOLOGY · 2026-06-28

Review sets out a framework for using AI in cancer research

A narrative review in the Journal of Translational Medicine outlines how artificial intelligence and machine learning could be used across cancer research, from preclinical work to clinical decision support. It discusses data integration, bias and regulation. The authors argue that useful tools need external validation and representative data, not only accuracy.

JOURNAL OF TRANSLATIONAL MEDICINE · 2026-06-27

Review: AI tools may help spot colitis-linked bowel cancer, but evidence is early

A narrative review in the International Journal of Molecular Sciences looks at machine learning for detecting colitis-associated cancer in people with inflammatory bowel disease. The authors say early studies, though limited, suggest AI may improve detection of precancerous changes and risk prediction. The review also covers technical and clinical challenges before routine use.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES · 2026-06-27

AI model sorts brain MRI scans by Alzheimer's stage with 94.5% accuracy

Researchers reported in Frontiers in Aging Neuroscience a deep learning model that classifies MRI scans as normal, mild cognitive impairment or Alzheimer's. It was trained on 2,100 people and tested on 900 others. Accuracy was 94.5% on the first dataset and 92.8% on the second. It is a computing study, not a clinical trial.

FRONTIERS IN AGING NEUROSCIENCE · 2026-06-26

Review: brain imaging is improving diagnosis of neurodegenerative diseases, but challenges remain

A review in Frontiers in Aging Neuroscience surveys MRI, PET and other imaging used for Alzheimer's, Parkinson's, frontotemporal dementia and ALS. It describes a "blood-first" approach, where blood tests help decide who gets advanced scans. The authors say standardization, sensitivity, specificity and clinical translation are still problems.

FRONTIERS IN AGING NEUROSCIENCE · 2026-06-26

Scoping review: AI reading CT scans shows promise for telling fracture causes apart

A scoping review in the International Journal of Burns and Trauma found six retrospective studies, with 1,767 participants, that used AI on CT scans to tell benign from cancer-related spinal compression fractures. Area under the curve, a measure of diagnostic performance, ranged from 0.76 to 0.99. Deep learning performed comparably to experienced radiologists. The authors say the data are limited and more multicentre work is needed.

INTERNATIONAL JOURNAL OF BURNS AND TRAUMA · 2026-06-25

Machine-learning model uses routine blood tests to flag colorectal cancer in a retrospective study

According to a retrospective case-control study in Translational Cancer Research, researchers built machine-learning models from lab test data. They compared 1,068 people with confirmed colorectal cancer with 1,068 matched healthy controls at one hospital. The work is described as exploratory. The text provided does not give the model's accuracy.

TRANSLATIONAL CANCER RESEARCH · 2026-06-25

Review outlines current and emerging ways to diagnose lung fibrosis

A structured narrative review in Frontiers in Medicine looks at how lung fibrosis, a group of scarring lung diseases, is diagnosed. Diagnosis is hard because symptoms are non-specific and scan patterns overlap. High-resolution CT remains the gold standard for non-invasive diagnosis. The authors also cover biopsy methods, molecular tests and artificial intelligence, and propose an updated diagnostic algorithm.

FRONTIERS IN MEDICINE · 2026-06-23

Review: gait sensors may help track and detect neurological disease

A review in Medical Sciences describes how walking patterns reflect nervous system function. It says wearable sensors, motion capture and machine learning may support diagnosis, predict falls and track disease progression. The authors say changes such as stride variability may appear before clear clinical decline. The text describes these measures as promising, not proven.

MEDICAL SCIENCES (BASEL, SWITZERLAND) · 2026-06-23

Review: AI is turning the ECG into a tool for detecting hidden disease

A review in European Heart Journal – Digital Health describes how artificial intelligence is changing the electrocardiogram. AI may help interpret ECGs, detect signs of disease not yet obvious, and predict outcomes. The authors note problems with model transparency and real-world use. They say most tools have been tested retrospectively and need randomised clinical trials.

EUROPEAN HEART JOURNAL. DIGITAL HEALTH · 2026-06-20

Teen footballers with more nutrition knowledge showed higher fitness scores

A cross-sectional study in the journal Sports assessed adolescent male football players using body composition analysis, maximal exercise testing and a sports nutrition questionnaire. Higher nutrition knowledge scores were associated with better VO2 max and anaerobic threshold, but not with body mass index or fat-free mass. The authors call the findings exploratory and hypothesis-generating, and the design cannot show cause.

SPORTS (BASEL, SWITZERLAND) · 2026-06-05

School interval training study finds mostly non-significant changes over eight weeks

A study in Life analysed 145 adolescents from the experimental arms of a school-based trial. They were grouped by sex and by HIIT or HIPT training, done twice weekly for eight weeks. Most pre-to-post changes in body fat, blood pressure and predicted fitness showed no significant main effects. Greater intensity progression was associated with larger drops in diastolic blood pressure in the female and male HIIT groups.

LIFE (BASEL, SWITZERLAND) · 2026-06-04

Meta-analysis finds sprint interval training linked to fitness gains in adolescents

A systematic review and meta-analysis in PeerJ pooled 18 randomised trials with 565 adolescents. Sprint interval training was associated with improvements in aerobic capacity, anaerobic power, jumping, sprint ability and body composition, including lower body mass index and body fat percentage. The study concerns adolescent fitness rather than ageing directly.

PEERJ · 2026-06-02

Review argues reactive hyperemia better reflects fitness-related blood vessel changes

A review in Exercise and Sport Sciences Reviews examines how blood vessels are assessed in fit people. The authors say flow-mediated dilation is not well suited to detecting endurance training adaptations in healthy individuals. They propose reactive hyperemia, which adds small-vessel responses, as a measure that more closely reflects fitness-related vessel changes.

EXERCISE AND SPORT SCIENCES REVIEWS · 2026-06-02

Fitness test gives reliable, valid readings in young male futsal players

A study in Scientific Reports tested the 30-15 Intermittent Fitness Test in 58 male futsal players under 21. Repeat tests a week apart gave very consistent results. Estimates of aerobic capacity also correlated with laboratory measurements (r = 0.78). The authors conclude the test is reliable and valid for this group.

SCIENTIFIC REPORTS · 2026-06-01

Cooper 12-minute run test underestimates fitness in college team athletes

A study in the International Journal of Exercise Science compared the Cooper 12-minute run with lab-measured VO2 max in 73 varsity athletes. The run test underestimated VO2 max by 6.0 mL per kg per minute on average. It missed many fit athletes, but a positive result was usually correct. The authors call it a screening tool, not a lab replacement.

INTERNATIONAL JOURNAL OF EXERCISE SCIENCE · 2026-06-01

Italian schoolchildren's fitness rose over time, led by cardiorespiratory gains

A repeated cross-sectional study in the Journal of Public Health assessed five fitness areas in Italian elementary school children. Overall fitness rose over time, and cardiorespiratory fitness improved most, especially at ages 10 to 11. Gains in speed-agility and limb strength among 6- to 9-year-olds plateaued in older groups. Balance declined in 10-year-old boys. The authors call for national fitness surveillance.

JOURNAL OF PUBLIC HEALTH (OXFORD, ENGLAND) · 2026-06-01

Fitter elite athletes show larger hearts and lower heart tissue T1 and T2 values

An observational study in the European Journal of Preventive Cardiology assessed 125 healthy elite athletes with fitness testing and cardiac MRI. Greater fitness was associated with larger heart volumes and mass, and with lower T1 and T2 values. Endurance athletes showed the most heart remodelling. The authors say this is the first such link shown, and it does not prove cause.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY · 2026-06-01

Review: exercise combined with low oxygen may help brain health, evidence limited

A review in AIMS Neuroscience looked at exercise combined with low-oxygen exposure, including athletes' altitude camps. The authors say traditional altitude training has been poorly studied for brain health. They say intermittent low-oxygen conditioning has shown various benefits in pilot studies. They note unresolved challenges, including standardising methods and choosing the best protocols.

AIMS NEUROSCIENCE · 2026-06-01

Opinion paper questions whether stair climbing truly protects the heart

An opinion paper in Healthcare reviewed observational studies and meta-analyses. Habitual stair climbing is consistently linked with lower risks of atrial fibrillation and death. But the authors say reverse causation may explain this, since fitter people climb stairs more. They say more research is needed before the link is treated as causal.

HEALTHCARE (BASEL, SWITZERLAND) · 2026-06-01

SLEEP SCIENCE & CIRCADIAN BIOLOGY 10

In mice, surgery-like stress disrupted brain signalling tied to delirium-like behaviour

A study in aged mice, published in Alzheimer's & Dementia, tested anaesthesia, surgery and intensive-care-like stress. The stress reduced BDNF signalling, dendrite complexity and attention. It also changed epigenetic markers. A drug that inhibits histone deacetylase eased these effects and improved short-term cognition. This is animal research, not a human trial.

ALZHEIMER'S & DEMENTIA : THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION · 2026-06-01

Fruit flies lacking CCHamide1 sleep poorly and live shorter lives

A study in Genetics used fruit flies, not humans. Flies lacking the gut and brain signal CCHamide1 had fragmented sleep, higher fat stores and better survival under starvation. They also laid more eggs in mid-life but had shorter lifespans. The authors suggest the molecule links nutrition, sleep and longevity in flies.

GENETICS · 2026-06-01

Gene variant may change how short sleep relates to early Alzheimer's tau

An observational analysis in Alzheimer's & Dementia used 450 dementia-free Framingham Heart Study participants. The AQP4 gene was not linked to amyloid or tau overall. But short sleep was linked to more tau in the brain's medial temporal region among minor-allele carriers, and the reverse in others. The authors say variation may influence vulnerability.

ALZHEIMER'S & DEMENTIA : THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION · 2026-06-01

Insomnia therapy did not improve thinking or amyloid in older adults at one year

A randomised controlled trial in Alzheimer's & Dementia tested cognitive behavioral therapy for insomnia in 200 cognitively normal older adults. After one year, the groups did not differ in cognitive performance. Amyloid, measured in a subsample of 50, also did not differ. The authors say longer follow-up is needed.

ALZHEIMER'S & DEMENTIA : THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION · 2026-06-01

In older adults, more moderate-to-vigorous activity linked to better cognition

An observational analysis in The Journals of Gerontology: Series A used wrist accelerometer data from 927 older adults in the ARIC study. More time in moderate-to-vigorous activity, relative to other activity, was associated with better cognitive scores. More low-intensity light activity was linked to poorer scores. These are associations, not proof of cause.

THE JOURNALS OF GERONTOLOGY. SERIES A, BIOLOGICAL SCIENCES AND MEDICAL SCIENCES · 2026-06-01

Review: casein kinase 1 enzymes linked to cancer and other diseases

A review in BMB Reports looks at casein kinase 1, a family of enzymes found across many species. They help control cell division, DNA integrity, gene activity and body clock rhythms. The review links disrupted CK1 activity to cancer, neurodegenerative disease, metabolic syndromes and immune problems. It also discusses CK1 as a possible drug target.

BMB REPORTS · 2026-06-01

In Alzheimer's mice, immune cells called microglia drove sleep loss linked to amyloid plaques

A study in mice, published in Alzheimer's & Dementia, found amyloid plaques caused loss of non-REM sleep. Removing microglia restored more than two hours of sleep a day without changing plaque burden. The authors suggest microglia drive this sleep loss. The findings are in mice and may not apply to people.

ALZHEIMER'S & DEMENTIA : THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION · 2026-06-01

About a quarter of UK Biobank respondents met criteria for a sleep disorder

A report in Sleep describes a 2023 sleep questionnaire completed by 185,056 UK Biobank participants, mostly White and averaging about 70 years old. Around 40 per cent reported sleeping under 7 hours. About 25 per cent met criteria for a sleep disorder, most often insomnia. Sleep disorders were associated with anxiety, depression, fatigue and cognitive complaints. Responses were self-reported.

SLEEP · 2026-06-01

Review: delirium in hospitalised older adults is common and often missed

A narrative review in Cureus covered literature from 2005 to 2026 on delirium in hospitalised older adults. It reports that delirium is linked to longer stays, functional decline, long-term cognitive problems and higher mortality. The quiet, hypoactive form is often missed. The authors say better screening and prevention in routine hospital care may reduce its occurrence.

CUREUS · 2026-05-31

Paper proposes three social and psychological pillars behind the Mediterranean lifestyle

A conceptual paper in Advances in Nutrition, grounded in nutrition anthropology, proposes that the traditional Mediterranean lifestyle rests on cheerful frugality, belongingness and purpose in life. The authors suggest mindfulness ties these together and supports moderation. It is a perspective piece, not a trial or study measuring health outcomes.

ADVANCES IN NUTRITION (BETHESDA, MD.) · 2026-05-30

Review links early gut inflammation to later thinking and mood problems

A review in the World Journal of Clinical Pediatrics examined the gut-brain connection in early life. Animal studies showed early stress, antibiotics and infection caused lasting inflammation and cognitive problems. Human studies link severe early gut illness to attention, memory and executive function deficits. The review describes associations and proposed pathways, including inflammation and nutrient shortfalls.

WORLD JOURNAL OF CLINICAL PEDIATRICS · 2026-06-09

Review links low-fiber diets, gut bacteria and Alzheimer's disease, but cause is unproven

A review in Frontiers in Microbiomes looks at how diet and gut microbes may relate to Alzheimer's disease. It says preclinical and limited clinical evidence links low-fiber diets to changes in gut bacteria. These changes may contribute to the disease's onset and progression. The review describes possible links, not proven causes.

FRONTIERS IN MICROBIOMES · 2026-06-08

Review suggests postbiotics may affect mood-related pathways in mental health conditions

A systematic review in Health Promotion Perspectives examined postbiotics, metabolic byproducts of probiotics, in depression, psychosis and mania, covering studies from 2015 to 2025. The authors report that postbiotics modulate serotonin and GABA, reduce neuroinflammation and influence the body's stress-response system. They call postbiotics promising potential treatments, but the published abstract does not state how many studies were included or whether they involved people or animals.

HEALTH PROMOTION PERSPECTIVES · 2026-06-06

Review summarizes how oligosaccharide prebiotics affect gut bacteria and host health

A review in 3 Biotech covers prebiotics such as inulin, FOS and GOS. It reports that lab, animal and clinical studies show increases in Bifidobacterium and Lactobacillus and in short-chain fatty acids. These changes are linked to better gut barrier integrity and less inflammatory signaling. The review also covers production methods and delivery technologies.

3 BIOTECH · 2026-06-06

Review links gut bacteria imbalance to diabetes complications, but cause is unproven

A narrative review in Microorganisms examines gut microbiota and complications of type 2 diabetes, such as kidney, eye and nerve problems. The authors say most evidence is associative. They suggest gut imbalance may modify disease development. They call for longitudinal and mechanistic studies to clarify causality and test microbiome-targeted treatments.

MICROORGANISMS · 2026-06-06

Plant compound AS-IV protected Parkinson's-model mice, apparently via gut bacteria

A study in Communications Biology tested astragaloside IV in mice given rotenone to mimic Parkinson's disease. The compound reduced movement problems, nerve cell loss and inflammation markers. Transplanting gut bacteria from treated mice gave similar benefits to other mice. This is animal research, so it does not show the same effect in people.

COMMUNICATIONS BIOLOGY · 2026-06-06

Small twin study finds lower Lachnospiraceae gut bacteria in twins with mild cognitive impairment

A small study in Medicina compared gut bacteria in identical twin pairs where one twin had mild cognitive impairment. The clearest finding was lower Lachnospiraceae in affected twins. Other results were exploratory. With few pairs and limited control for diet and medication, the study cannot show cause.

MEDICINA (KAUNAS, LITHUANIA) · 2026-06-06

Review examines gut-brain links between inflammatory bowel disease and anxiety or depression

A review in the International Journal of General Medicine examines why inflammatory bowel disease often occurs alongside anxiety and depression. It describes four inflammatory pathways that may reinforce each other in a cycle. The authors note that whether one condition causes the other is unresolved, and that gut microbiota studies are often hard to reproduce. They call for longitudinal studies.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE · 2026-06-06

Fermented rose fruit extract eased irritable bowel symptoms in mice

A study in Frontiers in Nutrition tested a fermented extract of Rosa roxburghii pulp in mice with a model of diarrhea-predominant irritable bowel syndrome. Compared with untreated model mice, the extract reduced diarrhea, gut damage and inflammatory markers. It also changed gut bacteria and improved anxiety-like behaviour. This was animal research, not a human trial.

FRONTIERS IN NUTRITION · 2026-06-05

Review links gut bacteria changes to Alzheimer's, but cause remains unclear

A review in Frontiers in Molecular Biosciences looked at human studies from the past five years. It found gut microbiome changes are associated with Alzheimer's disease and may appear before symptoms. The authors say it is unclear when these differences start or how they contribute. Few microbiome-based treatments have been validated in humans.

FRONTIERS IN MOLECULAR BIOSCIENCES · 2026-06-04

STRESS RESILIENCE & NERVOUS SYSTEM 10

Review argues non-invasive vagus nerve stimulation does engage vagal pathways

A review in Frontiers in Neuroscience gathered anatomical, imaging, electrical and immune evidence on stimulating the vagus nerve through the skin of the neck. The authors conclude it activates vagal pathways and is hard to explain by placebo alone. They cite sham-controlled randomised trials in cluster headache and migraine that favoured the stimulation.

FRONTIERS IN NEUROSCIENCE · 2026-06-10

Review proposes gut bacteria may explain how acupuncture eases irritable bowel syndrome

A review in Frontiers in Neuroscience gathers evidence on acupuncture and irritable bowel syndrome. The authors propose that acupuncture changes gut bacteria and their products, which may relate to symptom relief. The review is a theoretical framework built from existing studies. It does not report a new trial.

FRONTIERS IN NEUROSCIENCE · 2026-06-10

Review proposes link between military stress and glandular tumour biology

A review in Frontiers in Oncology discusses chronic military stress and PTSD-related stress molecules. It combines this with earlier fruit fly spaceflight work that flagged five genes as possible weak points in human glandular tumours. The authors propose that stress may help tumours progress. This is a hypothesis, not a demonstrated cause.

FRONTIERS IN ONCOLOGY · 2026-06-09

Review links bile acid signaling to Alzheimer's disease processes

A narrative review in Naunyn-Schmiedeberg's Archives of Pharmacology examines bile acids in Alzheimer's disease. It notes that altered bile acid profiles have been reported in Alzheimer's and mild cognitive impairment. Some bile acids may harm the blood-brain barrier, while others may protect. The review gathers existing evidence and does not test a treatment.

NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY · 2026-06-09

Review links chronic inflammation to treatment-resistant depression

A review in Frontiers in Pharmacology discusses how inflammation may contribute to treatment-resistant depression. The text says this affects about one-third of patients who do not respond to standard antidepressants. Low-grade inflammation is described as a hallmark and may raise blood-brain barrier permeability. The authors argue for treatment based on biological subtypes.

FRONTIERS IN PHARMACOLOGY · 2026-06-08

Intermittent fasting eased stress-linked depression-like behavior in mice

A study in Translational Psychiatry used male mice exposed to 14 days of chronic stress. Mice on an intermittent fasting regimen showed fewer depression-like behaviors and less loss of myelin, the nerve insulation, than mice fed freely. Fasting also changed their gut bacteria. This is mouse research, and the gut link is an association.

TRANSLATIONAL PSYCHIATRY · 2026-06-07

New questionnaire measures lifelong sense of safety in Kenyan adults

Researchers writing in Communications Medicine developed and tested a scale that asks adults to rate how safe they felt across their lives. It showed adequate reliability. Women and people experiencing poverty reported lower lifetime safety. Higher scores were linked with less stress and anxiety, and with more resilience and better memory. These are correlations only.

COMMUNICATIONS MEDICINE · 2026-06-06

Review explores how electroacupuncture might affect inflammation pathways relevant to long COVID

A review in Frontiers in Integrative Neuroscience examines electroacupuncture and long COVID. Experimental studies point to effects on vagus nerve anti-inflammatory and metabolic pathways. Clinical evidence is described as indirect. The authors say links to improved long COVID symptoms are hypotheses that need further testing, and they sort the evidence by strength.

FRONTIERS IN INTEGRATIVE NEUROSCIENCE · 2026-06-05

Small study links psychosocial factors to vascular measures in Métis adults

A study in CJC Open gave questionnaires to 72 Métis adults in Canada and measured vascular and neurovascular indicators. Self-efficacy and cultural identity were associated with arterial stiffness. Housework responsibilities altered the links between self-efficacy and both baroreceptor sensitivity and heart rate variability. The study shows associations only. It cannot show that these factors cause changes in heart or blood vessel health.

CJC OPEN · 2026-06-04

Review examines anxiety around surgery and how it is assessed and managed

A narrative review in Healthcare summarises evidence on anxiety before and after surgery in adults. It reports a global prevalence of about 48%. The authors describe the biology involved, newer assessment methods and management approaches. They note gaps remain in standard screening, biomarker validation and support for high-risk groups.

HEALTHCARE (BASEL, SWITZERLAND) · 2026-06-03

Review examines how cell senescence and stem cell traits interact

A review in the journal Aging discusses cellular senescence, where cells stop dividing, and stemness, the capacity to renew tissue. The authors say the two often act against each other in normal settings. In cancer, they describe a synergy, where senescent-cell features may promote cancer stem cells. The interaction varies by cell type and context.

AGING · 2026-05-30

Review summarizes why blood-forming stem cells decline with age

A review in Genome Biology covers aging of hematopoietic stem cells, which form blood and immune cells. Aged cells show reduced self-renewal, a bias toward myeloid cell types, and clonal hematopoiesis. The authors summarize mechanisms behind this aging and discuss strategies that might rejuvenate these cells. It is a review, not new data.

GENOME BIOLOGY · 2026-05-29

Review explores links between psoriasis, chronic inflammation and cell ageing

A narrative review in Psoriasis describes how psoriasis, long-term low-grade inflammation and cellular senescence may be connected. Senescent cells release inflammatory signals, and several of these are altered in psoriasis. The authors outline two possible cause-and-effect directions. They say the mechanisms still need to be clarified.

PSORIASIS (AUCKLAND, N.Z.) · 2026-05-28

Senescence-linked drug resistance in NK/T-cell lymphoma traced to a protein called LCP2

A study in Cell Death & Disease looked at NK/T-cell lymphoma, an aggressive blood cancer. It used patient plasma, resistant cancer cells and an animal model. Levels of the protein LCP2 were lower in patients with relapsed or resistant disease. Targeting the related pathway partly cleared senescent cells and improved chemotherapy response in animals. Human benefit is not shown.

CELL DEATH & DISEASE · 2026-05-28

Mouse study: DNMT1 protein rises with age and is tied to graying hair

A study in mice and cells, published in Autophagy, found DNMT1 protein increases in aged mouse tissues. It was linked to reduced autophagy, more cellular senescence and less hair pigment after radiation. Deleting or inhibiting DNMT1 reversed these changes in the experiments. Senolytic treatment also lowered DNMT1 in aged organs.

AUTOPHAGY · 2026-05-28

Senolytic drugs reduced spine degeneration and pain behavior in mice

A study in Advanced Science tested two senolytic agents, o-vanillin and RG-7112, in mice prone to spine problems. Treated mice showed less pain-related behavior and fewer markers of senescent cells in spinal tissues. Early treatment also preserved disc volume and bone structure. The work was done in mice, not people.

ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) · 2026-05-25

Review proposes using skin to test treatments that target aging

A review in GeroScience argues that skin is an accessible place to study aging, because doctors can observe and sample it directly. The authors describe skin-based markers that could help judge anti-aging interventions. They also suggest skin problems may influence aging elsewhere in the body. It is a conceptual framework, not a test of any treatment.

GEROSCIENCE · 2026-05-22

Review links aging-type cell changes in kidney filters to diabetic kidney disease

A review in Cellular and Molecular Life Sciences looks at senescence, a state of cell aging, in the kidney's filtering cells in diabetic kidney disease. It says podocytes, endothelial cells and mesangial cells age in different ways. The authors propose that treatments targeting senescence could be tailored by cell type. This is a review, not a trial.

CELLULAR AND MOLECULAR LIFE SCIENCES : CMLS · 2026-05-22

Paper proposes a new theoretical framework for why ageing happens

A paper in Ageing Research Reviews proposes a conceptual framework for ageing. It says ageing is mainly the loss of coordination among signalling, energy and repair machinery, and epigenetic controls, rather than the decline of any one part. This is a theoretical proposal. The text does not report new experimental or human data.

AGEING RESEARCH REVIEWS · 2026-05-22

Review links senescent cells to survival-prone giant cancer cells

A review in Cancers discusses polyploid giant cancer cells, a rare, resilient cell type found in tumours. It reports emerging evidence that senescent cells, which build up with age and treatment, reshape surrounding tissue in ways that promote these cells. The cells can survive chemotherapy and radiation and may contribute to recurrence. Much of the cited work uses lab models.

CANCERS · 2026-05-22

NITRIC OXIDE & VASCULAR HEALTH

10

High homocysteine linked to stiffer arteries and poorer kidney function in heart patients

A prospective observational study of 133 people having coronary angiography, published in the Journal of Clinical Medicine, found high homocysteine was linked to worse kidney function and stiffer central arteries. It was not linked to the severity of coronary artery disease or to peripheral arterial disease. The authors say more research is needed. This shows association, not cause.

JOURNAL OF CLINICAL MEDICINE · 2026-06-25

Strength training linked to better blood vessel function in adults with vascular risk

A systematic review and meta-analysis in Frontiers in Cardiovascular Medicine pooled 20 randomised trials. Resistance training, alone or with aerobic exercise, reduced arterial stiffness slightly and improved flow-mediated dilation, a measure of vessel function. The authors urge caution. Publication bias, small-study effects and a limited evidence base may affect the dilation result. The stiffness evidence was less robust.

FRONTIERS IN CARDIOVASCULAR MEDICINE · 2026-06-24

Review outlines cell-level causes of coronary artery spasm

A review in Cells describes coronary artery vasospasm, a temporary narrowing of heart arteries that can cause chest pain or serious heart events. It outlines contributing factors, including overactive smooth muscle, poor blood vessel lining function and chronic inflammation. The authors say emerging drug approaches, such as ROCK inhibitors, may help patients with hard-to-treat cases.

CELLS · 2026-06-24

Review finds mouth bacteria may influence heart health through nitric oxide

A narrative review in the Journal of Clinical Medicine looked at how oral bacteria turn dietary nitrate into nitric oxide, a molecule tied to blood vessel function. Studies link disrupted mouth microbiomes to changes in blood pressure and related markers. Findings are mixed. Many studies are small, short and rely on surrogate markers rather than heart events.

JOURNAL OF CLINICAL MEDICINE · 2026-06-23

Review links low Klotho protein to cognitive problems in dialysis patients

A review in Frontiers in Aging Neuroscience summarises clinical and lab evidence on Klotho, a protein made mainly in the kidney. Low Klotho appears to be associated with cognitive impairment in people on dialysis. Proposed pathways include oxidative stress, inflammation, blood vessel problems and a leaky blood-brain barrier. Its use as a biomarker or treatment target is still being evaluated.

FRONTIERS IN AGING NEUROSCIENCE · 2026-06-23

In people with long COVID, diet composition was linked to some artery measures

A cross-sectional study in Nutrients looked at 304 people with long COVID. Higher energy and carbohydrate intake were linked to lower arterial stiffness on one measure. Carbohydrate and fat shares of energy showed opposite links with another measure. Four other vascular markers showed no link. A single snapshot cannot show cause.

NUTRIENTS · 2026-06-22

Review outlines how far-infrared heat may affect blood vessels and inflammation

A review in Circulation Reports describes proposed mechanisms by which far-infrared therapy may act. These include mild heating, effects on blood vessel function, reduced oxidative stress and lower inflammation signalling. The authors say preclinical and clinical studies point to better microvascular blood flow and tissue repair. The text does not give results from specific trials.

CIRCULATION REPORTS · 2026-06-20

In mice, oestrogen helped brain blood vessels only without the APOE4 variant

A study in The Journal of Physiology used young female mice carrying human APOE3 or APOE4 gene variants. In APOE3 mice, removing the ovaries impaired brain artery function, and oestradiol restored it. In APOE4 mice, neither had an effect. The work was in mice, so it does not show the same pattern occurs in people.

THE JOURNAL OF PHYSIOLOGY · 2026-06-19

Phosphatidylserine improved some blood vessel measures in mice and people with type 2 diabetes

A study in the Journal of Applied Physiology combined lab work, diabetic mice and a randomised, double-blind, placebo-controlled trial. In mice, phosphatidylserine improved artery dilation and reduced stiffness. In people with type 2 diabetes, four weeks of supplementation improved leg blood flow responses and reduced a measure of aortic stiffness. The authors say it may have therapeutic potential.

JOURNAL OF APPLIED PHYSIOLOGY (BETHESDA, MD. : 1985) · 2026-06-18

Citrus compound reduced preeclampsia-like damage in pregnant rats

A study in rats, published in Naunyn-Schmiedeberg's Archives of Pharmacology, tested naringenin against a drug-induced model of preeclampsia. Pre-treated rats had less fetal death, lower placental inflammation markers and higher nitric oxide levels. Fetal weight and length also improved. This is early animal research with small groups, and human effects are untested.

NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY · 2026-06-17